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Abstract 
 
Background 
Respiratory diseases are common in children. These diseases are multifactorial, with both 
environmental and genomic influences associated. Various epidemiological research has 
been carried out to understand the association between ambient air pollution and adverse 
outcomes in respiratory disease. Along with environmental factors, pharmacogenomics has 
shown that asthma medication efficacy can be affected by someone’s genotype. Lately, 
research has examined if adverse drug reactions (ADRs) are similarly affected.  
 
Methods 
This thesis has systematically reviewed the health effects of ambient air pollution 
(particulate pollutants (diameter <2.5μm (PM2.5) or <10μm (PM10) and gaseous pollutants 
(nitrogen dioxide (NO2), sulphur dioxide (SO2), carbon monoxide (CO), ozone (O3)) in 
children, as a review of hospitalisation with bronchiolitis and as an overview of systematic 
reviews of all common paediatric respiratory diseases requiring healthcare utilisation (HRU). 
A systematic review was completed analysing studies examining the association between 
pharmacogenomics and adverse drug reactions in asthma medications in the whole 
population. A survey was subsequently sent to members of the Pharmacogenomics in 
Childhood Asthma (PiCA) consortia, to determine priorities for ADR pharmacogenomic 
studies. 
 
Results 
In the bronchiolitis systematic review eight studies were included. Long term exposure to 
particulate pollutants may be associated with increased risk of hospitalisation with 
bronchiolitis. In addition, short-term exposure to NO2 and SO2 may also be associated with 
hospitalisation, while results for other pollutants were inconsistent.  
 
In the overview, 11 systematic reviews were included, ten had incorporated meta-analysis 
data. There was moderate quality evidence that risk of HRU for asthma exacerbations in 
children are associated with increased concentrations for each ambient air pollutant, and 
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that risk of HRU with pneumonia is positively correlated with concentrations of PM2.5, 
PM10, and O3. 
 
In a systematic review examining pharmacogenomics and ADRs five studies were included, 
one examined inhaled short acting beta-2 agonists (SABA), one long acting beta-2 agonists 
(LABA), and three examined corticosteroids (one included inhaled, all included oral). The 
ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal 
suppression (rs591118), decreased bone mineral density (rs6461639) and bone mineral 
accretion (rs9896933, rs2074439). The priorities for future pharmacogenomic ADR studies 
in asthma gained from the survey were tachycardia (SABA/LABA), adrenal suppression/crisis 
and growth suppression (Corticosteroids), sleep/behavior disturbances (Leukotriene 
Receptor Antagonists), and nausea and vomiting (Theophylline). 
 
Conclusion 
This thesis highlights the need to recognize adverse effects of ambient air pollution on 
children’s respiratory health. It also confirmed that ADR’s should be recognized and 
examined in future pharmacogenomic studies. The combination of these factors could help 
to decrease the burden respiratory disease has on healthcare resources worldwide as could 
help limit the risk of hospitalization for both the disease and complications of management 
of the disease.  
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Chapter 1: Introduction 
 
1.1 Background 
 
Globally, in the paediatric population, respiratory diseases are a major burden of disease [1-
3]. There are numerous different diseases that affect each part of the respiratory system, 
from the upper airways to the nerves responsible for breathing, at various ages across 
childhood [4-6]. The most susceptible group in children is those under the age of five years, 
a key age range for lung development [4]. Some of the common respiratory diseases in 
children include acute lower respiratory infections (ALRI) such as bronchiolitis and 
pneumonia, and asthma [7, 8]. The cause of these diseases are multifactorial, from 
environmental factors, such as smoking, to a genetic predisposition for a disease [9, 10]. In 
2012, environmental factors had been associated with 12.6 million deaths, 26% were in 
children under the age of five [11]. Some environmental factors can be modified to help 
decrease the risk of incidence or severity of the disease. One of the environmental factors 
that has recently been brought to attention for its negative impact on health is air pollution 
[12], particularly ambient (outdoor sources) pollution. Ambient air pollution has been 
increasing for several decades. In 2005, with the World Health Organisation (WHO) created 
international guidelines for the main air pollutants [13, 14], these inform countries of safe 
concentration levels for air pollutants in order to minimise harm to individual’s health. 
Ambient air pollution is known to affect childhood mortality [15], however, its effects on 
aspects of healthcare utilization is unclear. Apart from environmental factors, other 
variables influence respiratory health such as genomics. For asthma an increase 
susceptibility in childhood to the disease occurs if certain loci are present [16]. 
Interindividual variation is known with asthma medication, pharmacogenomics has been 
shown to have an effect alleviation of disease and reduction of symptoms [17]. The 
discipline of pharmacogenomics, which examines variations in genetic characteristics 
related to drug responses, has shown that efficacy is affected in certain populations with 
particular genes [18-20]. Although, medication efficacy has been examined, medicines can 
cause harm via adverse drug reactions (ADRs), this has not been thoroughly explored. ADRs 
are a significant cause of hospital admissions, with incidence rates ranging from 0.4% to 
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10.3% in all children [21]. To help synthesise existing primary research to assess the current 
knowledge on topics and possible gaps in the evidence, this MPhil has used systematic 
reviews [22-25]. The methodology and benefits of this technique adopted in this research 
are discussed below. 
 
1.2 Respiratory Disease in Children  
 
Respiratory disease has an impact on the health of millions of people worldwide, as a 
leading cause of ill health in both adults and children [2]. After birth, additional respiratory 
development occurs, with full functionality achieved at roughly six years old [26-28]. For 
example, at birth, the lung’s still need to form 80% of the alveoli [29]. Also, a child’s 
respiratory epithelium layer has greater permeability than an adult’s [30]. Children spend a 
greater period of time outside compared to adults [31, 32], have a larger surface area per 
kilogram of body weight than adults [26], and have a higher minute ventilation rate [33]. 
Young children are also predominantly oral breathers, this means that the nasal filters are 
bypassed so a variety of pollutants can then enter the lower airways [34]. All of these 
factors make children more vulnerable and susceptible to the harmful effects of pollutants.  
 
It is understood that lifestyle can impact on a person’s respiratory health; nutritional 
deficiencies can impact lung growth, increase the risk of infections and decrease 
inflammatory control [35, 36]. Each respiratory disease has further risk factors that 
contribute to their incidence and prevalence [37]. Risk factors are classified as any attribute, 
characteristic or exposure of an individual that increases their chances of developing a 
disease or injury [38, 39]. In children, different respiratory diseases affect children at 
different ages; from bronchiolitis when an infant [40], to acute lower respiratory infections 
when a child [41], to asthma that can occur at any age [42]. Specific respiratory diseases, 
acute lower respiratory infection, asthma, and croup in children are described in the 
following sections.  
 
1.2.1 Lower Respiratory Tract Infections  
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Acute lower respiratory infection (ALRI) is a broad term that covers a range of diseases, it is 
defined in the international classification of diseases as infections that manifest below the 
epiglottis [43, 44]. The majority of study definitions are based on signs, such as tachypnoea, 
difficulty breathing, chest wall indrawing, and abnormal auscultatory findings [45]. ALRI is a 
major cause of morbidity and mortality worldwide [46]. It is in the top three most frequent 
causes of mortality worldwide in children [10]. Globally, it accounts for one in five deaths in 
children below the age of five, in developing countries it is one of the largest causes of 
death in this age group [47-50]. In the past decade the admissions rates in England for 
children under the age of 15 years who were diagnosed with an ALRI has increased by 40% 
[51]. This is set to only increase if modifiable risk factors are not monitored and controlled. 
Risk factors for ALRI’s are numerous with key factors being malnutrition, exposure to wood 
smoke, low birth weight, second hand smoke and ambient air pollution [49, 52-55]. The 
burden of disease in disability adjusted life years (DALYs) for ALRI in children under the age 
of five that is attributable to the environment is 57% [56]. ALRI’s can be sub divided into 
further diseases, including bronchiolitis and pneumonia, often based on differentiation by 
pathogen [44]. Bronchiolitis and pneumonia are described in further detail in the following 
sections.  
 
1.2.1.1 Bronchiolitis  
 
Bronchiolitis is a respiratory infection that occurs in infancy, it has a high prevalence in the 
first year of life [57-59]. It is predominantly caused by the pathogen respiratory syncytial 
virus (RSV), responsible for approximately 80% of cases [60], although there are many other 
viral pathogens that cause bronchiolitis [40, 61]. The majority of children will contract 
bronchiolitis during their early years, however not all children who have bronchiolitis 
require intervention by healthcare professionals. Only 2-3% of children are admitted to 
hospital [59, 62, 63], with 2-6% of those admitted needing intensive care [62, 64, 65]. 
However, the high prevalence of the illness means that infants represent a significant 
proportion of overall paediatric admissions. Bronchiolitis accounts for 18% of all hospital 
admissions in children less than one year in the United States (US) [66], while in England, 
between 2004 and 2012 bronchiolitis counted for 11.8% of all intensive care admissions in 
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children less than one year old [67]. The healthcare utilisation burden for bronchiolitis is 
therefore high [67, 68]. As bronchiolitis is more prevalent during particular seasons 
depending on geographical location, the burden is not spread across the year but causes a 
marked seasonal impact on healthcare resources [67].  
 
There are known risk factors that contribute to an infant being at a higher risk of requiring 
hospitalisation for bronchiolitis; low birth weight [69], exposure to smoke [70], history of 
atopy [71], and co-morbidities (e.g. congenital heart disease) [72]. However, 50-80% of 
emergency admissions that occur globally are in full term healthy infants [73, 74]. Another 
risk factor is a child’s socioeconomic status. This risk factor has been seen in developed 
countries between areas of different socioeconomic status, with higher rates of admissions 
for bronchiolitis seen in England in areas of low socio-economic status. The greatest 
proportion of deaths related to RSV associated respiratory infections in children younger 
than five years is from low income countries [75, 76]. Other variables, such as 
environmental pollution, may contribute to bronchiolitis as well.  
 
1.2.1.2 Pneumonia  
 
Pneumonia is one of the most common infections in the paediatric cohort [77], particularly 
in low and middle income countries. It is a leading cause of mortality in children, particularly 
those under the age of five years where it contributes to 15% of childhood mortality causes 
[30]. In developing countries it counts for a large proportion of avoidable deaths [78]. 
Pneumonia is an acute infection due to viral, bacterial or fungal infections, causing alveoli 
function to be affected by pus and fluid (pneumonia fact sheet). There is no standard 
definition, clinical diagnosis varies between developed and developing countries based on 
healthcare resources available, such as chest radiographs, and physician judgement [79]. 
Not all clinical cases of pneumonia result in an hospitalisation, however, 12% of cases 
worldwide do progress to severe requiring hospitalisation [80]. Of the 120 million episodes 
of pneumonia worldwide that occur in children less than five years old, 14 million will 
progress to severe episodes that require hospitalisation, and 1.3 million deaths [80]. The 
development of pneumonia is multifactorial with the pathogen, the host, and 
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environmental factors contributing to the disease [78]. Numerous risk factors increase the 
probability of severe pneumonia; age less than six months, nutrition and diet, and indoor air 
pollution [41, 81, 82]. Indoor air pollution has been shown to increase the incidence of 
severity and mortality [83] and the effect of outdoor air pollution is understood for 
mortality [30].  
 
1.2.2 Asthma 
 
Asthma affects 334 million people worldwide [84], it is one of the most common chronic 
diseases in children globally [42]. Asthma is most common in children under the age of ten 
years old [84]. It is caused by eosinophilic activity and inflammation of the airways due to 
airway hyperresponsiveness from atopic or non-atopic triggers [85, 86]. Hospitalisation from 
asthma occurs when a child’s asthma is exacerbated by a known trigger causing a severe 
symptomatic response [87]. There are known risk factors for the development of asthma; 
exposure to smoke, genetics, family history of atopy, environmental factors, and diet and 
nutrition [88, 89]. Environmental factors, such as air pollution have both been shown in 
studies to have a positive association with the development of asthma [34, 88, 90, 91]. 
Triggers for asthma exacerbation are varied and dependent on the individual person with 
the disease. Asthma has been shown to be aggravated by dust [92], allergens [93], and 
other environmental factors such as thunderstorms [94]. Air pollution has been shown to be 
another factor to aggravate asthma, studies showed that high exposure levels can increase 
the rate of emergency room visits and the use of asthma medication compared to other 
times [95].  Systematic reviews researching the effect of air pollution on asthma 
exacerbations have been undertaken, with evidence showing an increased risk of asthma 
exacerbations [96, 97].   
 
 
1.2.3 Croup  
 
Croup is a respiratory disease that often affects children aged between six months to three 
years [98]. It is most commonly caused by the parainfluenza virus [60, 99]. In the USA, it 
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annually affects 3% of children under the age of three years, with five per cent of 
emergency admissions in children under six years old being attributed to the disease in the 
USA and Canada [98]. Globally, the annual incidence rate ranged from 1.5% to 6% in 
children less than six years old [99-101]. The global hospitalisation rate for patients with 
croup is between 1.3% to 2.6% [101, 102]. The majority of croup symptoms resolves within 
48 hours, with mortality being rare. However, severe croup can lead to respiratory failure 
and ultimately respiratory arrest [98]. The viral pathogen leads to inflammation and oedema 
in the upper airways as well as increased production of laryngeal mucosa, this can lead to 
blockages of the airways causing respiratory distress [98, 103]. Risk factors for croup are not 
completely clear, it has been associated with gender, boys being at greater risk of 
developing croup [104], as well as history of croup in the siblings [105].  
 
1.3 Pollution  
 
 Pollution is defined as material that is unwanted, and possibly dangerous that has been 
introduced into the environment by human activity [106]. It has been highlighted as an 
important environmental hazard that needs to be addressed worldwide, although is 
currently undervalued [107]. Pollution can be broken down into subsections depending on 
the environmental material; air, water, or soil [108]. With air pollution, this is further 
subdivided into indoor and ambient (outdoor sources) pollution, however a lot of hazardous 
materials overlap between the two sub sections, such as particulate matter [109-114]. 
There are six main pollutants that are recognised to contribute to pollution [14, 115, 116]. 
They are particulate matter; diameter less than 10 micrometres (PM10) and diameter less 
than 2.5 micrometres (PM2.5), and gaseous pollutants; nitrogen dioxide (NO2), sulphur 
dioxide (SO2), carbon monoxide (CO), and ozone (O3). These are included in the 
recommended guidelines from the World Health Organisation (WHO) that countries and 
cities should follow [13, 14], see Table 1.  
 
Sources for the ambient air pollutants are interlinked between all, thus reduction in all 
sources will have wide reaching effects [13, 14, 30, 117], see figure 1.   
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Table 1. WHO ambient air pollutant recommended concentration levels for the six main pollutants [13, 14] 
 
 
 
  
 WHO ambient exposure 
threshold  
Particulate Matter diameter <2.5μm 
(PM2.5) 
 
10 μg/m3 annual mean 
25 μg/m3 24 hour mean 
Particulate Matter diameter <10μm 
(PM10) 
 
20 μg/m3 annual mean 
50 μg/m3 24 hour mean 
Nitrogen Dioxide (NO2) 40 μg/m3 annual mean 
200 μg/m3 1 hour mean 
Sulphur Dioxide ( SO2) 20 μg/m3 24 hour mean 
500 μg/m3 10 minute mean 
Carbon Monoxide (CO) 10 mg/m3 8 hour mean 
Ozone ( O3) 100 μg/m3 8 hour mean 
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Figure 1. Major sources of production of each of the six ambient air pollutants [13, 14, 30, 114] 
 PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm, NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: ozone 
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With indoor air pollutants, a wide range of sources cause harmful effects; household 
combustion, mould, dust mites, wood burning smoke and volatile organic compounds [118-
120]. The effect of household fuel combustion have been highlighted to have harmful 
effects by WHO, in 2012 an estimated 4.3 million premature deaths were associated [120]. 
Indoor air pollution affects those in lower income and rural areas more, as concentration 
levels are higher [121]. The effects of indoor air pollution are particularly seen in Asian and 
African nations due to solid fuel cooking and limited ventilation methods [83, 110]. 
Exposure to indoor pollutants increases the risk of an adverse health event and mortality for 
an estimated three billion people [121]. Although, mortality rates are substantial, numbers 
have remained consistent between 2013 and 2015 [3], unlike ambient air pollution.  
 
No country is unaffected by ambient air pollution [122]. Currently, the WHO ambient air 
pollutant guidelines are exceeded in cities worldwide; 98% of cities in low and middle 
income countries and 56% of cities in high income countries [123]. This means that an 
estimated 80% of the world population are exposed to levels above the guidelines that may 
be harmful to their health [123]. For particulate matter pollution a substantial number of 
children live in areas that exceed the international recommended levels [124], shown in 
figure 2, with 300 million children residing in areas exceeding levels by six times the 
recommended WHO threshold [124]. The highest levels of particulate matter were noted to 
be in South-East Asian countries, normally exceeding thresholds by five to ten times [125]. 
Recently, China has been making a conscious effort to address this issue [126, 127], in 2015 
roughly 17% of all deaths in China were linked to air pollution [128]. The high levels of air 
pollution experienced by China is due to increased coal consumption, vehicle usage and 
industrial dust production from rapid urbanization that has occurred in the past several 
decades [129].  India is another low performing country for air pollution threshold 
adherence [30], and only increasing in concentration levels. Some nations that do not 
recognise air pollution as a significant problem [107, 130, 131], thus effort to decrease 
exposure levels does not occur. Concentration levels have improved in North America and 
Europe, but even in these areas places still experience levels exceeding the guidelines [30]. 
With new environmental regulations and the use of new technologies, the possibility of 
decreases in concentration levels may occur [30, 132].  
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Figure 2. World map showing number of children living in areas exceeding international ambient air limits [121]  
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The driving forces of air pollution continue to be economic development, urbanization, 
energy consumption, transportation and vehicle usage [133]. WHO estimated that urban 
outdoor air pollution has increased by eight per cent from 2008 to 2013 alone [134], and 
levels are continuing to rise. It is estimated that two thirds of the world population are 
expected to live in an urban area by 2050 [30]. However, monitoring of air pollution levels is 
varied worldwide, low socio-economic and rural areas have the lowest number of monitors. 
In Africa, the air monitoring is sparse at ground level so it is difficult to estimate the exact 
levels of air pollution and thus their effect on the population [30]. This could mean that 
current effect estimates are understated.    
 
Indoor and outdoor pollution are estimated to be responsible for around 6.5 million deaths 
worldwide, with a larger proportion being associated with outdoor air pollution [37, 49, 
135]. Outdoor air pollution was responsible for around 3.7 million deaths in 2012 according 
to WHO, with 127,000 being in children under the age of five [121, 136, 137]. Compared to 
estimates from the Global Burden of Disease study in 2015, 4.2 million deaths [37], there 
has been a considerable increase in mortality numbers. Air pollution has been shown to be 
linked with one out of every eight deaths globally [15]. Estimated childhood mortality 
numbers for different areas worldwide due to ambient air pollution is shown in figure 3 
[125].  There has been evidence to show that short-term exposure to ambient air pollution 
has a known effect on cardiovascular disease [138-142], and all-cause mortality for long-
term exposure [143]. The current 2005 air quality guidelines are currently under review with 
a new set to be released in 2020 [136]. Until then, pollution remains a major problem that 
needs to be addressed and will continue to pose a risk to morbidity and mortality.  
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Figure 3. Estimate of overall mortality in children aged 0-18yrs, including children aged 0-5yrs associated with ambient air pollution exposure [122] 
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1.3.1 Particulate matter  
 
Particulate matter is formed of a mixture of small particles and liquid droplets [144]. These 
consist of sulfates, nitrates, ammonia, sodium chloride, black carbon, and soil or dust 
particles [30]. The majority is formed from fossil fuel emissions from industrial combustion 
and from traffic related emissions, particularly diesel car emissions [14]. Particulate matter 
is further subdivided into the size of the particles and where they deposit within airways 
[145]. The size of particles determines the duration of stay in the atmosphere, along with 
the exposure window [145]. This can help to determine the effects particulate matter 
particles may have on the respiratory system and subsequently respiratory disease. Fine 
particles, those with a diameter less than 2.5m (PM2.5), have been shown to penetrate 
deep inside the lungs and even enter a person’s blood stream [30]. In mice, particulate 
matter has been shown to cause considerable pulmonary damage [146]. Particulate matter 
can trigger the oxidative pathway and inflammatory response in the respiratory system 
[147, 148]. Particulates have been thought to exacerbate existing respiratory disease, impair 
pulmonary mechanisms [133], and with long-term exposure lead to airway remodelling and 
chronic inflammation [149].  
 
The effect of particulate matter on health is similar in both developed and developing 
countries [133], although different areas have high exposure levels for varying diameter 
sizes. For particulate matter with a diameter less than 10m (PM10) the highest levels are 
shown in Asia, Africa and Latin America [133]. PM10 has been shown worldwide by WHO to 
increase mortality for all ages (OR 1.006(1.004-1.008)) [150, 151]. For exposure to PM2.5, 
WHO has estimated that it contributes to 800,000 premature deaths per year [152]. The 
majority of interest analysing the effect of particulate matter has been focused on the 
cardiovascular system with links shown with both short and long-term exposure [153, 154]. 
Related to the respiratory system, along-term study in children has shown that those 
exposed to high levels were at an increased likelihood of having a low FEV1 compared to 
those in low concentration level [155]. Another study has shown that those in high areas of 
particulate matter exposure have decreased lung function growth [156]. For PM10 exposure 
increases in respiratory hospital admissions have been seen at concentrations rise [157, 
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158]. When you combine this with the knowledge that two billion children live in areas that 
exceed the current WHO guidelines for particulate matter [30], the effect that particulate 
matter may have on children is significant.  
 
1.3.2 Nitrogen dioxide  
 
Nitrogen dioxide (NO2) is a gaseous pollutant that is mainly associated with traffic-related 
pollution [159], but other sources contribute as well such as industrial combustion [160]. 
Concentrations of NO2 may vary daily within a city, as well as average concentrations 
varying from distance from major roads [14]. NO2 promotes the release of inflammatory 
mediators in a person [161], effecting the lungs due to oxidative and immune modulatory 
responses [162]. This causes irritation in the lungs increasing bronchial reactivity and 
susceptibility to infections and allergens [14, 163, 164]. Daily concentrations of NO2 have 
been shown to increase all-cause mortality and specifically respiratory mortality [165]. In a 
European study, a 1.3% increase in daily mortality rates was seen for each increase of 
50mg/m3 of NO2 [166]. Furthermore, NO2 exposure has been associated with asthma 
hospital admissions [167], and in panel studies in asthmatic children it has been shown to 
have an effect on the incidence of viral infections [168].  
 
1.3.3 Sulfur Dioxide 
 
Sulfur dioxide (SO2) is a colourless gas, with the majority produced when sulphur containing 
coal and oil is burned as fossil fuel or during the smelting of mineral ores [169]. In Australia, 
99% of SO2 in the air is from these human sources [169], this is similar to the other 
countries. Natural sources that produce SO2 are volcanoes and the oceans, however, this 
accounts for a small part, around two per cent, of the overall production of SO2 [170]. 
Although, there has been a decrease in SO2 levels around the world, particularly in the USA 
and Europe [171], due to legislation tackling fossil fuel combustion, about 15% of cities in 
the WHO data between 2000 and 2005 still exceed SO2 guidelines [14]. It has been shown in 
studies that SO2 is linked with all cause respiratory and cardiovascular mortality [172]. When 
examining hospital admissions, cardiovascular disease admissions are significantly increased 
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by short-term exposure to SO2 in adults [173, 174]. It has been shown to have an association 
with all respiratory hospital admissions [150], particularly in asthmatics [175]. This may be 
due to the effect that SO2 has on the respiratory system by acting as an irritant on the 
airways, promoting airway inflammation, inducing bronchospasm, and leading to airway 
fibrosis [14, 163, 164, 176]. This causes coughing, mucus secretion, aggravation of asthma, 
and chronic bronchitis [177]. In children, these effects may contribute to their likelihood of 
needing hospital admission when experiencing a respiratory disease.  
 
1.3.4 Carbon Monoxide 
 
Carbon monoxide (CO) is a colourless, odourless gas that is mainly produced in urban areas 
that experience heavy traffic [178, 179]. It is a product of incomplete fuel combustion 
produced by vehicular emissions [170]. CO has been shown to effect both cardiovascular 
and respiratory diseases in all age groups. In adults, short-term exposure has been shown to 
have effects on both cardiovascular mortality [180], and hospital admissions for 
cardiovascular disease [181]. When examining the effects of CO on the respiratory system, 
there is less evidence available. Studies have shown that short-term exposure effects the 
paediatric asthmatic cohort [182], with increases in asthma visits and decrease in lung 
function in this sub-group [183]. For the whole population, when examining emergency 
room department visits CO was associated with an increase in visits for upper respiratory 
tract infections [184]. CO affects a person’s body by interfering with oxygen’s ability to bind 
to haemoglobin, therefore affecting oxygen transport and reducing oxygen availability to 
organs [163, 164]. These could have an effect on respiratory diseases particularly in 
children. 
 
 
1.3.5 Ozone 
 
Ozone (O3) is formed by a photochemical reaction in the atmosphere involving sunlight, 
nitrogen oxides and volatile organic compounds [26, 30]. The O3 produced is different from 
atmospheric O3 as refers to ground level O3. Due to O3 not being directly produced from 
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pollutant sources like the other major pollutants, there has been shown to have strong 
seasonal variation in levels [185]. This pollutant has been shown to have an effect on cardio 
and respiratory mortality in urban USA communities, increasing mortality by 0.64% for each 
increase of 20mg/m3 [186]. It has been shown that the effect of O3 on respiratory hospital 
admissions is higher in the warmer seasons [133], this highlights the seasonal variation that 
occurs. Short term exposure to O3 has been shown to increase emergency department visits 
in Californian residents for asthma, acute respiratory infections, pneumonia and upper 
respiratory tract infections, with results being larger in the warm season [187]. Also, chronic 
exposure to ozone has been indicated to decrease lung function in young adults [188]. It has 
been thought that O3 is a powerful respiratory irritant that induces respiratory tract mucosal 
inflammations, damage the epithelium lining the airways [163, 164]. This can lead to 
shortness of breath, chest pain, wheezing, coughing, and exacerbation of respiratory 
illnesses [14, 30, 161]. Thus, examining the effect that ozone has on healthcare resource 
utilisation in children who suffer from respiratory disease is important. 
 
1.3.6 Pollution and respiratory disease 
 
A third of all disease in children has been attributed to modifiable environmental factors 
such as water quality, sanitation, exposures to chemical and air quality [11]. The Committee 
on Environment Health of American Academy of Paediatrics stated in 2004 that there is a 
link between ambient air pollution and children’s health [33]. In children an association 
between exposure to air pollutants and morbidity [189, 190], and mortality [191, 192] has 
been highlighted. The 2018 environmental performance index stated that poor air quality is 
one of the greatest threats to public health [193], with the Organization for Economic Co-
operation and Development (OECD) estimating that ambient air pollution will become the 
greatest cause of environmental related child death by 2050 [194]. The WHO air quality 
guidelines were produced to provide international reference for levels that cause adverse 
effects on human health [133], however, they may be out of date in the current 
environment if updated figures and evidence are to be trusted.  
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Respiratory diseases and air pollution have been found to have a close relationship 
worldwide [195-202]. Along with the hazardous effects that ambient air pollution has, 
especially on the oxidant pathways in the lungs [203, 204], the age of the child at the time 
of exposure to inhaled pollutants plays a major role in the pattern of the injury [205], with 
younger children being more susceptible to the effects. Even when examining adults, 
ambient air pollution has been linked to occurrence and exacerbations of respiratory 
diseases, particularly chronic obstructive pulmonary disease (COPD) and lung cancer [206-
209]. Reducing air pollution has been shown to lead to improvements in children’s 
respiratory health [156, 210, 211].  In the USA, children who relocated to areas of lower 
levels of ambient PM10 had an increase in their lung function compared to those still 
residing in high levels of pollution [156]. Lung capacity has been highlighted to reduce by an 
estimated 20% if children reside in highly polluted environments [212]. This can lead to 
respiratory problems later on it life, especially if chronically exposed to pollutants [213, 
214].  Air pollution has been linked to respiratory diseases such as asthma, bronchitis and 
wheezing [30, 34, 215-219]. Ambient air pollution has been associated in both asthmatic 
[220] and non-asthmatic [221] children when it comes to adverse respiratory effects. 
Although in some studies increases in morbidity or mortality related to respiratory disease 
have been small when extrapolated to a worldwide scale then the public health concerns 
are significant  [133, 222]. One way to help reduce the effects of air pollution is to increase 
the monitoring systems available at local and national levels to emphasise the effect air 
pollution can have on the population [30]. Reducing air pollution is a target of the 
sustainable development goals (SDG) [30, 223], which replaced the millennium 
development goals (MDGs). Thus, the targets will hopefully help force governments and 
policy makers to recognise the hazardous effects pollution has on respiratory health.  
1.3.7 Pollution and inequalities 
 
Air pollution is a global problem, yet, there is a difference in how it effects countries. 
Outdoor air pollution is an issue that needs to be resolved across all countries regardless of 
income, as each country contributes to the hazardous effects it has on the population [136]. 
This struggle is not one that will be solved quickly but is a long-term task for all [224-226]. 
The most susceptible groups of the population at risk are children, the elderly and those in 
low socioeconomic status (SES) countries [133].  Air pollution levels have been decreasing 
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particularly in developed countries due to the implementation of pollution management 
controls and legislation, yet, developing countries are undergoing a transitional period of 
development with their concentration levels rising [133], particularly with traffic pollutants 
[227, 228]. However even with the improvement seen in developed countries, a large 
proportion still have high concentration levels [134]. These numbers highlight the 
considerable problem that remains with air pollution levels and production.   
 
When examining the effect of those in low or middle income countries the disproportionate 
burden experienced by this population is high, with 90% of deaths from outdoor air 
pollution occurring in these countries [136]. When the effect is further analysed for 
children, those in low and middle income countries contribute to 88% of all deaths from 
illnesses that are associated with outdoor air pollution [136]. With the vast bulk of the total 
deaths occurring in Asia, although, the proportion of deaths from Africa is increasing [30, 
229]. Furthermore, the Global Burden of Disease estimated that in children less than five 
years old who reside in low and middle-income countries the likelihood of dying from 
exposure to air pollution is increased by 60% [37]. It is not just children in low and middle 
income countries that are most likely to be affected but even in developed countries the 
lower income areas is where exposure to pollutants is highest [230]. Thus, overall poorer 
children are more likely to be affected by air pollution. It has been shown in studies that 
children who live in areas where pollution levels are high regardless of country are 
disproportionately from poorer communities [231, 232]. In the USA, air pollution has been 
shown to be higher in non-white and low income neighbourhoods [233, 234]. An example is 
in South Bronx in New York City which is known to be a lower income community, here 
asthma rates are four times higher than the national average  [235]. Emphasising the 
disparity between populations and that concentration needs to be focussed on areas that 
are poorer as they are at greater risk of the hazardous effects of air pollution, as 
concentration levels are known to be high [236].  
 
1.3.8 Pollution and Regulations  
 
Air pollution episodes have occurred in the United Kingdom (UK) since the early 17th century 
when industrialisation started. However, increased concern in this area has led to new 
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legislation being implemented in the past century to limit the harmful effects from 
pollution. For the UK, some of the first legislation that was implemented occurred in 1956, 
being updated in 1968, was the Clean Air Act [237].  This has since been replaced by the Air 
Quality Strategy, but this is now out of date [238, 239]. For the USA, the Clean Air Act, was 
one of the first environmental laws, it set limits for the major pollutants and stated that 
violations would be penalised [240-242]. Legislation has been shown to work in other 
environmental areas, such as smoking exposure, where it has had a positive health benefit. 
The smoke-free legislation in the UK has shown that since the ban a reduction in childhood 
asthma has occurred, with at least a 10% decrease in hospital visits for children [243]. This 
highlights the importance of implementing further legislation in areas of air pollution, as 
current legislation in areas of the world have not reduced the harmful effects of pollution so 
far. By highlighting these hazardous effects that air pollution has on child health, it could 
highlight to policy makers the need for better, updated legislation.  
 
 
 
1.4 Epidemiological study designs  
 
Numerous study designs have been applied in epidemiological research to assess exposure 
of air pollution and adverse health effects [133]. Each has the ability to assess either short 
or long-term exposure in the population. For short-term exposure, some study designs used 
are time series, case-crossover or panel studies. Whereas for long-term exposure, cohort 
studies are used the majority of the time.  
 
The time series study design involves estimating the influence of temporal variations via 
statistical models, and assesses changes in health events in a geographically defined 
population using air pollution measurements [244]. The majority of evidence has been 
generated using this method. Increases in availability of health record data, usually 
computerised, and air pollution measurements has helped facilitate the use [245]. 
Additionally, substantial developments in statistical analysis has helped to control for 
confounding factors, such as weather and seasonality [246]. Flexible smoothing techniques, 
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such as generalised additive models (GAM) help adjust for confounders. The use of locally 
weighted scatterplot smoothing (LOESS) or degrees of freedom need to be applied 
depending on the time span examined, helping to adjust for non-linear regression [246, 
247]. There are disadvantages of this design, due to the use of computerised data for health 
records there is reporting bias as variation in judgement may occur in diagnosis, recording 
or reporting of diseases, introducing variability. The advantages of this method are that 
socio-economic conditions, occupation, tobacco smoke exposure cannot confound 
relationships, and there is reduced cost involved due to data readily available.  
 
Another study design, case-crossover, is based on the case-control design where cases act 
as their own control [248]. Risk estimates are based on within subject comparisons to 
exposure at the time of effect with exposure periods before or after the event [248]. This 
design is used for recent exposure as otherwise there is the possibility of increased risk of 
carry-over effects causing bias. Disadvantages of this design revolve around the inability to 
control for changes in characteristics over time, it’s less precise than a time series analysis, 
and is not suitable for cumulative effect estimation [246]. The advantages are that cases act 
as their own control, so remove subject specific confounders, it’s relatively easy to 
implement, and if performed bi-directionally can control for time trends [14].   
 
Panel studies are an alternative design methodology for short-term exposure assessment, 
they allow outcomes to be explored in susceptible populations [14]. Participants are 
followed up prospectively for a short time period, multiple measurements are obtained 
from each subject at various intervals [249]. The benefit of this design is the ability to obtain 
health and exposure information from individuals, with the possibility of using personal 
monitors due to small sample sizes [14]. This design requires covariates across time to be 
controlled for in analysis [250].  
 
For long-term exposure, the majority of evidence uses cohort studies that can provide larger 
estimates of pollution effects than time series. Cohort studies are able to compare chronic 
health effects in people residing in different geographical locations [244]. A key feature to 
confound for variables that may interfere with estimates is based on the availability of 
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individual information, such as smoking and occupation. Disadvantages of cohort studies are 
the high cost of implementation, the logistical difficulties, and follow up can result in losses.  
  
It is difficult to determine which study design is best as the majority can provide reasonable 
estimates of risk for short-term exposure or long-term exposure.  
 
1.5 Asthma and pharmacogenomics 
 
Analysing the effects of the environment is only one component of respiratory diseases, 
other factors influence the natural history of diseases and their management. A key part of 
treatment for respiratory disease is the use of pharmacotherapy. Respiratory medications 
are commonly prescribed in the paediatric population [251]. The exposure level to 
respiratory medication is largest in early childhood. Anti-asthmatic medication accounts for 
a large proportion of prescribed medication in children, in a Danish cohort study a third of 
young children received anti-asthmatic medication [251]. In another cohort study, the 
prevalence rate for asthma medication for children under 14 years old was 22.6% [252]. The 
use of medication to help alleviate or control a child’s asthma is common. Depending on a 
child’s severity of disease and age, the exact medication used varies according to the 
treatment steps [253]. Even with the recommended international treatment pattern there is 
variation between patients [254, 255].  
 
ADRs are a substantial health risk to children. The WHO database between 1995-2005 
reported that 11% of all ADR’s reports in children were due to respiratory medications 
[256]. ADR’s have previously been reported in children in systematic reviews [257-259], 
where they have been highlighted as a considerable issue on healthcare resources and 
hospital admission rates. In children, hospitalisation rates due to ADR’s have been shown to 
range from 0.4% to 10.3% [260]. With asthma medications in children ADRs can have a 
greater effect due to children still developing than in adults, such as growth restriction when 
on corticosteroids [261].  
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The discipline of pharmacogenomics is an increasingly recognised area when it comes to 
medication efficacy and toxicity, it refers to the effect of genetic variation on a drug’s effects 
on the patient [20, 262, 263]. It has been shown that a person’s genotype can influence the 
efficacy of asthma medication [264]. The beta 2 adrenoreceptor (ADRB2) has been shown at 
the single nucleotide polymorphism (SNP) rs1042713 to show varied outcomes to beta 2 
agonists when it came to pulmonary function responsiveness [265]. With ADRs, these 
reactions had previously been considered to be difficult to predict in individuals, however, 
the application of pharmacogenomics may now allow this [266]. In a recent study, ADRs in 
inhaled corticosteroids were examined in the childhood population, with adrenal 
suppression found in a specific sub group of patients [267].  
 
Asthma requires long-term management, with the use of pharmacotherapy being one of the 
components needed. The need to balance between efficacy and toxicity when it comes to 
medication use is an important factor to consider. By using pharmacogenomics to 
understand an individual’s risk of ADRs, it is possible to only prescribe medication to those 
who are least at risk of an ADR [268]. Identifying these susceptible groups will then 
contribute to healthcare professionals being able to personalise treatment plans for 
patients.  
 
Pharmacogenomic studies have the opportunity of being randomised controlled trials, a 
high standard for evaluating relations in research [269]. However, cohort studies are also 
known to be used due to their lower cost, wider range of patients that can be entered due 
to looking for certain outcomes that may have already happened and quicker timing [270]. 
Cohort studies are useful to look for rare events, which would require large sample sizes 
that are not possible except as a cohort study. Both types of studies can be assessed to 
determine likelihood of bias of results [271, 272] and thus determine the usefulness of 
conclusions.  
 
1.5 Systematic reviews 
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Systematic reviews are a useful tool to help synthesise evidence, particularly in healthcare 
[24]. They are increasing in practice due to their methodological rigor and effectiveness in 
reducing bias when performed correctly [24]. Systematic reviews should be based on pre-
defined eligibility criteria along with a methodical protocol that has been pre-designed [24]. 
This ensures that the review has been carefully considered, promoting consistency, 
transparency and holding the review team to accountability for the process [24].  The 
conclusions and decisions gathered from systematic reviews can be made and then 
undertaken due to the reliability of the findings if performed robustly [273, 274]. The use of 
overviews of systematic reviews allows authors to combine multiple systematic reviews that 
have been performed and assess the results in a methodological manner, increasing the 
chance of forming reliable results for decisions to be formed from. These methods have 
been undertaken in this thesis to analyse the current evidence for both air pollution and 
pharmacogenomics.  
 
 
1.6 Conclusion 
 
Respiratory diseases are complex, with multiple factors influencing disease and patient 
outcomes. Understanding these factors is vital in helping to improve respiratory health in 
the population, particularly for children who are at increased susceptibility to certain 
elements.  Various environmental parts are understood to affect the risk of respiratory 
outcomes, one of which is ambient air pollution. The current understanding of ambient air 
pollution in children identifies that it has hazardous effects on mortality, however, it fails to 
recognise and quantify the importance when it comes to healthcare utilisations, such as 
hospital admissions. The susceptibility of children to ambient air pollution requires further 
in depth analysis and understanding to see if the current WHO air quality guidelines [13, 14] 
have low enough thresholds, and if current legislation in countries is acceptable to prevent 
adverse health outcomes. In addition to understanding air pollution, other variables that 
affect respiratory disease outcomes need to be tackled. Respiratory medication is 
commonly prescribed in children, especially anti-asthmatics [251], to help manage 
respiratory diseases. The use of anti-asthmatics accounts for a large proportion of 
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medication prescribed [251]. With asthma medication the discipline of pharmacogenomics 
has identified that medication efficacy is affected by a person’s genotype, supporting the 
interindividual variation seen in patients on the same medication. Although efficacy has 
been shown, the identification of susceptibility to ADRs is still in progress. The use of 
systematic reviews in these areas will collaborate the current knowledge available. This can 
then help form conclusions about both ambient air pollution and respiratory health in 
children, as well as pharmacogenomics relating to ADRs in asthma medications. These 
variables then may be able to help reduce the burden of respiratory diseases on healthcare 
and in individuals.  
 
 
1.7 Aims 
 
The aim of this thesis is to improve the understanding of how the environment and 
genomics influences respiratory health in children. The systematic reviews undertaken, each 
contribute to this aim.  
 
Chapter two is aimed to systematically review the current literature relating to bronchiolitis 
hospital admissions and ambient air pollution. This is the first systematic review to be 
completed in this topic area and will help to contribute to the current evidence available in 
other respiratory diseases and ambient air pollution.   
 
An overview of systematic reviews is undertaken in chapter three, it aims to collaborate all 
current systematic reviews available to investigate the effect of ambient air pollution on all 
acute respiratory diseases in children. Due to the work carried out in chapter two, evidence 
highlighted the possible effect that current air pollution guidelines may not be sufficient to 
protect respiratory health in children. Therefore, the need to compare the results with other 
previously undertaken systematic reviews was needed. The main finding from this overview 
is the current evidence available for asthma exacerbations and the lack of evidence for 
other respiratory diseases.  
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Chapter four aims to examine the role of pharmacogenomics and ADRs in asthma 
medications. Secondly, it aims to undertake a survey to determine the priorities of future 
pharmacogenomic studies. This review highlighted the importance of recognising ADRs as 
an outcome that needs to be investigated in future studies.  
 
In chapter five, the outcomes from these reviews are discussed, where future directions 
should head and the relevance of the outcomes in clinical practice.   
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Chapter Two - The effect of outdoor air pollution on the risk of 
hospitalisation for bronchiolitis in infants: a systematic review 
 
2.1 Background  
 
Bronchiolitis is a common respiratory infection that affects children during infancy, with the 
majority contracting the disease within their first year of life [59], although can occur later. 
The majority of cases are due to the pathogen respiratory syncytial virus (RSV), responsible 
for between 43% to 80% of bronchiolitis cases [275-280]. Although other pathogens such as 
rhinovirus, parainfluenza, adenovirus and influenza can cause bronchiolitis, see table 2 [275] 
for main viral pathogens of bronchiolitis and approximate frequency.  
 
Table 2. Viruses detected in hospitalised children and approximate frequencies 
Virus Approximate frequency (%) 
Respiratory syncytial virus 43-80 
Human rhinovirus 5-25 
Parainfluenza virus 5-25 
Human metapneumovirus 5-10 
Coronavirus 5-10 
Adenovirus 5-10 
Influenza virus 1-5 
Enterovirus 1-5 
 
RSV, spread through close contact via droplet transmission [281], causes bronchial  cell 
necrosis, airway inflammation, destruction of ciliated epithelial cells and infiltration by 
lymphocytes [275, 281]. This leads to small airway obstruction due to mucus and oedema of 
the airway, as well as bronchospasm [275]. Bronchiolitis is usually mild and self-limiting in 
children [74], manifesting as coryzal symptoms two to three days before the development 
of a cough, wheeze, tachypnoea, increased work of breathing, and hypoxia [282, 283]. 
Hospitalisation from bronchiolitis usually occurs in severe cases, when respiratory distress 
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may be present [283]. Admissions due to bronchiolitis account for a third of all hospital 
admissions in infants due to respiratory infections [284]. The disease is one of the major 
causes of hospital admission in both developed countries [66, 67, 282]and developing 
countries [285, 286] worldwide. In the past 30 years bronchiolitis admissions have increased 
from one per cent to three percent [282, 287, 288], increasing the burden on healthcare 
resources. In England, since the 1980s rates of bronchiolitis admissions have increased, 
particularly in industrialised areas [67]. When analysing between viral pathogens of 
bronchiolitis, cases due to RSV have been associated with longer hospital length stays, and 
increased risks of ICU admission compared to those with non-RSV bronchiolitis[61].  
 
Along with the viral pathogen contributing to severity of disease, there are known risk 
factors for severe disease that needs hospitalisation including those that affect structural 
and functional lung development or generate airway inflammation. Some of the risk factors 
include prematurity [40], low to very low birth weight [289], chronic lung disease or 
congenital heart disease [290], and tobacco smoke exposure [70]. However, in an English 
cohort study the majority of children admitted to hospital with bronchiolitis did not have 
any of the associated severe risk factors, with only 24% of children having a risk factor [74]. 
This has been shown in other studies looking at bronchiolitis admissions, with the majority 
having no risk factors but are usually healthy, full term infants [63].  
 
There is known seasonal variation with admission rates for bronchiolitis with peak seasons 
in most regions being during the winter [291], however, this does depend on geographical 
variation. In tropical and subtropical areas, bronchiolitis peaks occur in the cool, rainy 
season, whereas in regions below the equator peaks occur in the cool, dry months [292]. 
Along with seasonal variation, geographical variation occurs especially in areas of 
industrialisation [67] and deprivation [293]. This variation may also be linked to air pollution 
levels, as it is known that children from lower socioeconomic backgrounds and in areas of 
high urbanization are more effected [133]. As urbanization has increased in the last few 
decades and air pollution levels rise, the effect of air pollution on bronchiolitis admissions 
may become more apparent in evidence available. 
Air pollution is measured through various exposure lengths. Lag exposure refers to the time 
period from when a study participant is exposed to air pollution until when the end point is 
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measured. Bronchiolitis effects children at a very young age, thus their exposure to air 
pollution chronic lifetime exposure has been limited. Lag exposure in this systematic review 
refers to multiple different exposure lengths divided into acute, sub chronic and chronic 
exposure. For acute, lag exposure refers to the average air pollution exposure from the time 
of admission up to the previous seven days. Sub chronic lag exposure is when air pollution is 
measured from hospital admission up to one month before and averaged. Lastly, chronic 
exposure is the average lifetime air pollution exposure concentration from birth until 
hospital admission.  
 
This chapter describes a systematic review of studies that addresses the question of 
whether ambient air pollution effects bronchiolitis hospital admissions in infants.  
 
2.2 Aims 
 
The aim of this chapter is to identify studies that have analysed ambient air pollutant levels 
and bronchiolitis admissions in infants. A secondary aim is to assess whether the current 
WHO guidelines for ambient air pollutants are sufficiently low enough to protect children’s 
health related to bronchiolitis.  
 
2.3 Methods 
 
A protocol was written a priori and submitted to PROSPERO, see Appendix 1 for the 
submitted protocol. PROSPERO is an online registration database of prospective systematic 
reviews to help limit the reproduction of similar reviews by different research groups.  
 
2.3.1 Inclusion and exclusion criteria  
 
Studies that evaluated the impact of ambient air pollution levels (PM2.5, PM10, NO2, SO2, 
CO, and O3) on the pre-specified outcome in the protocol (risk of hospitalisation, excluding 
emergency department visits, with bronchiolitis) were eligible for inclusion. Studies had to 
be observational in design, thus were either cohort, time series, case-crossover, or case 
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control studies. This inclusion criteria was determined from a previous systematic review 
analysing the effect of air pollution and stroke [294].  
 
Studies were included that evaluated exposure to ambient air pollution at a time period 
(lag) before hospitalisation occurred and were categorised into acute exposure (less than 
seven days), sub-chronic exposure (one month prior to hospitalisation), and lifetime 
exposure (average daily exposure concentrations since birth to hospitalisation). Secondary 
outcomes that were examined included emergency department visits, critical care 
admission, length of stay and mortality.  
 
Studies were excluded for the following reasons.  
1) Evaluated the impact of ambient air pollution on more than one respiratory illness, such 
that bronchiolitis data could not be extrapolated.  
2) Looked at temporal associations between air pollution levels and number of hospitalisations 
for bronchiolitis in a particular region.  
3) If they examined pollutants that were not the six main ambient pollutants stated or 
commented on ambient air pollution levels as a general outcome with no specifics.  
 
2.3.2 Identification of relevant studies  
 
An array of electronic databases was searched to increase the likelihood of identifying 
eligible studies.  
 
The specific databases used in this systematic review were Medline, SCOPUS, and Web of 
Science. Medline is an online bibliographic database with access to 24 million references 
from 5,200 journals, specialised for life sciences and biomedicine [295]. It has articles 
available from 1966 to the present day [295]. SCOPUS is a databases of peer reviewed 
literature from scientific journals, books, and conferences [296]. Launched in 2004, it covers 
approximately 34,000 journals in the areas of life sciences, social sciences, physical sciences, 
and health sciences [296]. Web of Science, is a citation search database that covers articles 
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dating back to 1900 until present [297]. It covers the sciences, social sciences, arts and 
humanities with access to multiple databases [297].  
 
2.3.3 Design of search strategy  
 
The search strategy was constructed around the main concepts of the research question, 
with search terms modified to include synonyms and variations identified in previous 
publications [298].  The search strategies are shown in Appendix 2.  
 
The following search terms were used in the literature databases undertaken until 
November 2017 with no restriction placed on date or language of publication. The specific 
search terms “bronchiolitis”, “air pollution”, “particulate matter”, “nitrogen dioxide”, 
“sulphur dioxide”, “carbon monoxide”, “ozone”, and “infants” were used, these reflected 
the aim of the systematic review. Bronchiolitis can frequently be described by various 
terminology, these were included in order to capture all studies. Discussion with experts in 
the field of paediatric and respiratory research were consulted to insure all search terms 
had been identified.  
 
Synonyms within these words were combined using the Boolean operator OR, using this 
function allowed for any citations that had the key terms in their abstract, title or index 
words to be identified. Further synonyms were included using the MeSH function within 
Medline. To narrow the search results further the search terms were combined using the 
Boolean operator AND, so that studies with at least one key word from each section would 
be identified. As well as the use of synonyms, truncation was applied to increase the 
sensitivity of the search. The use of truncation, via the denotation of an asterix, identified 
various derivations of key words such as infan* would locate infancy, infant etc.  
 
Specific types of studies, “observational studies”, were not included in the search terms in 
order to prevent the reduction and exclusion of possible eligible evidence as they may not 
be included in the paper’s title, abstract or indexed words. Thus, preventing an overly 
precise search strategy.  
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2.3.4 Selecting eligible studies for inclusion  
 
Two independent reviewers (CK and IS) independently performed the screening process on 
the titles and abstracts, checking the eligibility of the results in accordance with the 
predetermined eligibility criteria. Full studies were examined by both reviewers to 
determine acceptability of inclusion in the review. From included studies, references and 
content were scanned for additional eligible studies.  
 
Disagreements between the two reviewers (CK and IS) were discussed to determine if an 
agreement could be reached, otherwise, a third reviewer (DH) assessed the information and 
formed a conclusion.  
 
2.3.5 Data extraction  
 
For each study the following information was extracted from eligible studies by one 
reviewer (CK), with queries discussed with the second reviewer (IS): 
 
1) Sample Size of Population and age range  
2) Odds ratio or relative risk of hospital admission for bronchiolitis  
3) Air pollutants mentioned and methodology of measuring pollution  
4) Time period of measured air pollution  
5) Level of air pollutants if reported 
 
2.3.6 Assessment of quality of studies  
 
The methodological quality of the included studies was assessed by CK, with it checked by a 
second reviewer. By assessing the quality of the studies, it allows the reviewers to 
determine the degree to which results from the literature are valid, and whether clinical 
implications can be determined.  
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The methods for quality review were dependent on the study design. For cohort and case 
control studies, the Newcastle-Ottawa scale has been formed as a tool for methodological 
appraisal [271]. This tool concentrates on a predetermined set of questions, with a star 
system developed for the tool, in addition a score out of nine at the end of the document 
depending on the results is given for studies. However, for time series and case-crossover 
study designs no specific quality tool exists to appraise them, thus, a modified Newcastle-
Ottawa scale was created. Based on the quality appraisal tools, an assessment of risk of bias 
was formed with those of high methodological quality or a score greater than seven on the 
Newcastle-Ottawa scale was considered to be of low risk of bias. 
  
 2.3.6.1 Development of assessment quality tool for time series and case crossover 
study designs 
 
Time series and case-crossover studies are similar to cohort studies, however, are designed 
so that cases act as their own control, therefore help to reduce confounding variables.  
 
Three main aspects were derived from the Newcastle-Ottawa scale and adapted to assess 
the quality of time series and case-crossover studies. These were selection bias and other 
quality criteria, exposure assessment, and adjustment for confounders. A score was not 
attributed to each area, rather a rating of low, medium or high methodological quality 
depending on information in the studies.  
 
For this review, selection bias and other quality criteria was assessed to be of high 
methodological quality if consecutive cases of hospital admission for bronchiolitis were 
included. If the cases had been identified from health records rather than parental recall. 
Studies were considered to be of higher quality when researchers had based the definition 
of bronchiolitis of the International Classification of Disease (ICD 9 or 10) criteria [43, 299, 
300], or had supplemented their clinical judgement of a bronchiolitis diagnosis with 
microbiological testing for RSV or the other infectious organisms. Also, studies were further 
classified as being of higher quality if infants included were less than two years old based on 
guidance by the National Institute for Health and Care Excellence (NICE) [58]. However, 
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studies were not excluded if the age of children was over the age of two years if they 
included a standard bronchiolitis definition.  
 
The other aspect examined in included studies was their exposure assessment of air 
pollution. From each study, the reported methodology was evaluated for how air pollutants 
were measured, specifically regarding the frequency of monitoring, the methodology of 
data collection and proximity of monitoring stations to participants. Studies were 
considered to be more systematically robust and thus of higher methodological quality if 
pollutants had been measured daily, measurements had been collected using standardised 
techniques, and monitors had been places within ten miles of a cases’ residence or the 
admitting hospital.  
 
The third area analysed in the modified quality assessment tool was adjustment for 
confounders. Adjustment for meteorological confounders (temperature, humidity etc), 
socioeconomic status, age and other clinical risk factors like maternal education and 
smoking were examined in each study. Studies were considered to be of high 
methodological quality if adjustment had occurred for at least two of these types of 
confounders. Due to the nature of time series and case crossover study designs age was 
already adjusted for as a confounding variable [248].  
 
2.3.7 Grading of evidence  
 
For acute, sub-chronic, and lifetime exposure to each pollutant, conclusions were 
formulated and evidence graded according to a strategy based on recommendations from 
the GRADE working group [301], such that each conclusion would be based on low, 
moderate or high quality of evidence as judged by two reviewers (CK and IS). The GRADE 
approach allows for a structured approach to be adopted when rating the quality of 
evidence so that recommendations can be formed in a systematic and transparent manner 
[302].  
 
Evidence was graded based on three main criteria; study design, inconsistency, and 
imprecision, with an overall grade then given. Evidence was considered to be low at the 
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beginning, as only observational studies were included. Evidence was further graded down 
if there were any studies in the analysis with one or more design limitations based on the 
assessment of methodological quality above and graded up if there were no flaws in the 
study’s methodology relevant to the analysis. Studies were considered to be further 
downgraded if there was inconsistency in results if there was wide variance across results, 
or if the results were conflicting. Evidence was further downgraded if there was imprecision 
in results with few patients, few outcomes and wide confidence intervals surrounding the 
effect estimate (odds ratio or relative risk). Specifically, evidence was downgraded if there 
were less than 5,000 infants in the studies and upgraded if more than 20,000 infants. 
Criteria surrounding indirectness was not included as this was covered in the quality 
assessment process. Publication bias was not formally assessed as there were too few 
studies to do this robustly  
 
2.3.8 Data analysis  
 
Meta-analysis was only considered to be undertaken in the presence of cohort studies, as 
they provide the strongest observational evidence in the absence of RCTs. Time series, case 
crossover studies and case control studies are reported descriptively, and results presented 
on forest plots without overall synthesis. This was undertaken due to the high levels of 
heterogeneity expected between studies. In addition, for each study the mean ambient 
pollutant value was compared with the recommended level by WHO.  
 
2.4 Results 
 
2.4.1 Study selection  
 
A total of 1253 studies were located from databases using the search criteria, of these 47 
studies were then assessed for full text eligibility, appendix 3 shows reasons for exclusion of 
papers. The remaining eight studies were then eligible for review. The review flowchart 
identifying the eligible studies is shown in Figure 4. 
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Figure 4. Review flowchart of included studies in systematic review of ambient air pollution and risk of 
hospitalisation with bronchiolitis  
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There were no cohort studies or time series studies identified from the eligible papers that 
analysed the effect of air pollution on risk of hospitalisation for bronchiolitis that matched 
the inclusion criteria. Thus, there was insufficient evidence to undertake a meta-analysis on 
the primary outcomes from the included studies, so results were reported descriptively.  
 
2.4.2 Quality of included studies  
 
Of the eight observational studies [303-310], four were case crossover studies and four case 
control studies.  
 
The four case crossover studies were each assessed via the modified methodological quality 
assessment tool previously described above, with the four case-control studies evaluated 
via the Newcastle-Ottawa scale for methodological quality. The results of the quality 
assessment, referring to risk of bias are shown in table 3. From these six were considered to 
be of high quality, thus were determined to have low risk of bias with regards to selection of 
participants, evaluation of exposure of air pollution, and adjustment for confounding factors 
in their analysis. One study was reported to be of low methodological quality, thus had a 
high risk of bias, as for selection bias the definition of bronchiolitis was not stated nor an 
age range, exposure assessment was based on large distances between monitoring stations, 
and there was no adjustment for confounding factors. One study was a conference abstract, 
so was unclear when it came to the assessment of their methodological quality due to 
limited information supplied.
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Table 3. Risk of bias assessment of studies included in systematic review of bronchiolitis and ambient air pollution 
Study Study design 
Selection of 
participants 
Evaluation of exposure 
Consideration of 
confounding factors 
Newcastle Ottawa Score 
Karr 2004 [303] Case crossover Unclear* Unclear* Unclear* N/A 
Karr 2006 [304] Case crossover Low Low Low N/A 
Karr 2007 [305] Case control Low Low Low 7 
Karr 2009 [306] Case control Low Low Low 7 
Karr 2009 [307] Case control Low Low Low 7 
Segala 2008 [308] Case crossover Low Low Low N/A 
Girguis 2017 [309] Case control Low** Low Low 8 
Rahman*** 2017 [310] Case crossover High High High N/A 
 
Legend 
*Unclear as conference abstract 
** In this study, hospital admissions, observational stays, and ED visits were combined into one outcome (‘clinical encounter’) but data for hospitalisations only were 
reported separately 
***Unclear risk of bias for selection as although all admissions were included, definition of bronchiolitis is not stated; High risk of bias for exposure evaluation based on 
large distance between measurement stations; no adjustment for confounding factors 
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The GRADE assessments of the included studies are summarised in table 4 and 5, for each 
pollutant at each time lag.
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Table 4. GRADE assessment of included studies in systematic review of bronchiolitis and particulate pollutants  
Pollutant and 
exposure 
Number of studies and design, and 
number of infants 
Conclusion 
Study 
limitations 
Inconsistency Imprecision 
Grade of 
evidence 
PM2.5 acute 
exposure 
2 case-crossover studies and of 
41,474 infants [303, 304] 
Does not seem to affect risk of 
hospitalisation 
No change No change +1 Moderate 
PM2.5 sub-chronic 
exposure 
3 case-control studies including 
33,394 infants [305-307] 
Unclear effect on risk of hospitalisation +1 -1 +1 Moderate 
PM2.5 lifetime 
exposure 
4 case-control studies of 52,768 
infants [305-307, 309] 
May increase risk of hospitalisation +1 -1 +1 Moderate 
PM10 acute 
exposure 
1 case crossover study of 16588 
infants [308] 
Unclear effect on risk of hospitalisation +1 No change No change Low 
PM10 sub-chronic 
exposure 
1 case control study of 11,675 infants 
[307] 
Does not seem to affect risk of 
hospitalisation 
+1 No change No change Low 
PM10 lifetime 
exposure 
1 case crossover study and 1 case 
control study, including 17,454 
infants[307, 310] 
Unclear effect on risk of hospitalisation -1 No change No change Low 
Legend  
PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm Acute exposure: less than seven days, Sub-chronic exposure: less than 30 days, 
Lifetime exposure: average exposure from birth until hospitalisation 
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Table 5. GRADE assessment of included studies in systematic review of bronchiolitis and ambient air pollution and gaseous pollutants 
Pollutant and 
exposure 
Number of studies and design, and 
number of infants 
Conclusion 
Study 
limitations 
Inconsistency Imprecision 
Grade of 
evidence 
NO2 acute exposure 
3 case-crossover studies of 58,062 
infants [303, 304, 308] 
Unclear effect on risk of hospitalisation +1 No change +1 Moderate 
NO2 sub chronic 
exposure 
2 case-control studies of 30,270 
infants [305, 307] 
Unclear effect on risk of hospitalisation +1 No change +1 Moderate 
NO2 lifetime 
exposure 
2 case control studies and 2 case 
crossover studies of 39,173 infants 
[305-307, 310] 
Unclear effect on risk of hospitalisation -1 No change +1 Low 
SO2 acute exposure 
1 case crossover study of 16,588 
infants [308] 
May increase risk of hospitalisation +1 No change No change Low 
SO2 sub chronic 
exposure 
1 case crossover study of 11,675 
infants [307] 
May increase risk of hospitalisation +1 No change No change Low 
SO2 lifetime 
exposure 
1 case control study of 11,675 infants 
[307] 
May increase risk of hospitalisation +1 No change No change Low 
CO acute exposure 
2 case crossover study of 41,474 
infants [303, 304] 
Does not seem to affect risk of 
hospitalisation 
+1 No change No change Low 
CO sub chronic 
exposure 
2 case control studies of 30,270 
infants [305, 307] 
Unclear effect on risk of hospitalisation +1 No change +1 Moderate 
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CO lifetime exposure 
2 case control studies and 1 case 
crossover study of 36049 infants 
[305, 307, 310] 
Unclear effect on risk of hospitalisation -1 No change +1 Low 
O3 acute exposure No studies No assessment can be made     
O3 sub chronic 
exposure 
2 case control studies of 30,270 
infants [305, 307] 
Does not seem to increase risk of 
hospitalisation and may be associated 
with lower risk of admission 
+1 No change +1 Moderate 
O3 lifetime exposure 
2 case control studies and 1 case 
crossover study of 36049 infants 
[305, 307, 310] 
Does not seem to increase risk of 
hospitalisation and may be associated 
with lower risk of admission 
-1 No change +1 Low 
Legend  
NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: Ozone 
Acute exposure: less than seven days, Sub-chronic exposure: less than 30 days, Lifetime exposure: average exposure from birth until hospitalisation 
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2.4.3 Study Characteristics 
 
Out of the eight included studies, five of the studies were from overlapping research groups 
in North America [303-307], one was from a different North American research group [309], 
one from France [308], and one from Malaysia [310]. The characteristics of the included 
studies are summarised in table 6. There were six studies that examined PM2.5 exposure 
[303-307, 309], three for PM10 exposure [307, 308, 310], seven for NO2 [303-308, 310], two 
that analysed SO2 exposure [307, 308], five examining CO [303-305, 307, 310], and three 
that surveyed O3 exposure [305, 307, 310] and risk of hospitalisation with bronchiolitis. 
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Table 6. Characteristics of included studies 
Study Study 
Design 
Years 
Conducted 
Country 
(Region) 
Bronchiolitis 
Definition 
Population Population 
Size  
Lag exposure Adjusted for confounders Pollutants 
Measured* 
Karr 
2004 
[303] 
Case 
crossover  
1995-2000 United 
States 
(California) 
Not stated  Three weeks 
to one year 
22365 Lag 1-2, Lag 3-
5 
Not stated PM2.5, NO2, 
CO 
Karr 
2006 
[304] 
Case 
crossover 
1995-2000 United 
Stated 
(California) 
ICD 9 Three weeks 
to one year 
19109 Lag 1-2 and 
Lag 3-5 days 
for PM2.5, Lag 
1 and 4 days 
for NO2, CO 
Day of week (PM2.5 only), mean 
daily temperature, mean daily 
humidity 
PM2.5, NO2, 
CO 
Karr 
2007 
[305] 
Case 
control  
1995-2000 United 
States 
(California) 
ICD 9  Three weeks 
to one year 
18595 Chronic and 
sub-chronic 
Gender, ethnicity (Hispanic vs. not 
Hispanic), insurance category 
(medical, private/health 
maintenance 
organization/preferred 
provider organization, other), 
mother’s highest level of education 
(0, 1–6, 7–12, or 13 years), any 
lung disease (chronic lung disease 
and pulmonary anomalies, 
including congenital diaphragmatic 
hernia), any cardiac anomalies, 
PM2.5, NO2, 
O3, CO 
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daily mean temperature, and daily 
mean humidity. 
Karr 
2009 
[306] 
Case 
Control 
1997-2003 United 
States 
(Washingt
on State)  
ICD 9 Three weeks 
to one year 
3124 Lifetime, 30 
day average 
and 7 day 
average 
(PM2.5 only)  
 Maternal education,  
mother’s self-reported smoking 
during pregnancy and infant 
race/ethnicity 
 
PM2.5, NO2 
Karr 
2009 
[307] 
Case 
control  
1999 to 
2002 
Canada 
(British 
Columbia) 
ICD 9 Singleton 
children 
aged 2-12 
months 
11675 Lifetime and 1 
month before 
Adjusted for infant sex, gestational 
age, First Nation status, parity, 
maternal age, maternal smoking 
during pregnancy, maternal 
initiation of breastfeeding at birth, 
income (quintile census), maternal 
education (quartile census). Cases 
and controls are matched on date 
of birth 
PM2.5, 
PM10, NO2, 
SO2, CO, O3 
Segala 
2008 
[308] 
Case 
Crossover 
1997-2001 France 
(Paris) 
Respiratory 
dyspnoea 
and/or 
sibilants and 
wheezing 
for children  
Less than 
three years 
16588 Lag 0-1, lag 0-
4 
Public holidays, holidays and 
weather variables. 
 
PM10, NO2, 
SO2 
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Girguis 
2017 
[309] 
Case 
Control 
2001-2008 United 
States 
(Massachu
setts) 
ICD 9 Three weeks 
to less than 
12 months 
19374 Lifetime High risk pregnancy, maternal age, 
birthweight, smoking during 
pregnancy, maternal education, 
adequacy of prenatal care, parity, 
income and insurance type. 
Matched on date of birth (+/− 6 
days) and gestational week. 
PM2.5 
Rahma
n 2017 
[310] 
Case 
Crossover 
2006-2010 Malaysia 
(Klang 
Valley) 
Not stated Not stated 5779 Lifetime Not stated PM10, CO, 
O3, NO2 
 
Legend  
PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm, NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: Ozone 
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2.4.4 Primary outcome – the association between air pollution and risk of hospitalisation for 
bronchiolitis   
 
The results from the included studies are summarised below and shown in figures 5-10, with 
the detailed results shown in in table 7 and 8.
   
 61 
 
Figure 5. Forest plots of PM2.5 exposure and risk of hospitalisation with bronchiolitis without meta-analysis 
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Figure 6. Forest plots of PM10 exposure and risk of hospitalisation with bronchiolitis without meta-analysis 
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Figure 7. Forest plots of NO2 exposure and risk of hospitalisation with bronchiolitis without meta-analysis
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Figure 8. Forest plots of SO2 exposure and risk of hospitalisation with bronchiolitis without meta-analysis 
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Figure 9. Forest plots of CO exposure and risk of hospitalisation with bronchiolitis without meta-analysis 
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Figure 10. Forest plots of O3 exposure and risk of hospitalisation with bronchiolitis without meta-analysis 
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Table 7. Results of included studies for particulate pollutants 
Pollutant Study Lag Exposure Crude Odds Ratio Adjusted Odds Ratio 
PM2.5 
Karr 2009 [307] 
1 month Exposure 0.93 (0.89–0.97) 0.96 (0.92-1.01) 
Lifetime 0.90 (0.84–0.97) 0.97 (0.90-1.04) 
Karr 2009 [306] 
7 days Not stated 1.12 (0.94-1.33) 
30 day Not stated 1.15 (0.90-1.47) 
Lifetime Not stated 1.14 (0.88-1.46) 
Karr 2006 [304] 
1-2 days Not stated 0.96 (0.94-0.99) 
3-5 days Not stated 0.98 (0.96-1.00) 
Karr 2004 [303] 
1-2 days 0.98 (0.95-1.00) Not stated 
3-5 days 0.98 (0.96-1.00) Not stated 
Girguis 2017 [309] Lifetime 1.05 (1.02, 1.07)* 1.09 (1.05-1.13)* 
Karr 2007 [305] 
Sub-chronic (30 days) Not stated 1.09 (1.04-1.14)* 
Chronic (Lifetime) Not stated 1.09 (1.04-1.14)* 
PM10 
Karr 2009 [307] 
1 month Exposure 0.97 (0.94–10.01) 1.00 (0.96-1.03) 
Lifetime 0.99 (0.94–1.04) 1.03 (0.98-1.08) 
Rahman 2017 [310] Lifetime 1.12 (1.09-1.14)* Not stated 
Segala 2008 [308] 
0-1 day Not stated 1.01 (0.99-1.03) 
0-4 day Not stated 1.06 (1.03-1.10)* 
Legend  
*statistically significant 
PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm,  
Acute exposure: less than seven days, Sub chronic exposure: less than one month, Lifetime exposure: average exposure from birth until hospitalisation 
Odds ratio refers to increase in PM2.5 and  PM10  with a unit increase of 10 μg/m3 
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Table 8. Results of included studies for gaseous pollutants 
Pollutant Study Lag Exposure Crude Odds Ratio Adjusted Odds Ratio 
NO2 
Karr 2009 [307] 
1 month Exposure 1.06 (1.03–1.09)* 1.11 (1.08-1.14)* 
Lifetime 1.06 (1.02–1.09)* 1.12 (1.09-1.16)* 
Karr 2009 [306] Lifetime Not stated 1.00 (0.96-1.04) 
Karr 2006 [304] 
1 day Not stated 0.97 (0.95-0.99) 
4 days Not stated 0.96 (0.94-0.99) 
Karr 2004 [303] 
1 day Not available 
Not available (stated as not statistically 
significant association) 
4 day Not available 
Not available (stated as not statistically 
significant association) 
Rahman 2017 [310] Lifetime 1.01 (0.98-1.03) Not stated 
Karr 2007 [305] 
Sub-chronic (30 day) Not stated 1.04 (1.00-1.08) 
Chronic (Lifetime) Not stated 1.03 (0.99-1.07) 
Segala 2008 [308] 
0-1 day Not stated 1.01 (0.98-1.03) 
0-4 day Not stated 1.04 (1.02-1.07)* 
SO2 
Karr 2009 [307] 
1 month Exposure 1.00 (0.98–1.02) 1.03 (1.01-1.05)* 
Lifetime 1.00 (0.98–1.02) 1.04 (1.01-1.06)* 
Segala 2008 [308] 
0-1 day Not stated 1.10 (1.06-1.15)* 
0-4 day Not stated 1.12 (1.07-1.16)* 
CO 
Karr 2009 [307] 
1 month Exposure 1.03 (1.00–1.06) 1.11 (1.08-1.15)* 
Lifetime 1.03 (0.99–1.07) 1.13 (1.09-1.18)* 
Karr 2006 [304] 1 day Not stated 0.99 (0.96-1.02) 
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4 day Not stated 0.97 (0.94-1.00) 
Karr 2004 [303] 
1 day Not available 
Not available (stated as not statistically 
significant association) 
4 day Not available 
Not available (stated as not statistically 
significant association) 
Rahman 2017 [310] Lifetime 0.89 (0.24-3.23) Not stated 
Karr 2007 [305] 
Sub-chronic (30 day) Not stated 1.00 (0.97-1.03) 
Chronic (Lifetime) Not stated 1.00 (0.97-1.03) 
O3 
Karr 2009 [307] 
1 month Exposure 0.97 (0.94–1.01) 0.90 (0.87-0.94) 
Lifetime 0.98 (0.94–1.02) 0.89 (0.85-0.93) 
Rahman 2017 [310] Lifetime 0.99 (0.98-1.00) Not stated 
Karr 2007 [305] 
Sub-chronic (30 day) Not stated 0.92 (0.88-0.97) 
Chronic (Lifetime) No 0.92 (0.88-0.97) 
Legend  
*statistically significant 
NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: Ozone 
Acute exposure: less than seven days, Sub chronic exposure: less than one month, Lifetime exposure: average exposure from birth until hospitalisation 
Odds ratio refers to increase in NO2, SO2 and O3 with a unit increase of 10 μg/m3, and for CO a unit increase of 1 mg/m3 
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2.4.4.1 Particulate Pollutants  
 
Based on moderate quality evidence (according to the GRADE assessment), acute exposure 
to PM2.5 does not seem to increase the risk of hospitalisation (figure 5). Three studies [303, 
304, 306], found no association with an increased risk of hospitalisation with bronchiolitis 
due to PM2.5 at different time lags in the acute exposure window. Sub-chronic effects are 
unclear, with two studies discovering no increased risk with 30 day exposure [306, 307], 
however, one study did find an increased risk with sub-chronic exposure [305](OR 1.09, 95% 
CI 1.04-1.14). For lifetime exposure, there may be an increased risk of hospitalisation with 
bronchiolitis associated. Two studies [306, 307] found no increased risk of hospitalisation, 
yet, in two studies there was an increased risk of hospitalisation shown (OR 1.09, 95% CI 
1.04-1.14 [305] and OR 1.09, 95% CI 1.05-1.13 [309]). 
 
There is less evidence around PM10, and the evidence available is of low quality (see GRADE 
assessment). Acute effects of PM10 on hospitalisation is unclear, with one study [308] 
having found an association at a lag of 0-4 days (OR 1.06, 95% CI 1.03-1.10), but not at a 
smaller lag of 0-1 days. Sub-chronic exposure does not seem to be associated with an 
increased risk of hospitalisation, however, there was only one study that examined these 
effects [307]. Of the two studies that examined lifetime exposure, the results were unclear, 
as one [307] found no association, but one [310] found a statistically significant association 
with lifetime exposure (OR 1.115, 95% CI 1.093-1.138).   
 
2.4.4.2 Gaseous Pollutants 
 
The association between exposure length of gaseous pollutant and risk of hospitalisation 
admission varied between pollutants, and results were inconsistent across studies.  
 
Based on moderate quality evidence (see GRADE assessment), the acute, sub-chronic, and 
lifetime effects of NO2 are unclear, although longer term exposure may be associated with 
an increased risk of admission for bronchiolitis (figure 7) Two studies found no increased 
risk of acute exposure [303, 304], and one study found a statistically significant association 
   
 71 
at a lag of 0-4 days (OR 1.04, 95% CI 1.02-1.07), but not at a lag of 0-1 days [308]. For sub-
chronic and lifetime exposure, three studies [305, 306, 310] found no association with risk 
of hospitalisation with bronchiolitis, but one study [307] found a statistically significant 
association with sub-chronic (OR 1.11, 95% CI 1.08-1.14) and lifetime exposure (OR 1.12, 
95% CI 1.09-1.16). 
 
For SO2, the quality of evidence was graded as low (see GRADE assessment). The results of 
two studies suggest that acute, sub-chronic, and lifetime exposure to SO2 may be associated 
with increased risk of hospitalisation (figure 8). One study [308] that examined acute 
exposure found that statistically significant associations were seen at lags of 0-1 days (OR 
1.10, 95% CI 1.06-1.15) and 0-4 days (OR 1.12, 95% CI 1.07-1.16). In another study [307], the 
effects of longer term exposure were assessed, and s statically significant association was 
found with risk of hospitalisation for sub-chronic exposure (OR 1.03, 95% CI 1.01-1.05) and 
lifetime exposure (OR 1.04, 95% CI 1.01-1.06).  
 
Based on low quality graded evidence from two studies [303, 304], CO does not seem to 
have an acute effect on the risk of hospitalisation for bronchiolitis (figure 9). For sub-chronic 
effects, based on moderate quality graded evidence, the risk of hospitalisation with 
bronchiolitis is unclear. One study [305] found no association with risk of hospitalisation, 
but one study [307] found a statistically significant association (OR 1.11, 95% CI 1.08-1.15). 
With lifetime exposure, based on low quality graded evidence, the risk of hospitalisation is 
difficult to determine, two studies [305, 310] found no association, but one study [307] did 
find a statistically significant association (OR 1.13, 95% CI 1.09-1.18).  
 
Three studies assessed the longer terms effects of O3 exposure, but none evaluated acute 
effects. The quality of evidence for sub-chronic was graded as moderate, but low for 
lifetime exposure. Most studies showed a reduction in the risk of admission associated with 
ozone exposure (see figure 10). Two studies [305, 307] found no association with increased 
risk for sub-chronic exposure, with both finding a statistically significant decrease in 
hospitalisation risk (OR 0.90, 95% CI 0.87-0.94 [307] and OR 0.92, 95% CI 0.88-0.97 [305]). 
For lifetime exposure, three studies [305, 307, 310] found no increased risk of 
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hospitalisation, with two studies finding a statistically significant decrease (OR 0.89, 95% CI 
0.85-0.93 [307] and OR 0.92, 95% CI 0.88-0.97 [305]).  
 
2.4.5 Secondary outcomes  
 
There were two studies that had assessed a secondary outcome as well as the primary 
outcome. One case crossover study [308], examined the acute effects of PM10, NO2 and SO2 
on the risk of emergency visit consultations for bronchiolitis. A statistically association was 
found in all three pollutants for a lag of 0-4 days, PM10 (OR 1.06, 95% CI 1.04-1.08), NO2 (OR 
1.03, 95% CI 1.02-1.05), and for SO2 (OR 1.12, 95% CI 1.09-1.15). For SO2 exposure, a 
positive association was also seen at a lag of 0-1 days (OR 1.08, 95% CI 1.06-1.11). There was 
nearly triple the amount of average number of patients in this cohort, 139 cases per day, 
compared the average number of hospitalisations, 45 cases per day. There was one case 
control study [309] that evaluated the lifetime exposure of PM2.5 on the risk of a clinical 
encounter (emergency department visits and hospital admissions combined) for 
bronchiolitis with no association found after adjustment for confounding variables.  
 
2.4.6 Comparison between effect of air pollution and WHO recommended guidelines 
 
Of the eight included studies, five reported that one or more of the ambient air pollutants 
was associated with an increased risk of hospitalisation with bronchiolitis [305, 307-310]. Of 
these, four measured air pollutant average levels, comparing these to WHO recommended 
guidelines, three [307-309] had levels below the recommendations where pollutant 
exposure had reached statistical significance for risk of hospitalisation with bronchiolitis. 
One study [305], that measured air pollutant levels, that had found an association with 
longer term exposure and risk of hospitalisation, had PM2.5 mean levels above those 
recommended. One study [309] found statistically significant associations with lifetime 
exposure to PM2.5 at levels below WHO guidelines, this was similarly seen in one study for 
acute PM10 exposure [308], one study for longer term exposure to NO2 [307], two studies 
for all exposure windows for SO2 [307, 308], and one study for longer term exposure for CO 
[307].  
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2.5 Discussion  
 
This is the first systematic review analysing the effect of exposure to ambient air pollution 
on the risk of hospital admission with bronchiolitis. Although the findings are inconsistent 
across studies a suggested association with longer term exposure to the all pollutants, apart 
from ozone, and risk of hospitalisation with bronchiolitis is seen.  Acute exposure to NO2 
and SO2, may also be associated with increased risk of hospitalisation with bronchiolitis, 
with SO2 exposure association seen in low levels of SO2 concentrations. In some of the 
studies [307-309], where you would expect risk of hospitalisation with bronchiolitis to be 
decreased association was seen at concentration levels lower than the recommended WHO 
guidelines.  
 
The effects seen with ozone should not be assumed to suggest a decrease in risk of 
hospitalisation with bronchiolitis, and that ozone is a protective factor. Ozone is known to 
be a unique air pollutant that doesn’t correlate to the pattern seen in the other pollutants. 
Due to how ozone is produced the peak exposure window is usually during the hot, summer 
months when there is plenty of sunshine, which is when bronchiolitis epidemics especially 
due to RSV are low. The negative association seen could be due to that in the winter 
months, other pollutants confound the effects of ozone, with multipollutant modelling a 
possible way to assess this reasoning [305]. Furthermore, due to the seasonal variation seen 
with ozone, it may be that bronchiolitis as it is also considered to be seasonal in its peaks 
may not be as affected as respiratory diseases that occur all year round, or effect infants as 
strongly compared to children who are more active outdoors in the summer when exposure 
levels are high. This idea should be considered when comparing the effect of ambient air 
pollutants against a range of respiratory diseases in the future.  
 
Maximum levels of air pollutants in current WHO air quality guidelines may not be 
sufficiently low enough to protect infants, who may be particularly vulnerable to their 
harmful effects [311]. In a study that examined adverse effects of air pollution exposure on 
children’s health, infants younger than two years of age were most susceptible to the health 
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effects of air pollutants, particularly NO2, SO2 and PM10 [312]. This systematic review 
highlights that even at low levels associations are still seen with pollutants. This emphasises 
the need for the current legislation to be stricter when it involves ambient air pollutants, as 
there is a high proportion of areas that exceed the current guidelines, and for a review of 
the current WHO guidelines as over time new hazardous effects of air pollutants are being 
realised.  
 
This review was conducted in a systematic manner, but the validity of the conclusions is 
hampered by the variation seen between studies. From current evidence, it is difficult to 
estimate the proportion of cases of hospitalisation from bronchiolitis that may be 
attributable to air pollution but given the ubiquity of this infection even the modest 
associations identified in this review are likely to have a substantial impact on the morbidity 
and global burden of the disease. Seasonality is known to affect the variability of air 
pollution, with traffic associated air pollutants increasing in the winter and ozone higher in 
the summer months. The majority of studies included accounted for temperature and 
humidity along with matching within the same time period for time-series and case 
crossover studies to limit these confounding variables [304-306, 308, 309].  
 
Although there were inconsistencies found between the results in this review, a recent 
study [313] analysing bronchiolitis in a different cohort has been released after the search 
period. This study has further highlighted positive associations between traffic related 
pollutants, PM2.5, CO and nitrogen oxides (this includes NO2), and bronchiolitis clinical 
encounters. The results from this study increasingly highlight the association seen in some 
of the studies in this review where statistically significant results were seen. This supports 
the view that air pollution may have an association with increased risk of hospitalisation 
with bronchiolitis.  
 
2.5.1 Limitations  
 
The results of the included studies were unable to be synthesised as no studies were 
identified that utilised a cohort design. One source of imprecision is that the diagnosis of 
bronchiolitis, even when made according to standardised definition, relies upon the 
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subjective judgements by individual clinicians.  Although bronchiolitis usually occurs within 
the first year of life, there was variation in age cut offs in the studies. Variation in the age 
definition may have resulted in viral wheeze or mild cases of pneumonia being misclassified 
as bronchiolitis, particularly when including children over the age of one year [308, 310]. 
There were differences in the confounding factors that were considered in the analyses of 
each of the studies, with some adjusting for a wider range of covariates than others. As 
expected, crude odds ratios that showed statistical significance were found [307, 309], yet 
the adjusted ORs did not, highlighting the importance of considering confounding factors in 
observational studies. It was noted that studies measuring exposure to more than one 
pollutant did not describe a pre-specified primary analysis with regards to clinical outcome, 
pollutant, and lag time. It is possible, therefore, that individual studies may be at risk of 
selective outcome reporting, a practice that is commonplace in RCTs [314]. International 
consensus, around potential confounding factors and a core outcome set [315, 316] to 
measure and report in observational studies of air pollution, may help reduce these 
problems.  
 
2.6 Conclusion 
 
As hospitalisation for bronchiolitis and ambient air pollution effects had not been 
considered in previous studies, the aim of this chapter was to assess this association that 
has already been highlighted in other respiratory diseases in children. This review suggests 
an association between different air pollutants and risk of hospitalisation with bronchiolitis 
in infants, particularly with particulate matter, NO2 and SO2 exposure. The review has 
highlighted the need for a multicentre cohort or time series study to examine this possible 
association further comparing with the recent study seen with traffic air pollution and 
bronchiolitis, and this would be strengthened by development of a standardised 
methodological approach. A combination of the current evidence around air pollution and 
respiratory disease, including this systematic review, would be beneficial to assess the 
differences and similarities that may appear in relation to air pollution concentrations and 
respiratory disease. Revision of the international recommendations around air quality levels 
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may be warranted and should incorporate specific consideration around the impact of 
outdoor air pollution on infants.  
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Chapter 3 – The effects of ambient air pollution on the risk of 
hospitalisation with acute respiratory illnesses in children: an 
overview of systematic reviews.  
 
3.1 Background  
 
The effects of outdoor air pollution on respiratory disease outcomes is rapidly growing in 
evidence. The previous chapter highlights how outdoor air pollution effects bronchiolitis, 
yet this is not the only systematic review that has analysed a respiratory diseases and 
pollution. A systematic review [317] analysing Canadian epidemiological studies showed a 
positive association of healthcare services utilisation and general respiratory conditions in 
children. This result was further evidenced when concentrating on asthma in children, 
where positive associations were also seen, specifically with acute exposure to NO2, SO2 and 
CO. In this systematic review similar to the bronchiolitis review in chapter two, positive 
associations were seen at low levels of pollutant exposure. Increased frequency of asthma 
exacerbations and wheeze has been shown in in a meta-analysis examining exposure to 
traffic related air pollution [318]. With the increasing levels of air pollution [133, 319, 320], 
the evidence from these systematic reviews will help to emphasise the importance of 
monitoring and controlling pollution levels.  
 
Children are at particular risk of the harmful effects of air pollution, even when levels are 
low [321]. This age group are known to be susceptible due to the developmental growth 
periods that occur [322], the increased proportion of time that they spend outside exposed 
to pollution [323], the higher volume of air exchange relative to body mass compared with 
adults [27], and the increased normal respiratory rate of 20 to 40 breaths per minute [324] 
compared to a adults 12 to 20 breaths [325]. All these factors contribute to the adverse 
effect air pollution can have on respiratory health. The adverse effect on a child’s lung 
function is well described [326], and there is emerging evidence regarding prenatal traffic 
air pollutant exposure and low birth weight, which can further affect the respiratory system 
[327].  
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Air pollutants have been implicated as risk factors for pulmonary exacerbations in children 
with chronic illnesses such as cystic fibrosis [328-330], and respiratory infections in children 
without comorbidities [331, 332]. The possible mechanism that increases susceptibility to 
respiratory infections due to air pollution may be a result of oxidative stress and allergic 
sensitisation of the respiratory system [333].  
 
Acute respiratory events such as infection and asthma exacerbations are a major burden on 
healthcare utilisation and a significant contributor to global childhood mortality rates [334-
337]. A paper analysing asthma outcomes estimated that the total health care costs from 34 
countries was around $1.7 trillion in 2010 [338], this estimation has only likely increased as 
air pollution have risen along with adverse health effects. By identifying factors, such as 
outdoor air pollution, that may influence healthcare utilisation rates, efforts can be made to 
address this large cost on the health service and help to reduce the part that respiratory 
diseases in children may contribute to it.  
 
This chapter describes an overview of systematic reviews that was undertaken to determine 
the current evidence available that examined the effects of ambient air pollution on 
unscheduled healthcare resource utilisation (HRU) due to acute respiratory events such as 
infection and asthma exacerbations.  
 
3.2. Aims  
 
1) To perform an overview to collate and appraise current evidence from systematic 
reviews examining the risk of air pollution and unscheduled healthcare resource 
utilisation (HRU) for acute respiratory events in children.  
a. Specifically, the impact of ambient levels of particulate and gaseous 
pollutants on the risk of hospitalisation for asthma exacerbations, 
pneumonia, bronchiolitis, acute lower respiratory infection, bronchitis, acute 
wheeze, croup, influenza, and pertussis will be examined.  
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3.3 Methods 
 
The protocol for this was published a priori in PROSPERO, see appendix 4.  
 
3.3.1 Inclusion and exclusion criteria  
 
Systematic reviews were included if analysed observational studies, that had evaluated the 
impact of air pollution levels, PM2.5, PM10, NO2, O3, SO2 and/or CO, on unscheduled HRU 
for acute respiratory events in children and adolescence, under the age of 20 years. The pre-
specified primary outcome was the risk of unscheduled HRU defined as a composite of 
outcomes of acute hospitalisation and/or emergency department (ED) visits. Secondary 
outcomes will be analysed in included systematic reviews, looking at the risk of critical care 
admission, unscheduled primary care visits and mortality.  
 
Air pollution exposure analysed at any time period (lag) before unscheduled HRU, and 
subsequently categorised results in short-term (less than seven days) or lifetime exposure 
(average daily from birth to hospitalisation). No primary pollutant of interest was specified 
out of PM2.5, PM10, NO2, SO2, CO and O3 as each may contribute differently to illnesses to 
varying degrees.  
 
Systematic reviews were excluded if they were narrative reviews, did not analyse the 
specific ambient air pollutants and commented generally on outdoor pollution levels, or had 
solely meta-analysed studies without a systematic review.  
 
3.3.2 Identification of relevant systematic reviews 
 
Relevant reviews were identified via an array of electronic databases in order to optimise 
the chances of locating eligible reviews. The specific databases Medline, Embase (via OVID), 
Database of Abstracts of Reviews of Effects (DARE), and Cochrane Database of Systematic 
Reviews (CDSR) (via the Cochrane Library) were searched until January 2018. Medline is the 
same as reported in chapter two. With the database Embase, it is a biomedical database 
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that has coverage of articles since 1947 [339]. DARE uses a comprehensive search strategy 
to capture reviews including unpublished work, and is a complement system to CDSR as 
identifies studies not carried out via the Cochrane Collaboration, however, it has not been 
updated since 31st March 2015 [340]. The database CDSR is a leading source of information 
for systematic reviews in healthcare and includes Cochrane reviews and protocols, with 
coverage since 2003 [341].  
 
3.3.3 Search Strategy 
 
The search strategy applied for the databases was constructed around relevant search 
terms for acute respiratory events; “respiratory infection”, “asthma”, “pneumonia”, 
“bronchiolitis”, “acute lower respiratory infection”, “bronchitis”, “acute wheeze”, “croup”, 
“influenza” and “pertussis”. Synonyms, MeSH terms and the use of truncation was used to 
increase the likelihood of identifying systematic reviews, similar to the search technique 
described in chapter two. The respiratory search terms were joined using the Boolean 
operator term OR, and then combined with other key words for “child”, “air pollution”, and 
“systematic review”. The full search strategy is shown in appendix 5.  
 
3.3.4 Identification of eligible studies 
 
Eligible studies were identified by two independent investigators (CK and IS) who executed 
the initial screening of the titles and abstracts. Included screened abstracts then had their 
full text examined for eligibility, with the quality of eligible systematic reviews evaluated by 
the two reviewers (CK and IS) as well.  
 
3.3.5 Data extraction  
 
From the included systematic reviewers, one reviewer (CK) extracted the predefined review 
characteristics into a table. These included: 
 
- Respiratory outcome 
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- Time period of exposure 
- Pollutant measured (and if average concentrations mentioned or supplied) 
- Effect size (relative risk or percentage increase) 
 
Effect size refers to the risk per unit of increase for each pollutant of the outcome occurring, 
stated as either relative risk or percentage increase. For PM2.5, PM10, NO2, SO2 and O3 the 
unit increase is per 10 μg/m3 , and for CO a unit increase is per 1 mg/m3. 
 
From systematic reviews with meta-analysis, we extracted pooled effect estimates with 95% 
confidence interval, and I2 measures of between-study heterogeneity.  
 
3.3.6 Quality assessment of studies  
 
Eligible systematic reviews were assessed using AMSTAR-2 criteria, which assesses the 
methodological quality of the systematic reviews using a 16-item tool [342] which enables 
ranking of the confidence in the results of individual reviews as high (zero or one non-critical 
weakness), moderate (one or more non critical weakness but no critical flaw that would 
affect the confidence in the quality of results), or low/critically low grade (at least one 
critical flaw that may reduce the validity of the results).  
 
In order to fully evaluate the quality of the evidence we evaluated risk of bias in individual 
studies using the following criteria: 
 
 
3.3.6.1 Selection bias and additional quality criteria 
 
Studies were considered to be of low risk of selection bias if the study sample included 
consecutive cases of hospitalisations and/or emergency visits for acute respiratory events, 
and if these were identified from healthcare records. We also considered studies to be of 
higher quality if the case definition of the acute respiratory event was based on 
International Classification of Disease Criteria (ICD 9 or 10) [300, 343].  
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3.3.6.2 Assessment of Exposure 
 
Within each individual study, we evaluated the methodology with which the individual air 
pollutants were measured, the frequency of monitoring, technique of data collection and 
the proximity of monitoring stations to the participants or hospitals. Studies were 
considered to be of higher quality if pollutants were measured daily, using standardised 
techniques, and monitors were within 20 kilometres of the hospitals or residences of 
included participants.  
 
3.3.6.3 Adjustment for confounding variables 
 
Confounding variables were examined in each study such as meteorological confounders, 
socioeconomic status, environmental confounders and other clinical risk factors. Studies 
were considered to be of low risk of bias if two or more types of confounders were 
accounted for when results were adjusted.  
 
In addition, systematic reviews were graded along with the included individual studies to 
form a judgement regarding the overall quality of the reviews. The grade of evidence 
around the association between each pollutant and the risk of unscheduled HRU for each 
disease was classes as high quality, if both the systematic review and included studies had 
high methodological quality and a high AMSTAR-2 score, moderate quality, if there was a 
flaw in the systematic review or if the included studies were of moderate methodological 
quality, or low quality, if there was a critical flaw in the systematic review according to the 
AMSTAR-2 criteria or had low methodological quality of the included studies.  
 
3.3.7 Data Analysis  
 
Systematic reviews were reported descriptively for each respiratory disease due to the 
variation in methodology undertaken in the reviews.  
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3.4 Results  
 
3.4.1 Results of search  
 
The search yielded 1331 possible eligible articles once duplicates had been removed. Of 
these 1269 records were excluded through screening of titles and abstract. The remaining 
60 records had full text reports retrieved and 50 were subsequently excluded, see appendix 
6 for reasons of exclusion. The systematic review from the previous chapter was included 
for analysis. Thus, eleven systematic reviews were then eligible for inclusion, the review 
flowchart is shown in figure 11. 
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Figure 11. Review flowchart of included systematic reviews in overview examining acute respiratory events and ambient air pollution 
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No reviews were found that examined the other respiratory diseases; acute lower 
respiratory infection, bronchitis, acute wheeze, croup, influenza and pertussis. 
 
3.4.2 Description of included studies  
 
Of the eleven included reviews, ten had conducted meta-analysis on the included individual 
studies. Unscheduled HRU was reported in all eleven systematic reviews [344-354]. These 
were defined as hospital admission in five reviews [344, 346, 347, 349, 350], ED visits in one 
review [345],and a composite of both outcomes in four reviews [351-354]. Nine systematic 
reviews examined asthma exacerbations related to HRU, one examined risk of HRU with 
pneumonia, and one examined the risk of HRU with bronchiolitis.  
 
Eight reviews included individual studies from high income countries such as United States 
of America, Canada and Western Europe [344-350, 352, 353]. Six reviews had at least one 
study from a low or middle-income country in Asia, South America or Eastern Europe [344-
347, 350, 353]. No reviews analysed studies from Africa.  Two of the eligible reviews did not 
state locations of individual studies. 
 
Only the systematic review relating to bronchiolitis considered long-term exposure of air 
pollutants [347]. The other ten reviews assessed only short-term exposure up to a maximum 
of seven days of air pollutants and unscheduled HRU. 
 
The characteristics of the included studies are summarised in table 9. 
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Table 9. Characteristics of included systematic reviews 
Author 
(reference) 
Databases searched (end 
date) 
No. of studies 
No. of 
participants 
Countries analysed 
in systematic 
Reviews 
(continents) 
Study 
designs 
included 
Pollutant(s) 
measured 
Respiratory 
disease(s) 
analysed 
Outcome(s) 
measured 
Romeo 
[352] 
Pubmed (2003) 
33 (16 for 
asthma 
hospitalisations) 
n/a 
n/a (Europe and 
other including 
America) 
Time series 
studies and 
panel 
studies 
PM10 Asthma 
Hospital 
admission or 
emergency 
room visits 
Koranteng 
[348] 
Pubmed, Medline, Embase 
(December 2004) 
13 (7 studies for 
asthma, 2 for 
respiratory 
illness) 
n/a Canada 
Time series 
and Case 
Crossover 
Studies 
PM2.5, 
PM10, O3, 
NO2, SO2, CO 
Asthma and 
Respiratory 
Illness 
(definition 
stated) 
Hospital 
admission or 
Emergency 
Department. 
Visit 
Meng Ji 
[346] 
Pubmed (2008) 
96 (29 studies 
for children) 
n/a (children 
0-14 years) 
n/a (North America, 
Europe and some 
Asian cities) 
Time series 
and Case 
Crossover 
Studies 
Ozone 
Asthma and 
Respiratory 
Illness 
(definition 
stated) 
Hospital 
admission and 
ED visit 
Ding [344] 
Pubmed, EBSCO, Ovid, China 
Biomedical Literature, Wei Pu 
Chinese Science Technology 
Database, Wang Fang 
Database, CNKI (China 
National Knowledge 
Infrastructure) (December 
2013) 
18 
n/a (children 
from 0-18 
years) 
Denmark, UK, USA, 
Brazil, South Korea, 
Greece, Northern 
Ireland, Canada, 
Italy, Turkey, China 
Time series 
and Case 
Crossover 
Studies 
PM2.5, 
PM10 
Asthma 
Hospital 
admission 
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Zhang 
[353] 
Pubmed, Web of Science 
(December 2014) 
26 (8 studies for 
children) 
n/a (children 
aged 0-14yrs) 
China, Hong Kong, 
Taiwan, Japan, 
Korea 
Time series 
and Case 
Crossover 
Studies 
PM2.5, 
PM10, O3, 
NO2, SO2, CO 
Asthma 
Hospital 
utilization (all 
types, general 
admissions, 
emergency 
admissions) 
Fan [345] 
Embase, Pubmed, Cochrane 
Library, Web of Science, 
China Biomedical Literature 
Database (January 2015) 
16 (7 papers 
specifically for 
children) 
777,563 
asthma ED 
visits for 
whole 
population 
(children <18 
years old) 
USA, Canada, 
Finland, Taiwan 
Peer 
reviewed 
studies - did 
not specify a 
design 
PM2.5 Asthma 
Emergency 
Department 
Visits 
Zheng 
[354] 
Embase, Pubmed, Cochrane 
Central Register of Controlled 
Trials and EMB reviews, 
Cochrane Database of 
Systematic Reviews, Web of 
Science, Ovid, Highwire 
(March 2015) 
87 studies (50 
studies for 
children) 
n/a n/a 
Time series 
and Case 
Crossover 
Studies 
PM2.5, 
PM10, O3, 
NO2, SO2, CO 
Asthma 
Hospital 
admission and 
ED visit 
Lim [349] 
Pubmed, Embase (March 
2016) 
26 
n/a (children 
from 0-20 
years) 
n/a (Europe and 
North America) 
Time series 
and Case 
Crossover 
Studies 
PM2.5 Asthma 
Hospital 
admission or 
emergency 
department 
visits 
Orellano 
[351] 
Pubmed, SCOPUS, Google 
Scholar (October 2016) 
22 (19 studies 
for children) 
267,413 
asthma visits 
for whole 
population 
n/a 
Case 
crossover 
design 
PM2.5, 
PM10, O3, 
NO2, SO2, CO 
Asthma 
Hospital 
admission or 
emergency 
department 
visits 
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Nhung 
[350] 
Pubmed, Web of Science 
(January 2017) 
17 
425,000 
pneumonia 
cases 
United States, 
Brazil, Chile, New 
Zealand and 
Australia, Italy, 
Spain, China 
Time series 
and Case 
Crossover 
Studies 
PM2.5, 
PM10, O3, 
NO2, SO2, CO 
Pneumonia 
Hospitalisations 
(hospital 
admissions and 
ED visits 
combined) 
King [347] 
Medline, SCOPUS, Web of 
Science (November 2017) 
8 
116,609 
(children aged 
0-2years 
North America, 
France, Malaysia 
Cohort, Time 
series, Case 
crossover 
and Case 
control 
studies 
PM2.5, 
PM10, O3, 
NO2, SO2, CO 
Bronchiolitis 
Hospital 
admission 
Legend 
PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm, NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: Ozone 
n/a : no data available 
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3.4.3 Quality assessment of included studies  
 
Of the eleven systematic reviews, according to the AMSTAR-2 criteria there was one review 
rated as high quality [351], five as moderate quality [344, 345, 347, 350, 354], two as low 
quality [346, 353], and three as critically low quality [348, 349, 352]. The majority of critical 
flaws reflected the assessment of risk of bias in individual studies and failing to reflect this in 
the subsequent meta-analysis, table 10 shows the AMSTAR-2 criteria.
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Table 10. AMSTAR-2 results for systematic reviews included in overview  
 
Romeo 
2006 
[352] 
Koranteng 
2017 [348] 
Meng Ji 
2011 
[346] 
Ding 
2015 
[344] 
Zhang 
2016 
[353] 
Fan 
2015 
[345] 
Zheng 
2016 
[354] 
Lim 
2016 
[349] 
Orellano 
2017 
[351] 
Nhung 
2017 
[350] 
King 
2018 
[347] 
Were components of PICO included in the 
review? Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Was an a priori design (protocol) 
provided? No No  No  
Partial 
Yes No No  No No Yes No  Yes 
Was an explanation for study design 
selection included? No No  No  No No No  No No No No  Yes 
Was a comprehensive literature search 
performed? No Yes No  Yes 
Partial 
yes Yes 
Partial 
yes 
Partial 
yes 
Partial 
yes 
Partial 
yes 
Partial 
Yes 
Was study selection performed in 
duplicate? No No  No  No No  Yes Yes Yes Yes Yes Yes 
Was data extraction performed in 
duplicate? No No  No  Yes No Yes Yes Yes Yes Yes Yes 
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Was a list of excluded studies provided 
and justified? No No  
Partial 
yes 
Partial 
Yes 
Partial 
yes 
Partial 
yes 
Partial 
yes 
Partial 
yes 
Partial 
yes 
Partial 
yes Yes 
Were the characteristics of the included 
studies provided? No Partial yes 
Partial 
yes Yes Yes 
Partial 
yes Yes Yes 
Partial 
yes 
Partial 
yes 
Partial 
Yes 
Was risk of bias assessed in individual 
studies? No No  No  No  No Yes Yes No  Yes 
Partial 
yes Yes 
Were sources of funding for studies 
included? No No  No  Yes No Yes No  No  No No  No 
For meta-analysis: were appropriate 
methods used for statistical combination? Yes 
No meta-
analysis 
conducted Yes Yes Yes Yes Yes Yes Yes Yes Yes 
For meta-analysis: was the impact of risk 
of bias in individual studies on the results 
assessed? No 
No meta-
analysis 
conducted No  Yes Yes No  Yes No  Yes Yes Yes 
Did the authors account for risk of bias 
when discussing results? No No No  Yes No No  Yes No  Yes Yes Yes 
Did the authors provide explanation for 
any heterogeneity observed? Yes No Yes Yes Yes Yes Yes No  Yes Yes No 
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Was the likelihood of publication bias 
assessed? Yes 
No meta-
analysis 
conducted Yes Yes Yes Yes Yes Yes Yes No  No 
Was a conflict of interest included?  Yes No No  No  No Yes  No  Yes No Yes Yes 
Rating overall confidence in results  
Criticall
y Low Low Low 
Moderat
e Low Low  
Moderat
e 
Criticall
y Low  
Moderat
e 
Moderat
e 
Moderat
e 
 
Critical 
flaw - 
no risk 
of bias 
assess
ment  
Critical 
flaw - no 
risk of bias 
assessmen
t  
Critical 
flaw - 
risk of 
bias in 
studies   
Critical 
flaw - 
risk of 
bias in 
studies  
Critical 
flaw - 
risk of 
bias 
when 
meta-
analyse 
 
Critical 
flaw - 
risk of 
bias 
and 
hetero
geneity  
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From each of the included systematic reviews, CK extracted the individual study name to 
assess for potential overlap and risk of bias from the individual studies, due to a large 
proportion of systematic reviews not commentating on risk of bias. There were 203 
individual included studies between all the included reviews before de-duplication, after 
exclusion of duplicates 119 studies remained.  Within this, 94 studies evaluated HRU for 
asthma exacerbations, with 15 were considered to have high risk of bias. Of the 17 studies 
evaluating HRU for pneumonia, one was considered to be at high risk of bias. Lastly of the 
eight studies examining HRU for bronchiolitis, two were considered to be at high risk of bias. 
See appendix 7 for assessment of included individual studies and risk of bias. Specific 
outcomes from each individual study was not extracted, rather the meta-analysis performed 
by the included systematic reviews was used to assess association between air pollution and 
HRU, this is due to the low proportion of high risk of bias individual studies for each disease.  
 
The overall GRADE summary for association between each pollutant and the risk of 
unscheduled HRU is shown in Table 11. 
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Table 11. GRADE assessment of systematic reviews for each pollutant 
Pollutant Disease 
Quality of 
review 
Quality of included 
studies 
Number of 
studies 
Overall grade Conclusion 
PM2.5 Asthma Moderate Low-Moderate 46 Moderate Appears to increase risk of HRU 
PM10 Asthma Moderate Moderate 43 Moderate Appears to increase risk of HRU 
NO2 Asthma Moderate-High Moderate 55 Moderate Appears to increase risk of HRU 
O3 Asthma Low-Moderate Moderate 70 Moderate Appears to increase risk of HRU 
SO2 Asthma Moderate-High Moderate 48 Moderate Appears to increase risk of HRU 
CO Asthma Moderate Moderate 31 Moderate Appears to increase risk of HRU 
 
PM2.5 Pneumonia Moderate Low- moderate 13 Moderate 
Appears to increase risk of HRU: 
OR 1.02 (1.01, 1.03) 
PM10 Pneumonia Moderate Low-moderate 
13 
 
Moderate 
Appears to increase risk of HRU: 
1.02 (1.01,1.02) 
NO2 Pneumonia Moderate Low-moderate 12 Moderate 
May or may not increase risk of HRU 1.01 
(1.00,1.02) 
O3 Pneumonia Moderate Low-moderate 16 Moderate Appears to increase risk of HRU: 1.02 (1.01, 1.03) 
SO2 Pneumonia Moderate Low-moderate 10 Moderate 
May or may not increase risk of HRU: 
1.03 (1.00, 1.05) 
CO Pneumonia Moderate Low-moderate 7 Moderate 
May or may not increase risk of HRU 
1.01 (1.00, 1.02) 
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PM2.5 Bronchiolitis Moderate Moderate 3 Moderate Does not seem to affect risk of HRU 
PM10 Bronchiolitis Moderate Moderate 1 Moderate Unclear effect on risk of HRU 
NO2 Bronchiolitis Moderate Moderate 4 Moderate Unclear effect on risk of HRU 
O3 Bronchiolitis Moderate N/A 0 N/A No assessment can be made 
SO2 Bronchiolitis Moderate Moderate 1 Moderate Unclear effect on risk of HRU 
CO Bronchiolitis Moderate Moderate-High 2 Low Does not seem to affect risk of HRI 
 
Legend 
PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm, NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: Ozone 
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3.4.3 Primary outcome 
 
The results of the eleven systematic reviews are shown in table 12 and presented in figure 
12 for risk of asthma hospitalisations and figure 13 for pneumonia hospitalisations. 
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Table 12. Results from overview for each disease and acute exposure to pollutants 
Asthma Hospitalisation 
(Either combination, hospital 
admission or ER visit)  
Pollutant Review (number of studies) Effect size (relative risk) 
Heterogeneity if I2 performed in 
systematic review 
PM2.5 Zheng (20)  1.025 (1.013,1.037) 82% 
 
Zhang (4)  1.022 (1.019, 1.026) n/r 
 
Orellano (14)  1.022 (1.000, 1.045)  n/r 
 
Lim (10)  1.048 (1.029,1.067) 77.70% 
 
Ding (10) 1.0345 (1.0099,1.3358) 70% 
 
Fan (7) 1.036 (1.018,1.053) n/r 
PM10 Zheng (25)  1.013 (1.008,1.018) 83% 
 
Zhang (5)  1.021 (1.017, 1.024)  n/r 
 
Romeo (16) 1.017 (1.008,1.025) 43% 
 
Ding (16) 1.0175 (1.0102,1.0249) 62% 
NO2 Zheng (39)  1.018 (1.013,1.023) 87% 
 
Zhang (6)  1.035 (1.025, 1.046) n/r 
 
Orellano (12) 1.040 (1.001, 1.081)  n/r 
O3 Zheng (42)  1.008 (1.005,1.012) 89% 
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Zhang (7)  1.029 (1.022,1.037) n/r 
 
Meng Ji (6) 
-0.68 (-6.56,5.57) (percentage 
increase) 
n/r 
SO2 Zheng (37)  1.016 (1.011,1.022) 53% 
 
Zhang (4)  1.057 (1.008, 1.108) n/r 
 
Orellano (10) 1.047 (1.009, 1.086) n/r 
CO Zheng (29)  1.018 (1.013,1.023) 70% 
 
Zhang (2) 1.141 (1.093, 1.191) n/r 
 
Pneumonia Hospitalisations 
PM2.5 Nhung (13) 1.02 (1.01,1.03) 38.10% 
PM10 Nhung (13) 1.02 (1.01,1.02) 66.10% 
NO2 Nhung (12) 1.01 (1.00,1.02) 71.10% 
O3 Nhung (16) 1.02 (1.01,1.03) 75.20% 
SO2 Nhung (10) 1.03 (1.00,1.05) 71.10% 
CO Nhung (7) 1.01 (1.00,1.02) 68.10% 
Legend 
PM2.5: particulate matter diameter <2.5μm, PM10: particulate matter diameter <10μm, NO2: nitrogen dioxide, SO2: sulphur dioxide, CO: carbon monoxide, O3: Ozone 
n/r: no data reported  
Effect size  refers to increase in PM2.5, PM10, NO2, SO2 and O3 with a unit increase of 10 μg/m3, and for CO a unit increase of 1 mg/m3 
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A) 
B) 
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C) 
D) 
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E) 
F) 
 
 
 
Figure 12. Forest plots of risk of asthma exacerbation needing HRU admission and acute exposure to pollutants 
A) PM2.5 exposure    D) O3 exposure 
B) PM10 exposure    E) SO2 exposure 
C) NO2 exposure    F) CO exposure 
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Figure 13. Forest plot of risk of pneumonia needing HRU admission and acute exposure to pollutants 
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Nine systematic reviews examined the effects of ambient air pollution on risk of 
hospitalisation with an asthma exacerbation [344-346, 348, 349, 351-354]. Of those, eight 
meta-analysed the results from individual studies [344-346, 349, 351-354].  
 
Seven systematic reviews analysed the short-term effects of PM2.5 on risk of HRU for 
asthma exacerbation. Six reviews showed statistically significant association, with RR 
ranging from 1.022 (95% CI 1.019 to 1.026) [353] to 1.048 (95% CI 1.029,1.067) [349], and 
one review reported results of borderline statistical significance (RR 1.022, 95% CI 
1.000,1.045) [351]. Five systematic reviews analysed the effects of PM10 on short-term risk 
of HRU for asthma exacerbations. A statistically significant association between exposure to 
PM10 and risk of HRU was found in all four reviews, with RR ranging from 1.013, (95% CI 
1.008,1.018) [354] to (1.021, 95% CI 1.017,1.024) [353].  
 
NO2 was evaluated in four reviews, and of the three which presented meta-analysis data, all 
showed statistically significant association with unscheduled HRU for asthma. The effect size 
ranged from 1.018 (95% CI 1.013,1.023) [354] to 1.040 (95% CI 1.001,1.081) [351]. O3 was 
examined in four reviews. Pooled estimates of association with unscheduled HRU for 
asthma showed statistical statistically significant results in two reviews, with RR ranging 
from 1.008 (95% CI 1.005,1.012) [354] to 1.029 (95% CI 1.022,1.037) [353]. No association 
was seen in one review that measured effect size using percentage increase (-0.68, CI -
6.56,5.57) [346]. For SO2, a positive association was seen in four reviews; with three 
analysing results. Effect size ranged from 1.016 (95% CI 1.011,1.022) [354] to 1.057 (95% CI 
1.008,1.1.08) [353]. With CO three reviews examined the effects; two reviews showed 
statistically significant results ranging from 1.018 (95% CI 1.013, 1.023) [354] to 1.141 (95% 
CI 1.093,1.191) [353]. For each pollutant reviews demonstrated that there was significant 
heterogeneity between results of individual studies.  
 
Risk of hospitalisation for pneumonia was associated with PM2.5 (1.02, CI 1.01,1.03), PM10 
(1.02, CI 1.01,1.02), and O3 (1.02, CI 1.01,1.03) in the single systematic review for this 
disease [350]. This systematic review covered a large cohort of children with pneumonia 
(425,000 cases). The heterogeneity in the meta-analysis was greater than 50% for all 
pollutants apart from PM2.5, which was 38.10%.  
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Bronchiolitis was examined in one systematic review and descriptively reported on [347]. 
The systematic review assessed both short-term exposure to pollutants and long-term 
exposure (greater than seven days) with varying results for all pollutants. Exposure to 
PM2.5, NO2 and SO2 all demonstrated statistically significant results for both short-term 
exposure and long-term exposure [347] and risk of unscheduled HRU.  
 
3.4.4 Secondary outcomes  
 
None of our pre-specified secondary outcomes (risk of critical care admission, unscheduled 
primary care visits, and mortality) were reported in the included systematic reviews.  
 
Furthermore, no systematic reviews remarked on concentration levels of the ambient air 
pollutants in relation to outcomes and WHO concentrations guidelines.  
 
3.5 Discussion  
 
This is the first overview of systematic reviews evaluating the effect of ambient air pollution 
on the risk of unscheduled HRU with respiratory illness in children. On the basis of moderate 
quality evidence,  risk of unscheduled HRU with asthma was increased in all prespecified 
pollutants (PM2.5, PM10, NO2, O3, SO2 and CO), while for pneumonia only PM2.5, PM10, 
and O3 were associated with an increase in risk. The evidence was not clear for bronchiolitis. 
There were no systematic reviews found for either the other common acute respiratory 
diseases of childhood (acute lower respiratory infection, bronchitis, acute wheeze, croup, 
influenza and pertussis) or the secondary outcomes, risk of critical care admission or length 
of stay.  
 
Children are known to be an at-risk population with regards to air pollution [355-358], and 
an exposure – response relationship was seen in several studies. Although the relative risks 
produced from the meta-analysis are small, the results are derived from large cohorts of 
cases, covering a range of ethnicities and socioeconomic statuses [345, 350]. Acute 
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respiratory diseases in children are common and a major burden of disease [359], therefore 
the impact of air pollution on unscheduled HRU is likely to be high.  
 
A paucity of evidence regarding the long-term effects of ambient air pollution, or secondary 
outcomes such as critical care admission was also identified. Studies were concentrated in 
high income countries, with none undertaken in Africa. This may be due to the lack of 
monitoring stations available in developing countries, with the majority of monitors usually 
in urban areas. This disproportionate balance should be rectified as it is known that children 
in poorer and developing settings are at greater risk to harmful effects of pollution. To 
address the needs of low and middle-income countries, a broader range of locations should 
be included in future studies to reduce worldwide health inequalities [321].  
 
This overview was conducted according to a pre-specified protocol, using robust 
methodology. A comprehensive search strategy was utilised to capture all relevant 
systematic reviews that matched the eligibility criteria, and only reviews with standard 
definitions of disease were included to reduce subjectivity. We also conducted a rigorous 
process to grade the validity of the results, which is an important factor when presenting 
evidence and using findings of this overview to make decisions about air pollution and 
childhood respiratory health.  
 
The main limitations relate to a lack of standardisation in methodological reporting of air 
pollution measurement. Ambient air pollution was measured in a variety of ways including 
personal exposure, up to average levels for an entire city. The varied methodologies may 
affect the accuracy of exposure within individuals. However, we are reassured by the 
generalised agreement between studies, with similar effect sizes noted, regardless of 
methodology used.  Standardisation of data collection methodology would help future study 
meta-analysis. In addition, consensus around which confounding factors to account for, and 
a core outcome set [315, 316] for epidemiological studies in air pollution would help 
improve data quality. 
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3.6 Conclusion 
 
Increased concentrations of all types of air pollution correlate with unscheduled HRU for 
children with acute respiratory illnesses, but there are considerable gaps in the evidence. 
Reductions in ambient air pollution are likely to produce significant respiratory health 
benefits in children.  The results in this chapter efficiently describes the current evidence 
available examining ambient air pollution, thus other variables such as genetics need to be 
assessed.  
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Chapter 4 – Pharmacogenomic associations of adverse drug reactions 
in asthma: systematic review and research prioritization  
 
4.1 Background 
 
Another variable that can contribute to the burden of respiratory disease on healthcare 
resources is the role that genetics plays in relation to medication. It is known that genetics is 
a risk factor for incidence of respiratory diseases, particularly asthma in childhood. 
However, since the human genome project the area of pharmacogenomics has gained 
momentum. This discipline may help to explain the variation seen in patients using the same 
medication, such as with anti-asthmatic medication.  
 
Asthma is a common chronic condition, affecting over 230 million people worldwide [360-
362]. The management for asthma is guided by national and international evidence based 
guidelines [363, 364], but there is inter-individual variability in treatment response. This 
variation may be related to several factors, including adherence, disease subtype and 
severity, and environmental factors. In addition, a patient’s genotype can affect outcomes 
of treatment in asthma [365-367]. The data from these pharmacogenomic studies of asthma 
medication efficacy in children have progressed to the point where there are now 
polymorphisms approaching clinical utility [368].  
 
However, the overall effectiveness of a medicine is a balance between the intended benefits 
and the potential risks. ADRs in asthma patients need to be considered alongside the 
efficacy already assessed in these classes of drugs. Asthma medication accounts for a large 
proportion of respiratory medicine prescribed in childhood. The medications used in asthma 
have a well described set of ADRs associated with their use (Table 13) [369]. 
 
 
   
 108 
Table 13. List of ADR's of asthma medication from the BNFC [366] 
Short Acting ß2 
Agonist 
Long Acting ß2 
Agonist 
Corticosteroids Leukotriene 
antagonist 
Theophylline 
Arrhythmias Arrhythmias Adrenal crisis Abdominal Pain Arrhythmias 
Fine tremor Arthralgia Adrenal suppression Abnormal dreams CNS stimulation 
Headache Fine tremor Aggression/ 
behavioral changes 
Aggressive behavior Convulsions 
Hyperglycemia Headache Candidiasis Agitation/ Anxiety Diarrhea 
Hypersensitivity 
reactions 
Hyperglycemia Cushing’s syndrome Dizziness Gastric irritation 
Hypokalemia Hypersensitivity 
reactions 
Hyperglycemia Hallucinations Headache 
Lactic acidosis Hypokalemia Hypertension Headache Hypokalemia 
Muscle cramps Muscle cramps Reduced growth 
velocity 
Hyperkinesia Hypotension 
Nausea Nausea Reduced mineral 
bone density 
Sleep disturbances Nausea and 
vomiting 
Rash Rash  Thirst Tachycardia 
Sleep/ behavior 
disturbance 
Sleep/ behavior 
disturbance 
   
Tachycardia Tachycardia    
In adult patients, ADRs are responsible for 6.5% of all admissions, while 14.7% of adult 
inpatients experience an ADR [370, 371]. For pediatrics, 3% of all admissions are related to 
ADRs [372], while over 17% of all pediatric inpatients experience one or more ADR [373]. 
For asthmatic patients, ADR’s represent a significant burden, reducing their quality of life, 
and extract an economic cost on healthcare systems worldwide [374, 375].  
 
There is also inter-individual variability in the type and severity of ADR experienced by 
patients. Factors such as adherence, and disease subtype influence this, but genomic factors 
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are also important [376], with several genetic polymorphisms associated with severe ADRs 
identified [377, 378]. Regulatory information to guide prescribers has been updated to 
reflect these findings [379].  
 
While the effect size in pharmacogenomic studies is often larger than that seen in genetic 
epidemiology studies [380], large cohorts are still required, and replication of findings is 
essential if findings are to be adopted into clinical practice [381]. International consortia, 
utilizing the data from multiple groups, have been developed to facilitate this process [382].  
Within asthma, the pharmacogenomics in childhood asthma (PiCA) consortia is well 
established, containing multiple cohorts from studies around the world [383].  
 
This chapter describes a pilot review undertaken in pharmacogenomics that examines ADR’s 
in asthma medications. It also includes a survey undertaken amongst members of the PiCA 
consortia to identify priorities in pharmacogenomic studies relating to ADRs.  
 
4.2 Aims  
 
1) To undertake a systematic review of pharmacogenomic studies of ADRs related to 
asthma medication across the entire population.  
2) To complete a survey establishing the current prioritization of ADRs within asthma 
pharmacogenomic research, and to determine future research priorities.  
 
4.3 Methods 
 
4.3.1 Inclusion and exclusion of studies  
 
Studies were eligible for inclusion if they were either randomized control trials (RCTs) or 
observational studies, such as cohort studies. The studies had to undertake genome 
analysis, with the researchers examining a known asthma treatment medication and if they 
stated ADRs. If ADRs had been stated as either the primary or secondary outcome the 
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studies were included. An ADR was classified according to the WHO definition [384]. Studies 
had to state the specific ADRs related to asthma medication.  
 
Studies were excluded if ADRs were stated to be seen but no report was produced with 
data. Studies that commented asthma exacerbations as ADRs were excluded as are deemed 
to be classified as a failure of medication efficacy, thus an adverse event, rather than an 
ADR.  
 
4.3.2 Identification of studies and search strategy  
 
Electronic databases were searched to identify eligible studies. These online databases 
included Medline and Embase previously described in chapters two and three, as well as 
cumulative index of nursing and allied health literature (CINAHL). CINAHL is a database of 
around 3000 journals, books, articles, conference proceedings and abstracts related to 
research in nursing, biomedicine, and the allied health professions. Coverage has been from 
1981. The databases were searched until January 2018 to locate eligible studies.  
 
The search terms used included “asthma”, “pharmacogenomics”, and “asthma medication”, 
see appendix 8 for search strategy. A list of asthma medication based on drugs extracted 
from the British National Formulary for Children (BNFC) with both generic and brand names 
included was used. Synonyms and truncations were used based on previous strategies 
applied. Each search term within the groups were combined using the Boolean operator OR 
with the groups then combined using the operator AND.  
 
References of included studies were analysed to locate any relevant studies of interest. 
Comments from the survey regarding possible eligible studies was also considered.  
 
No limit was placed on language, publication date or age of study population. Reviewer CK 
constructed the search strategy and undertook the relevant searches in each strategy.  
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4.3.3 Study selection  
 
Studies were reviewed by two independent reviewers (CK and DH), who after removal of 
duplicates, screened titles and abstracts for inclusion. Full text was then analysed for 
eligibility with data extraction completed collectively by the two reviewers. Disagreements 
between the two reviewers was discussed and resolved mutually.  
 
4.3.4. Data extraction and statistical analysis 
 
From each study, data was extrapolated by reviewer CK into the predefined characteristics 
and results tables. These included: 
 
- Drug examined, with both the class and generic name of the medication 
- The ADR stated in the study 
- Method of gene identification and the associated single nucleotide polymorphism 
(SNP) and gene 
- Asthma severity  
- Study design and characteristics of participants  
- Effect of SNP in discovery cohort  
 
From studies with replication cohorts, the effect estimate in this group of participants was 
extracted.  
 
A qualitative analysis was conducted on the extracted data, with each asthma medication 
then individually reported. 
 
4.3.5 Quality assessment   
 
Methodological quality assessment was undertaken in the included studies using the 
Newcastle Ottawa quality assessment scale [385] for cohort and case-control studies, and 
the Cochrane Risk of Bias tool for randomised controlled trials (RCTs) [386]. 
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The Newcastle Ottawa scale has been described in chapter two. The Cochrane risk of bias 
tool [387] is a standard method for evaluating the risk of bias in RCTs. The tool comprises of 
seven domains that aim to cover the fundamental areas of bias that may occur in RCTs. 
These domains are selection bias, reporting bias, performance bias, detection bias, attrition 
bias, and other sources of bias that may be apparent. A judgement is then formed on a high, 
low or unclear risk of bias score for each of the domains.  
 
 These tools although do not cover all areas of bias allow for standardised comparisons to 
be developed between studies based on their methodological strength.  
 
4.3.6 Survey  
 
An online survey was undertaken of PiCA consortia members to establish if the review had 
identified all possible pharmacogenomic studies analysing ADRs and asthma medication. In 
addition, the survey aimed to collate responses regarding the importance of capturing ADRs 
in future studies, as well as identifying which ADRs survey members felt should be 
investigated in future studies as priorities.  
 
The anonymous survey included ten questions with comments sections supplied for issues 
regarding the questions, these are shown below:  
 
1) Member of PiCA consortia?  
2) Name of institution  
3) Do you think adverse drug reactions should be captured in pharmacogenomic 
studies of paediatric asthma? 
4) To date how well have studies captured these adverse drug reactions? 
5) What adverse drug reaction concerns you the most relating to beta-2 agonists?  
6) What adverse drug reaction concerns you the most relating to inhaled 
corticosteroids?  
7) What adverse drug reaction concerns you the most relating to leukotriene receptor 
antagonists?  
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8) What adverse drug reaction concerns you the most relating to theophylline?  
9) For each class of drugs please give your top three ADR’s you would wish to see 
captured in future studies.  
10) Any other comments  
 
The survey was open for two weeks with remainders sent to participants during the time 
period.  
 
4.4 Results  
 
4.4.1 Results of search  
 
There were 1409 results after removal of duplicated generated from the search strategy, of 
these three were eligible for inclusion [267, 388, 389]. From the survey sent, two additional 
studies were discovered [390, 391]. The review flowchart is shown in figure 8. 
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 Figure 14. Review flowchart of studies included in systematic review of pharmacogenomics and ADRs in asthma medication
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4.4.2 Description of included studies  
 
There were few studies that reported ADRs specifically and as a primary outcome. Adverse 
events such as decreased efficacy or increased asthma exacerbations were reported in 
other papers not included. Within the eligible studies, a small proportion reported on ADR’s 
as an end point of their studies. 
 
In the included studies, four were randomized control trials [388-391], and one was a cohort 
study [267]. Two of the studies were undertaken in the United Kingdom with the other 
three having been carried out in the USA. The overall sample size of the studies was small, 
1457 participants, with the largest proportion of participants being from a child population. 
The characteristics of the included studies are shown in Table 14.
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Table 14. Characteristics of included studies.  
RCT: Randomised controlled trial. GWAS: genome wide association study 
Study  Drug Asthma Severity  
Study Design and 
number of 
participants  
Method of gene 
identification Ethnicity (number recruited) 
Age range recruited 
years (mean) 
Israel 2004 
[388] Inhaled SABA  Mild asthma RCT, 78 Candidate gene 
White (56), Black (15), 
Hispanic (6), Other (11) 18-55yrs 
Tan 1997 
[389] Inhaled LABA  
Moderately severe 
asthma RCT, 22 Candidate gene Not stated No mean age given 
Park 2015 
[390] 
Oral 
corticosteroids  
Mild to moderate 
asthma RCT, 489 GWAS Caucasian 5-12yrs 
Park 2017 
[391]  
Oral 
corticosteroids  
Mild to moderate 
asthma RCT, 461 GWAS Caucasian  5-12yrs 
Hawcutt 2018 
[267] 
Inhaled +/- Oral 
Corticosteroids All severities Cohort study, 407  GWAS Caucasian 5-18 (11.6) 
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One study examined ADR’s with inhaled short acting beta-2 agonists (SABA) [388], one 
analyzed long acting beta-2 agonists (LABA) [389], three studies examined the use of 
corticosteroids [267, 390, 391], and no studies examined either leukotriene receptor 
antagonists (LTA) or theophylline. For the SABA and LABA studies the candidate gene 
approach was applied [388, 389], whereas in the three corticosteroid studies genome wide 
association studies (GWAS) locating novel SNPs was used [267, 390, 391]. 
 
All included studies had a low risk of bias, the results are shown in appendix 9. 
 
4.4.3 ADR’s and asthma medication  
 
When analyzing the genes identified in the studies, the candidate gene studies examined 
the same SNP, rs1042713, which is associated with the beta-2 adrenergic receptor gene 
(ADRB2). In contrast the platelet derived growth gene (PDGFD), the rap guanine nucleotide 
exchange factor 5 gene (RAPGEF5), the tubulin folding cofactor D (TBCD), and the tubulin 
gamma 1 gene (TUBG1) were all identified through GWAS. The ADR’s associated with each 
SNP, and presence of replication, is shown in Table 15.
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Table 15. Adverse drug reaction for each SNP in included studies 
Drug  Adverse Drug 
Reaction 
Associated 
SNP & Gene 
Effect of SNP in discovery cohort Replication cohort (Y/N) and effect(s) (p-
value) 
Inhaled Salbutamol  [388] Decrease in PEFR rs1042713, 
ADBR2 
23L/min improvement of PEFR on discontinuation of 
Albuterol in Arg16/Arg16 group (p=0.0162) 
N 
Inhaled Formoterol [389] Desensitization to 
bronchodilator effects  
rs1042713, 
ADBR2 
Homozygous Gly16/Gly16 patients exhibited greater 
desensitization, measured using FEV1, and FEF25-75  
N 
Oral prednisone [390] Decreased bone 
mineral accretion 
rs9896933, 
TBCD 
Decreased bone mineral accretion (p-value= 3.15x10-
8 in GWAS) 
N 
Oral prednisone [390] Decreased bone 
mineral accretion 
rs2074439, 
TUBG1 
Decreased bone mineral accretion (p-value= 2.74x10-
4 in GWAS) 
N 
Oral prednisone [391] Decrease in BMD-z 
score 
rs6461639, 
RAPGEF5 
One of top 100 SNPs but did not achieve genome 
wide significance 
Y. Statistically significant decrease BMD-z 
score in pediatric ALL cohort (p=0.016) 
Inhaled corticosteroids 
+/- additional 
corticosteroids [267] 
Adrenal suppression 
(peak cortisol 
<350nmol/L) 
rs591118, 
PDGFD 
Increased risk of adrenal suppression (OR 7.32, 95% 
CI 3.15-16.99) 
Increased risk of adrenal suppression in 
pediatric asthma cohort (OR 3.86, 95% CI 
1.19–12.50) and adult COPD cohort (OR 2.41, 
95% CI 1.10-5.28). Meta-analysis of all 3 
cohorts achieved genome wide significance. 
ALL: acute lymphoblastic leukaemia. FEV1: forced expiratory volume in 1 second. FEF25-75: forced expiratory flow at 25-75% of pulmonary volume. PEFR: Peak expiratory 
flow rate. BMD: Bone mineral density. GWAS: genome wide association study. COPD: Chronic Obstructive Pulmonary Disease. SNP: Single Nucleotide Polymorphism. CI: 
confidence interval 
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Regarding the ADR’s in SABAs, one study [388], examining 78 adults found that if 
participants had the homozygous Arg16/Arg16 allele then the performance was lower when 
on albuterol compared to the placebo, with the peak expiratory flow rate being 23L/min 
better when albuterol was stopped. However, when this was replaced with ipratropium 
bromide, an anti-muscarinic, this group of participants had higher peak flow rates than 
when on albuterol or placebo.  
 
For LABAs, one study [389], that had examined 22 adult participants found that participants 
with the homozygous Gly16/Gly16 genotypes their maximum FEV1, maximum FEF25-75, 6hr 
FEV1 and 6h FEF25-75 was lower compared to the Arg16/Arg16 genotype when given 
formoterol.  
 
With inhaled corticosteroids, one study [267], examining 407 children from the PASS 
(Pharmacogenetics of Adrenal Suppression with Inhaled Steroids) study aged 5-18 years 
found that the SNP rs591118, located at the PDGFD gene, was associated with a higher risk 
of adrenal suppression (odds ratio in the pediatric asthma replication cohort 3.86, 95% CI 
1.19–12.50).  
 
For oral corticosteroids, two studies [390, 391] examined children aged 5-12 years, from the 
CAMP (Childhood Asthma Management Program) trial, and the effect of prednisone on 
bone mineral density (BMD) z scores and bone mineral accretion (BMA). For decreases in 
BMD z scores one SNP was identified, rs6461639, and in the ALL (acute lymphoblastic 
leukemia) replication cohort it was significant (p-value=0.016)[391]. With the other study 
[390], two associated SNPs were found to worsen BMA with increased prednisone dosage, 
rs989633 and rs207439.  
 
Internal replication was undertaken in two of the studies, both that examined 
corticosteroids [267, 391].  However, additional publications attempting external replication 
of these polymorphisms have not been identified.  
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4.4.4 Results from survey 
 
There were 20 participants that undertook the survey, all members of the PiCA consortia, 
representing 15 institutes in eight countries. 95% identified ADRs as an area that should be 
captured in pharmacogenomic studies, and 80% of respondents agreed that only a small 
percentage of studies currently assessed this area. The survey respondents undertook a 
prioritization exercise to establish the ADRs for each asthma medication they believe should 
be subject to further pharmacogenomic research. The results of this prioritization exercise 
are shown in table 14 (ranked in order of highest priority to lowest).  The most important 
ADR’s by consensus for each drug class varies; for beta 2 agonists (SABA or LABA) it was 
tachycardia, corticosteroids it was both adrenal suppression/crisis and reduced growth, for 
leukotriene receptor antagonists it was sleep/behaviour disturbances, and for theophylline 
it was nausea and vomiting. Not all participants completed the survey for ADRs of each 
drug. For theophylline, 39% reported that the drug was no longer used in current treatment 
steps. 
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Table 16. ADR's from survey and number of people who prioritized each ADR ranked from highest  
ß 2 agonists Corticosteroids 
Leukotriene receptor 
antagonists 
Theophylline 
 Tachycardia (14) 
Adrenal suppression 
crisis (11) 
Sleep/behavior disturbances (12) Nausea and vomiting (9) 
 Arrhythmias (9) Reduced growth (11) Headache (7)  Arrhythmias (7) 
 Fine Tremor (8)  Candidiasis (4) Nausea and vomiting (5)  Headache (5) 
 Hypokalemia (6)  Hyperglycemia (4)  Tachycardia (3)  Tachycardia (4) 
Tachypnoea (4) 
Sleep/behavior 
disturbances (3) 
Hypersensitivity reactions (2) 
 Sleep/behavior 
disturbances (3) 
Lactic acidosis (3) 
 Bone complications 
(3) 
Rash (2) Hypokalemia (2) 
Nausea and vomiting 
(3) 
Fine Tremor (2)  Fine Tremor (1)  Tachypnoea (2) 
Headache (2) Headache (2) Abdominal pain (1)  Fine tremor (2) 
Asthma exacerbation 
(2) 
Nausea and vomiting 
(2) 
Hypokalemia (1)  Lactic acidosis (1) 
Hyperglycemia (2) Rash (1)  Lactic acidosis (1)  Hyperglycemia (1) 
Sleep/behavior 
disturbances (1) 
Asthma Exacerbation 
(1) 
Candidiasis (1) Rash (1) 
Tachyphylaxis (1)  Dizziness (1) CNS problems (1) 
  Agitation/anxiety (1)  
  
Infection/immunosuppression 
(1) 
 
  Asthma Exacerbation (1)  
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4.5 Discussion  
  
This is the first systematic review that considers the harms of anti-asthma medications and 
their relationship to an individual’s genetic variability. This systematic review has identified 
six different ADRs that have pharmacogenomic associations, but these are a small subset of 
the overall pharmacogenomic research in asthma. In addition, there is a lack of replication 
cohorts within the current evidence with only two studies including internal replication 
cohorts in their research. In both of these studies these replication cohorts successfully 
demonstrated the associations with individual polymorphisms identified in the discovery 
cohort.  
 
The survey of PiCA consortia members supported future pharmacogenomic research into 
ADRs in asthma, and prioritized ADRs for each anti-asthma medication. Although it is not 
surprising for consortia members to support future research, the lack of current evidence 
highlights that it has previously not been of importance by the members, through the 
survey the aim was to change this perception so that ADR’s are a priority. For most of the 
prioritized ADRs, we have not been able to identify any published pharmacogenomic data. 
In addition, we note that while ADRs associated with SABA/LABA medications were 
identified in the evidence these ADR’s are not the ones members prioritized in the survey. 
However, for corticosteroids the ADRs identified in publications did correlate well with the 
ADRs prioritized in the survey. Asthma is a disease that is particularly suitable for 
personalization of therapy to either select efficacious medicines or avoid harms, as there are 
several possible medications, and so alternate drug selections are possible.   
 
A minority of participants in the survey commented that asthma exacerbations concerned 
them as an ADR for beta-2 agonists, corticosteroids and LTA’s. They are included in the 
results of the survey. The protocol used excluded these a priori as they were considered a 
failure of treatment, not a worsening of disease. However, we note the core outcome set 
for childhood asthma does include risk of hospitalization secondary to asthma 
exacerbations. Reviewing the literature, asthma exacerbations have been defined as 
adverse events rather than ADRs in previous pharmacogenomic studies [365, 392, 393]. A 
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study, examining children with asthma who were on ICS plus LABA identified an increase of 
asthma exacerbations of 52% in those homozygous for the Arg16/Arg16 allele of ADRB2 
[392]. However, it needs to be determined if asthma exacerbations should be classified as 
an adverse drug reaction in future studies or is to do with efficacy instead.  
 
Along with understanding how pharmacogenomics affects asthma medication efficacy by 
using the evidence discovered in this systematic review, and the potential future evidence 
for ADR’s, the area of personalization of medication can grow. Personalizing medication will 
help patients to improve the control of their disease through pharmacotherapy. The 
practice of personalizing medicine is currently limited with asthma medication currently 
used in a stepwise approach [394]. The information from this systematic review may help to 
recognize that each patient is unique, thus each pharmacotherapy treatment plan should be 
unique.  
 
A limitation of this study is that, as for any systematic review, the quality of the data 
produced is dependent on the quality of existing publications, and there were a paucity of 
eligible papers covering a range of drugs and ADRs. These studies all had relatively small 
sample sizes, and the diversity of ADRs identified precluded meta-analysis. However, the 
identification and prioritization of ADRs by members of the PiCA consortia is a positive 
indicator that future pharmacogenomic studies may include more ADRs as well as markers 
of efficacy.    
 
4.6 Conclusion 
 
There are few pharmacogenomic studies of ADRs in asthma that have been undertaken. 
None of the studies that have been undertaken have been externally replicated. Future 
pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of 
efficacy. Drug specific ADR priorities have been established to guide researchers.     
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Chapter 5 – Discussion and main findings  
 
5.1 Main findings 
 
Several findings can be obtained from the evidence contained within this work. In chapter 
two, a systematic review of studies regarding the association between ambient air pollution 
and risk of bronchiolitis in infants is described. There were few eligible studies that analysed 
the specific outcome of hospitalisation, with half of these studies commenting on measured 
concentration levels of ambient air pollutants in their study. Positive associations were 
discovered for different pollutants at various time lags, even at low air pollutant 
concentrations. 
 
It is biologically plausible that air pollutants might increase the likelihood of severe 
bronchiolitis, because of the known effects exposure has on lung function [395, 396] and 
airway inflammation [397]. In systematic reviews of epidemiological studies, risk of asthma 
exacerbations in children was increased with exposure to particulate pollutants, O3, SO2 and 
NO2 [351], and the risk of acute lower respiratory infections is associated with PM2.5 
exposure [331]. The possible differences between pollutants with regards to the chronicity 
of their association with hospitalisation for bronchiolitis may reflect different pathogenic 
processes. With particulate pollution, PM2.5 and PM10 may have a more chronic pro-
inflammatory effect [398], whereas NO2 and SO2 may be associated with more acute 
damage to airways as are considered to be more irritative to the lung epithelium [399]. 
Further work is required to better understand the in vivo pathogenic effects of these 
pollutants in the airways of infants and children [400], and thus understand the difference 
seen in lag exposures between the pollutants and hospitalisation risks.  
 
Although the systematic review in chapter two analysed the effects of air pollution to the 
risk of hospitalisations after birth, emerging evidence suggests an association between 
antenatal air pollution exposure and low birthweight [327] which may also affect risk of 
severe bronchiolitis. In a Spanish cohort study, NO2 exposure in the second trimester was 
positively associated with an increased risk of doctor diagnosed lower respiratory tract 
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infection (LRTI), with 98% of the diagnosis being classified as bronchiolitis or bronchitis 
[400], and this study highlights the possibility that antenatal exposure to air pollutants 
should be considered as a risk factor for bronchiolitis.  
 
Differences in the methodological process for air pollution measurements between studies 
was observed, with no set standard. Some studies geocoded pollutant exposure levels to 
cases residential addresses, whereas others just measured the average concentrations 
between monitors in area. When using air pollutant monitors in a set area and then 
averaging the levels there may be some degree of misclassification of exposure levels, this 
may be due to the inclusion of remote monitoring sites that alter the concentrations. 
Furthermore, even though some studies correlated air pollution level concentrations to the 
patient’s residences or the admitting hospitals, in urbanised city areas monitoring sites will 
experience high concentrations along with greater fluctuations in those concentrations that 
may affect the results. Thus, overall these observational studies may then underestimate 
the overall association seen between hospitalisation with bronchiolitis and ambient air 
pollution.  
 
In the overview of systematic reviews to determine an association between acute 
respiratory events requiring healthcare resource utilisation and ambient air pollution 
exposure, described in chapter three, the link between the respiratory disease morbidity 
outcomes and air pollution was positively associated, particularly for short-term exposure. 
There were gaps in the evidence available regarding certain respiratory diseases and with 
time periods around asthma and pneumonia. These two respiratory diseases were only 
assessed according to short-term exposure with ambient air pollution by authors. 
Measurements surrounding exposure concentrations of ambient air pollutants in the 
systematic reviews was limited, with only a few reviews comparing concentrations observed 
to the WHO guidelines. Although, the need to review the WHO exposure threshold 
guidelines is apparent as positive associations were discovered in concentration levels 
below the set guidelines.  
 
Quantifying the potential benefits related to reductions in ambient air pollution on 
unscheduled HRU would require sophisticated modelling methodology, outside the scope of 
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the overview in chapter three. However, there are reasons to be optimistic about potential 
impact. In European countries asthma causes around 0.6% of hospital admissions [401], to 
help tackle the incidence of asthma admissions legislation on a known risk factors has 
previously been introduced. Smoke-free ban has been successful in reducing hospital 
attendances for asthma in children [402, 403]. It is not just national legislation that has 
shown to be successful, policies at the local level have shown similar results, improvements 
in asthma outcomes have been seen in Boston with the Asthma Prevention and Control 
Program [404-406]. Even modest reductions in ambient air pollution may therefore have the 
potential to avoid a significant number of unscheduled HRUs.  Detailed health economic 
analysis would be required to quantify these potential benefits.  
 
The work undertaken to examine the environmental factor, air pollution, on respiratory 
disease is only one part of the larger picture. Respiratory disease is known to be 
multifactorial with interindividual variation shown in people suffering from the same 
respiratory disease. This variation may be due to differences in a person’s environment, as 
shown in the work above, however other variables may contribute that need to be explored 
as well. One of these variables is the speciality of pharmacogenomics, this area has been 
shown to effect treatment of respiratory diseases, with asthma medication efficacy shown 
to be affected in previous studies [392, 407].  The emphasise in this area has been 
medication efficacy, however, ADR’s are of equal importance in this cohort, with no 
systematic review of current evidence previously undertaken. In chapter four, a pilot review 
was carried out and highlighted the limitations in the current evidence and emphasised the 
need for increased inclusion of examination of ADRs in studies. This recommendation was 
further supported through results from the survey, where international professionals 
recognised it as an undervalued but important area of future research. To help prospective 
studies a development of a list of ADR’s prioritized from highest to lowest for each class of 
asthma drugs has been completed.  
 
The main recommendations from this work are twofold. The first refers to 
recommendations revolving around ambient air pollution and adverse effects. Methodology 
between exposure assessment of air pollutant and associating this with outcomes, needs 
improved classification on the most appropriate study design and statistical analysis for 
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situations. Additionally, ambient air pollution is increasing, there is now sufficient evidence 
to move the discussion onto how interventions may help to reduce the impact seen by air 
pollution on health at both the national and personal exposure level. These are needed to 
reduce estimates of future hazardous effects air pollution will concur if the current path is 
continued. The second revolves around pharmacogenomics and recognising ADRs as an 
important factor to be considered in future studies, one that is equal to medication efficacy. 
The areas highlighted concerning the methodology of epidemiological studies and possible 
future interventions to limit air pollution exposure and are discussed in the sections below.  
 
5.2 Methodology of epidemiological exposure studies and adverse health outcomes 
 
When discussing pollution exposure there are various methods available to researchers to 
assess the effect, one of these is a general hierarchy system that has been proposed in 
literature to help [14, 408], figure 9 depicts the best approximation of exposure levels to the 
poorest. 
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Figure 15. Hierarchy of exposure assessment from least accurate in estimates to best for estimates [14] 
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Estimates of exposure levels decrease in accuracy the greater the distance a monitor is 
positioned away from a person, exposure models, multiple fixed sites and the use of 
proximity monitors further decrease the quality of exposure yet are better than the use of 
central monitoring sites due to spatial variation between individuals. The following 
paragraphs discuss the use of different exposure assessment systems. 
 
Despite the fact that for certain specific pollutants biological markers offer the best 
exposure assessment they are rarely used for various reasons. Biological markers are useful 
at the individual level, a common marker that is used is carboxyhaemoglobin levels as an 
assessment for CO exposure. Yet, there are high costs associated with this method, not all 
pollutants have biomarkers available that can assess for exposure, and unless the study is 
undertaken on a small scale it is difficult to obtain results.  
 
Another useful method to measuring at the individual level is the use of personal monitors. 
Personal monitors provide one of the better pieces of evidence for estimates of exposure at 
the individual level. As the name suggests the equipment is attached to a person as they 
carry out their normal day to day activities with additional information then supplied such 
as locations travelled each day by the participant. Although they are useful, there are some 
downfalls to this method, so in practice it is rarely used. Some of these issues are that the 
devices can be a burden on participants, particularly active devices that are battery 
operated due to the noise that is admitted, and often need regular re-calibration to provide 
valid measurement. This method is not feasible for measuring long-term exposure or 
assessing exposure retrospectively.  
 
A possible alternative method to personal monitors is the use of home monitors or monitors 
measuring microenvironments. This method doesn’t depend on a participant’s involvement 
as measures personal exposure indirectly. However, this method is not feasible for large 
scale use due to the set up and running of the monitors.  
 
A recent method that is gaining in popularity is the use of exposure modelling. This method 
can help to improve the equilibrium, missing from previous methods mentioned, between 
scale of study and exposure accuracy. Exposure modelling has the possibility of providing 
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individual exposure estimates in large studies without the need to interact with participants. 
There are two main types currently used; air dispersion models and land use regression 
(LUR) models. Air dispersion models use mathematical functions to predict the 
concentration of pollutants in the atmosphere dependent on source of pollutant and 
meteorological conditions. The method follows a logical path from source of pollutant to 
monitoring sites to help predict results. The advantage of this model is that is allows for the 
prediction of individual pollutants at specified locations if enough data is available 
surrounding that area.  However, the main issue with this way is that it is very expensive 
and time consuming particularly when applied to large study areas. An alternative method 
that is being applied is LUR modelling, this uses multiple pollutant concentrations at 
multiple sites in a specific area and then with the development of stochastic models using 
predictor variables through geographical information systems (GIS) a model can then be 
applied to an location without monitoring in that area [409]. This model has been applied in 
epidemiological studies in urban areas in Europe and North America, such as in the 
European Study of Cohorts for Air Pollution Effects [410]. Advantages of this method is that 
it can be readily applied in studies with large cohorts of participants and are relatively cost 
effective. However, the model is area specific thus for each new geographical area it has to 
be redone.  
 
Another method is the use of measurements from fixed monitoring sites. This provides 
periodic, accurate concentration information related to the monitoring site but cannot be 
applied to reflect exposures of individuals. This method assumes that individuals in areas 
will all have the same exposure concentration level, thus ignores the spatial distribution that 
occurs with air pollution and the idea that individuals will have differences in exposures. A 
disadvantage of this fixed site monitoring measurements is that it is difficult to assess the 
effect total exposure from indoor pollution when concentrations are large as correlation 
with the monitors is poor. However, it is good as can be used to reflect daily changes in 
ambient air pollutant levels, it is not too expensive due to the presence of monitoring sites 
already in most urban developed areas. This method has often been used in studies 
examining health effects of air pollution and short-term exposure.  
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Proximity analysis uses a geospatial method, such as the distance from a pollution source as 
a measure of exposure rather than specific concentration levels. An example of this is with 
traffic related pollution where researchers use distance from major roadways to determine 
exposure levels. The advantage of proximity analysis is that with advances in GIS software 
and the use of digital maps it has become an easy method to implement. Disadvantages of 
this method is that it cannot distinguish between specific pollutants, does not consider 
meteorological confounding variables, nor explains for spatial distribution of air pollution, 
can only be used to describe categorical variables, and has low precision due to the 
geocoding method used as relies on postcodes which can correspond to a large area when 
variables are produced in reference to metres. 
 
An important aspect of exposure assessment found in the included studies and in the 
systematic reviews related to whether studies had examined exposure at the individual or 
community level. At the community level it is assumed that air pollutant concentrations are 
similar throughout the area with little spatial variation present. Here studies would use 
central monitors and assign the same pollution exposure level to all, however this may not 
be the case as even in urban areas concentrations have been shown to fluctuate over very 
short distances. For the studies that assessed long-term exposure and used modelled data, 
this can create issues as data is modelled on a previous year’s concentrations and over a 
number of years this can change, thus may not be comparable to the year being examined.  
 
With confounding variables in the epidemiological studies, not all of them considered the 
same confounding factors such seasonal variation, indoor air pollutants, and meteorological 
factors. These variables are known to have an effect on ambient air pollution concentrations 
so need to be considered when designing exposure assessment methodology. This can lead 
to exposure misclassification if not assessed and thus add uncertainty to study results.  
 
The method for assessing exposure will vary depending on the time period being assessed 
i.e. for short-term exposure the use of modelling and fixed sites which are geocoded to a 
person’s residence would be more beneficial. If looking at population or community levels 
these methods provide a more accurate and valid exposure assessment than the use of 
proximity monitoring and even personal exposure is limited in these studies as they may be 
   
 132 
influenced by confounding pollutants and unrealistic for the large scale. In regard to using 
exposure models the ideas of combing dispersion and land use regression models has been 
used to help maximise the benefits with both without the drawbacks of using them 
individually.  
 
The ideal methodology would consider temporal and spatial variation of pollutants, 
variation between indoor and outdoor environmental concentrations and variation in 
location of participants at different times.  
 
5.3 Interventions  
 
The evidence that has been described supplies sufficient information to understand the 
hazardous effect of air pollution on respiratory health in children. With this effect known a 
new branch has to be addressed regarding possible interventions that can be developed and 
implemented into society to reduce pollution. These can be divided into governmental 
interventions or ones at the personal exposure level.  
 
Increasing air monitoring sites and data collection worldwide will help to reflect exposure 
levels and give people the information they require to be decisive when it comes to 
protecting their health. The current WHO guidelines on air pollution are recommendations 
for countries and policy makers to follow, thus do no need to be abided strictly. Policy 
makers and countries can produce their own legislative levels they deem reasonable.  
 
Recently, 22 countries in Europe, such as England, Germany, France, Hungary, Italy and 
Romania have been given warnings by the European court of justice (ECJ) regarding illegal 
high levels above those set out by the European Union (EU) [13, 106]. Even in the presence 
of fines and having to attend court, these countries are not rectifying the situations and 
failing to enact adequate clean air plans. Regarding the levels in the United Kingdom, a new 
clean air strategy has been produced, although this has received strong backlash from 
politicians and environmental activists [411]. One of these goals is to reduce the number of 
the population residing in places where particulate matter levels are above the WHO 
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guidelines by half by 2025, currently there are 90% of people in the UK residing in high level 
areas [412, 413].  
 
There is a large need for both manufacturers and countries to tackle air pollution, however 
without them on board the health impact will continue to grow. In 2015, the manufacture 
Volkswagen highlighted one of the major issues when it comes to tackling air pollution, 
diesel-gate occurred [414]. The deception in nitrous oxide (NOx) emissions above those 
legally allowed may have led to an uncertain amount of deaths due to excess pollution, 
particularly in Europe where the proportion of diesel vehicles is roughly half [415]. Since the 
diesel-gate scandal, countries have tried to tackle their diesel exhaust emissions through 
monetary fines for diesel owners and the introduction of car free days in cities [415]. In 
2017, another blow to tackling air pollution happened when the USA pulled out of the Paris 
Climate Change agreement, a decision which will have long lasting impacts on pollution 
emissions [416]. Countries and manufacturers need to implement policies and equipment 
that will have an impact on reducing air pollution to help reduce the impact it has on health 
and will continue to have.  
 
A possible intervention that could be introduced to decrease city and town levels of 
ambient air pollution is the introduction of clean air zones (CAZ) [412]. These zones would 
help to deter cars from entering certain areas, limiting the pollution due to vehicular 
emissions in these areas. Although these areas exist in locations in London and have been 
given the approval to be used in other local authorities there has been little action in other 
areas to introduce them. Another intervention to decrease vehicular emissions is the 
increased use of public transport and cycling in cities. In Norway, the government have 
aimed to ban all cars from city centres by 2019 [417]. Whereas, in Copenhagen they have 
low levels of vehicular emissions due to half of the population cycling to work [417].  
 
Some personal interventions that could be applied in areas with high levels is the use of air 
pollution estimates on weather maps. This allows people to take control of their risk to 
ambient air pollution levels, if people are warned that particular days may be high then they 
can limit the exposure. Another possibility is the use of home air filters which could act on 
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both indoor and outdoor air pollution entering the house. Although these would rely on the 
financial situation of families to install. 
 
Some physical barriers to exposure could be the use of facemasks [418, 419], with some 
being shown to be 90% effective in limiting air pollution exposure. However, the use of 
facemasks is variable depending on the type and if they are used correctly by the population 
wearing them[412]. Another idea that would be useful for infants who are a highly 
susceptible group is the use of pram covers when near main roads or on the school runs 
[420]. This would be particularly useful in London which has over 800 institutes for 
education such as nurseries in areas with illegal high levels of NO2.  
 
Overall, there are various interventions that can be introduced to help tackle air pollution. 
Although, even with these interventions the best route to addressing the problem is by 
reducing our emissions of pollution around the world and make a conscious effort as 
humans to do so for the good of our health.  
 
5.4 Conclusion 
 
This thesis emphasises the need for ambient air pollution to be recognised as a major risk 
factor for hospitalisation with respiratory disease in children. It is encouraging that in 
certain respiratory diseases such as asthma and pneumonia this association has been 
recognised in this vulnerable group, with further work still needed in other illnesses. 
However, there is a long way before air pollution levels will be improved to combat the 
consequences of exposure. Currently, although gaining in recognition, action to combat 
concentration levels is being hindered by individuals and policy makers who are opposed to 
change. Further effort at the local and national level needs to occur to reduce 
concentrations and limit dangerous exposure levels in areas around the world. Recognising 
environmental factors is not enough, other variables need to be considered in relation to 
respiratory disease to reduce the burden that it has on healthcare resources. This thesis has 
shown that a possibility is addressing ADRs in children related to pharmacogenomics. This 
could lead to a more personalised approach to medicine for children suffering from 
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respiratory disease. The combination of these variables it vital to reduce the burden of 
respiratory disease on individuals and resources.   
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Appendix 1 – Protocol for systematic review submitted to PROSPERO 
 
Review title  
 
A systematic review of the effect of outdoor air pollution on the risk of hospitalisation for 
bronchiolitis in infants  
 
Review team members and their organisational affiliations 
 
Dr Ian Sinha. Alder Hey Children's Hospital 
Dr Daniel Hawcutt. Alder Hey Children's Hospital  
Miss Charlotte King. University of Liverpool Institute of Translational Medicine, Department 
of Women's and Child Health  
 
Funding sources/sponsors 
 
Charlotte King is part-funded by The National Institute for Health Research Collaboration for 
Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).  
 
Conflicts of interest  
 
The views expressed here are those of the author(s) and not necessarily those of the NHS, 
the NIHR, or the Department of Health and Social Care.  
 
Collaborators 
 
Mr Jamie Kirkham. University of Liverpool, Department of Biostatics  
 
Review Question  
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Objective – to systematically review the evidence exploring the association between air 
pollution and bronchiolitis, including hospital admissions, length of stay, emergency 
department visits and mortality.  
 
Searches  
 
Studies will be identified using electronic search databases: MEDLINE, SCOPUS and Web of 
Science to find eligible studies for review.  
 
Search terms will include the general subject term ‘bronchiolitis’ as well as for the target 
age population that is of interest. Each search strategy will be tailored depending to the 
search database because of syntax, limits and available fields vary between databases.  
 
There will be no restriction for language or publication date.  
 
Types of studies to be included  
 
Studies that examine the relationship between air relationship and bronchiolitis. Cohort 
studies and case crossover study designs including time series study designs will be 
included. Animal studies and duplicates are to be excluded.  
 
Condition or domain being studied 
 
Bronchiolitis 
 
Participants/Population 
 
Children aged less than or equal to 2 years old.  
 
Intervention(s), Exposure(s) 
 
Exposure to air pollution both short-term and cumulative.  
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Exposure to any outdoor air pollutant will be examined:  
 
Gaseous pollutants including carbon monoxide, nitrogen dioxide, ozone and sulphur dioxide  
Particulate matter including PM2.5 and PM10  
 
Comparator/Control  
 
These will vary according to the individual study design.  
 
Context 
 
Primary Outcomes  
 
Bronchiolitis admission to hospital  
 
Secondary Outcomes  
 
Length of Stay in Hospital.  
Critical Care admission.  
Emergency Department visits.  
Unscheduled visits to healthcare professional.  
Bronchiolitis mortality.  
 
Data Extraction  
 
All abstracts and titles will be screened independently by two reviewers to determine 
potential studies for review.  
Full text articles that meet the study selection criteria will be reviewed for eligibility for the 
systematic review and meta-analysis. If there is disagreement a third review will be sought 
for consensus.  
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Data to be extracted will vary depending on outcomes in each individual study that meet 
the primary and secondary outcomes being analysed.  
Risk of bias (quality) assessment 
 
Publication bias will be assessed by constructing a funnel plot.  
The Newcastle-Ottawa Scale will be used to assess quality of non-randomised studies. A 
‘star system’ in the Newcastle-Ottawa Scale will be used to judge a study on three broad 
perspectives:  
a) the selection of the study groups; 
b) the comparability of the groups; and 
c) the ascertainment of the exposure or outcome of interest.  
The studies will be graded as poor (1-3 stars), intermediate (4-6 stars) and high (7-9 stars) 
quality. Heterogeneity will be examined using the standard I2 test.  
Strategy for data analysis 
 
Characteristics from studies will be presented in tables and narrative forms, guided by the 
use of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta Analyses) 
statement.  
 
Exposure effect will be measured using risk ratio as a measure of effect size. 
 
We anticipate heterogeneity between studies due to different study designs, methods of 
analysis, lag exposures, and geographical and population differences. A random effects 
model will therefore be used to account for heterogeneity between and within studies. 
 
Analysis of subgroups or subsets 
 
We will undertake sub group analysis between developing and developed countries  
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Appendix 2 – Search strategy used for systematic review on risk of hospitalisation with 
bronchiolitis and ambient air pollution  
 
Web of Science, Medline and Scopus were searched.  
 
Web of Science  
 
TOPIC: (baby) OR TOPIC: (infan*) OR TOPIC: (pediatric*) OR TOPIC: (paediatric*) ORTOPIC: (
peadiatric*) AND TOPIC: (child*) AND TOPIC: (toddler*) AND TOPIC: (pre-school*) 
 Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
TOPIC: (Bronchiolitis) OR TOPIC: (RSV) OR TOPIC: ("respiratory syncytial virus")  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
(sulphur dioxide) OR TOPIC: (SO2) OR TOPIC: (sulphur dioxide) 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
TOPIC: (nitrogen dioxide) OR TOPIC: (NO2)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
(carbon monoxide) OR TOPIC: (CO)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
(ozone) OR TOPIC: (O3)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
 
(particulate matter) OR TOPIC: (PM)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
(TS=(air OR ambient OR atmospher* OR outdoor) )  
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Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
(TS=(pollution OR quality))  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
#8 AND #9  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
#3 OR #4 OR #5 OR #6 OR #7 OR #10  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
#11 AND #1 AND #2  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-
EXPANDED, IC Timespan=All years 
 
Scopus 
 
TITLE-ABS-KEYS (baby OR infan* OR pediatric* OR paediatric* OR peadiatric* OR child* OR 
toddler* OR pre-school*) 
TITLE-ABS-KEYS (bronchiolitis or RSV or "respiratory syncytial virus") 
TITLE-ABS-KEYS (sulphur AND dioxide OR SO2) 
TITLE-ABS-KEYS (nitrogen AND dioxide OR NO2) 
TITLE-ABS-KEYS (ozone OR O3)  
TITLE-ABS-KEYS (carbon AND monoxide OR CO) 
TITLE-ABS-KEYS (particulate AND matter OR PM*) 
TITLE-ABS-KEYS (air OR ambient OR atmospher* OR outdoor) 
TITLE-ABS-KEYS (pollution OR quality)  
#8 AND #9 
#10 OR #7 OR #6 OR #5 OR #4 OR #3 
#11 AND #1 AND #2 
 
MEDLINE via OVID 
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Sulfur dioxide/ or (sulphur dioxide or SO2 or sulphur dioxide).mp. 
(nitrogen dioxide or NO2).mp. or Nitrogen Dioxide/ 
(ozone or O3).mp. or ozone/ 
(carbon monoxide or CO).mp. or Carbon Monoxide/ 
(particulate matter or PM*).mp. or Particulate Matter/ 
((air or ambient or atmospher* or outdoor) adj1 (pollution or quality)).mp. 
(bronchiolitis or RSV or "respiratory syncytial virus").mp. 
(baby or infan* or pediatric* or paediatric* or peadiatric* or child* or toddler* or pre-
school*).mp. 
or/1-6 
7 and 8 and 9 
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Appendix 3 – Table of excluded studies in bronchiolitis review after full text 
assessment  
 
Study Name and Year Reason for Exclusion  
Air pollution and admissions for acute lower 
respiratory infections in young children of Ho Chi 
Minh City  
[421] 
Bronchiolitis and pneumonia 
admissions not separated 
Clinical risk factors for life-threatening lower 
respiratory tract infections in children: A 
retrospective study in an urban city in Malaysia  
[422] 
 
Pneumonia admissions as clinical 
outcome 
Do environmental pollutants influence the onset 
of respiratory syncytial virus epidemics or disease 
severity? 
[423] 
Review paper 
Effect of air pollution on respiratory emergency 
room visits and hospital admissions  
[424] 
Asthma and bronchiolitis combined  
Health effects of air pollution exposure on 
children and adolescents in Sao Paulo, Brazil 
[312] 
 
All acute lower respiratory infections 
combined 
Impact of air pollution on physician office visits 
for common childhood conditions in Ontario, 
Canada 
[425] 
 
Air pollution sensitive conditions, 
does not separate out bronchiolitis 
visits 
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Ozone related respiratory morbidity in a low 
pollution region 
[426] 
 
Combined acute lower respiratory 
admissions for ages 0-14 years 
 
Part 4. Interaction between air pollution and 
respiratory viruses: time series study of daily 
mortality and hospital admission in Hong Kong 
[427] 
 
All ages of lower respiratory 
infections included  
Residential proximity to large airports and 
potential health impacts in New York State 
[428] 
 
Cross sectional study  
Respiratory hospital admissions in young children 
living near metal smelters, pulp mills and oil 
refineries in two Canadian provinces 
[429] 
 
Asthma and bronchiolitis combined  
Seven day cumulative effects of air pollutants 
increase respiratory ER visits up to threefold  
[430] 
Lower respiratory obstructive disease 
in less than 5 year olds, incorrect age 
group and combination of diseases   
Short term risk of hospitalization for asthma or 
bronchiolitis in children living near an aluminium 
smelter  
[431] 
 
Combined admissions for asthma and 
bronchiolitis  
Spatial clusters of child lower respiratory illnesses 
associated with community level risk factors 
[432] 
 
Not specific to bronchiolitis and air 
pollutant chemicals  
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The effect of traffic related air pollution on 
infantile bronchiolitis and susceptibility to 
childhood asthma 
[433] 
 
Experience of bronchiolitis, no data 
available 
The effects of air pollution on children  
[434] 
 
Respiratory symptoms combined  
Effects of short-term exposure on hospital 
admissions for acute lower respiratory infections 
in young children of Ho Chi Minh City, Vietnam  
[435] 
 
All acute lower respiratory infections 
combined  
A preliminary assessment of the role of ambient 
nitric oxide exposure in hospitalization with 
respiratory syncytial virus bronchiolitis  
[436] 
 
Looked at Nitric Oxide only, ineligible 
pollutant 
Air pollution and acute respiratory infections 
among children 0-4 years of Age: An 18 year time-
series study  
[437] 
 
Bronchiolitis and bronchitis 
admissions combined  
Air pollution and environmental tobacco smoking 
during infancy may increase the risk of 
bronchiolitis  
[438] 
 
Incorrect ages and too retrospective  
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Early life exposure to outdoor air pollution and 
respiratory health, ear infections, and eczema in 
infants from the INMA study  
[400] 
 
Doctor diagnosed lower respiratory 
infection not specific to bronchiolitis 
Effects of fine particles on children’s hospital 
admissions for respiratory health in Seville, Spain  
[439] 
 
Looked at city wide levels of pollution 
rather than to specific admission  
Exposure to traffic and early life respiratory 
infection: a cohort study  
[440] 
 
All acute lower respiratory infection 
not specific to bronchiolitis  
Fine Particulate Matter Pollution linked to 
respiratory illness in infants and increased 
hospital costs  
[441] 
 
Cross sectional study  
Haze is a risk factor contributing to the rapid 
spread of respiratory syncytial virus in children  
[67] 
 
Examines at geographical level 
Modifiable demographic factors that differentiate 
bronchiolitis from pneumonia in Nepalese 
children less than two years – a hospital based 
study 
[442] 
 
General outdoor air pollution – non-
specific to pollutants  
Modifiable risk factors associated with 
bronchiolitis 
[443] 
General outdoor air pollution – non-
specific to pollutants  
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Outdoor, but not indoor, nitrogen dioxide 
exposure is associated with persistent cough 
during the first year of life 
[444] 
 
Looked at respiratory problems not 
at outcome of interest 
Respiratory syncytial virus bronchiolitis, weather 
conditions and air pollution in an Italian urban 
area: An observational study  
[445] 
 
Association was between 
temperature and pollution levels in 
known RSV seasons  
 
Respiratory Syncytial virus infection in infants and 
correlation with meteorological factors and air 
pollutants  
[446]  
Not examine clinical outcome 
Association of acute bronchiolitis with 
environmental variables  
[447] 
 
City wide levels of pollutants 
examined  
Air pollution and acute respiratory diseases in 
children: regression analysis of morbidity data  
[448] 
 
Bronchitis and bronchiolitis cases 
combined 
Effect of air pollution upon the hospitalisation for 
acute lower respiratory tract infections among 
the Bucharest municipality’s residents 
[449] 
 
Not age specific examines 0-14 year 
olds 
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Effect of environmental air pollutants on 
wheezing airways respiratory infections in 
emergency room  
[450] 
 
Definition of bronchiolitis is for 
wheezing disorder 
Exposure to fine particles and bronchiolitis in 
infants  
[451] 
 
Same paper as written by Karr et al in 
2009 that has been included  
Exposure to vehicular traffic is associated to a 
higher risk of hospitalisation for bronchiolitis 
during the first year of life  
[452] 
 
Vehicular traffic not specific 
pollutants  
 
Impact of air pollution in paediatric consultations 
in primary health care: Ecological Study  
[453] 
 
Unclear definition of bronchiolitis  
Influence of respiratory viruses, cold weather and 
air pollution in the incidence of lower respiratory 
tract infections in infants and children 
[454] 
 
Combines respiratory syncytial virus 
across all ages 
Relationship of hospital admissions with 
respiratory syncytial virus (RSV) bronchiolitis to 
environmental nitric oxide 
[455]  
 
Looking at nitric oxide, incorrect 
pollutant 
The influence of respiratory syncytial virus 
infections and environmental conditions on 
Not look at bronchiolitis separately  
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pediatric health care demand during winter-2002 
in Santiago, Chile  
[456] 
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Appendix 4 – Protocol for overview of systematic reviews submitted to PROSPERO 
 
Review title  
 
Ambient air pollution and respiratory illnesses in children: an overview of systematic 
reviews 
 
Review team members and their organisational affiliations 
 
Dr Ian Sinha. Alder Hey Children's Hospital 
Dr Daniel Hawcutt. Alder Hey Children's Hospital  
Miss Charlotte King. University of Liverpool Institute of Translational Medicine, Department 
of Women's and Child Health  
 
Funding sources/sponsors 
 
Charlotte King is part-funded by The National Institute for Health Research Collaboration for 
Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).  
 
Conflicts of interest  
 
The views expressed here are those of the author(s) and not necessarily those of the NHS, 
the NIHR, or the Department of Health and Social Care.  
 
Review Question  
 
What is the evidence synthesised in systematic reviews and meta analyses about the 
association between ambient air pollution and the risk of hospital admission with 
respiratory illnesses in children? 
What is the relationship between air pollution and risk of hospitalisation for children with 
respiratory illnesses synthesised in systematic reviews and meta analyses of observational 
studies?  
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Searches  
 
Comprehensive searches of four electronic databases (MEDLINE, Embase, DARE and 
Cochrane) will be conducted to find eligible systematic reviews and meta analyses 
evaluating the association between ambient air pollution and childhood respiratory 
illnesses. 
Search terms will include general search terms for respiratory illnesses, air pollution, the 
selected age population, and systematic reviews. Each search strategy will be tailored 
depending to the search database because syntax, limits and available fields vary between 
databases. There will be no restriction on language or publication date.  
 
Types of study to be included  
 
We will include systematic reviews of observational studies (cohort, time series, cross 
sectionals, case crossover and case control studies), with or without meta-analysis. Reviews 
included will examine the association between childhood respiratory illnesses and ambient 
air pollution. Narrative reviews of literature will be excluded. To be included, a review must 
provide qualitative or quantitative results from observational studies about the association 
between one or more ambient air pollutant and one or more respiratory outcome.  
 
Condition or domain being studied 
 
Childhood respiratory illnesses including: respiratory infection, croup, asthma, acute lower 
respiratory infections, acute wheeze, bronchiolitis, bronchitis, pneumonia, influenza, and 
whooping cough.  
 
Participants/Population 
 
Systematic reviews that synthesise evidence for the study populations: infants, children and 
adolescents up to the age of 20 years old will be considered.  
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Intervention(s), Exposure(s) 
 
Exposure to any outdoor air pollutant will be examined for any lag period (acute, sub-acute, 
lifetime): a) particulate matter including PM2.5 and PM10 
b) gaseous pollutants including nitrogen dioxide, sulphur dioxide, carbon monoxide, and 
ozone 
c) traffic pollution including outdoor volatile organic compounds  
 
Comparator/Control  
 
Will be based on observational studies in the specific reviews.  
 
Context 
 
Primary Outcomes  
 
The primary outcomes of interest are effect estimates (pooled odds ratios, risk ratios) of the 
association between one or more air pollutant and the subsequent risk of hospitalisation or 
emergency visits with the stated respiratory illnesses above.  
 
Secondary Outcomes  
 
Secondary outcomes of interest include effect estimates (pooled odds ratios, risk ratios) of 
the association between one or more air pollutant and the subsequent risk of mortality, 
critical care admissions and physician/ambulatory care visits for the respiratory illnesses 
listed above.  
 
Data Extraction  
 
Two reviewers will independently screen titles and abstracts generated from the searches to 
identify potentially relevant systematic reviews. The full text of articles deemed relevant 
and those whose abstracts and titles provide insufficient information will be retrieved for a 
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closer inspection. Two reviewers will independently apply the eligibility criteria to all 
potentially relevant systematic reviews for inclusion in the overview. Disagreements about 
eligibility will be settled by a third reviewer. 
General information from all included systematic reviews will be extracted: first author, 
publication year, country, comprehensive literature search and evaluation process (e.g. 
years, databases, languages, inclusion/exclusion criteria, duplicate study selection), number 
of included studies, study designs of the primary studies, methods for quality 
assessment/risk of bias of primary studies, populations of interest, age group (s), air 
pollutants evaluated, respiratory illnesses reported, risk of hospitalisation or secondary 
outcome, method to analyse the results from primary studies (quantitative or qualitative), 
mention of confounders, results and review conclusions.  
For meta-analyses, we will extract information of the pooled effect estimates along with the 
95% confidence intervals, and the I2 values reported to inform heterogeneity across 
individual studies included in the reviews. Heterogeneity will be characterized as small (I2 
less than and including 25%), moderate (I2 between 26% and 74%) and high (I2 equal to and 
greater than 75%).  
Data from systematic reviews will be extracted by one reviewer and then independently 
verified for accuracy and completeness by a second reviewer. Any discrepancies in data 
extraction will be resolved by consensus between the data extractor and the data verifier.  
 
Risk of bias (quality) assessment 
 
Two researchers will independently appraise the methodological quality of systematic 
reviews using the Assessment of Multiple Systematic Reviews-Revised tool (AMSTAR-R). To 
the extent that Amstar works with scores, we will also evaluate the information extracted 
qualitatively.  
 
Strategy for data analysis 
 
A PRISMA flow diagram will be used to inform review selection in the overview. We will 
produce evidence tables and forest plots to aid in data presentation when appropriate.  
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Appendix 5 – Search strategy for overview of systematic reviews 
 
• Respiratory Health  
o Respiratory infection 
▪ Respirat* infect* 
▪ Vir* infect* 
▪ Bacteria* infect* 
▪ Respiratory disease 
▪ Respiratory tract diseases 
▪ Respiratory infection Mesh  
o Croup  
▪ Crou* 
▪ Parainfluenza virus  
▪ Croup Mesh 
o Asthma  
▪ Asthma Exacerbat* 
▪ Asthm* 
▪ Asthma Mesh 
o Acute lower respiratory infections  
▪ ALRI  
▪ ARI 
▪ LRI  
▪ Acute Lower respiratory infection 
o Acute wheeze  
▪ Wheez* 
▪ Acute wheeze 
▪ Wheeze Mesh (respiratory sounds) 
o Bronchiolitis/ Bronchitis 
▪ Bronchitis Mesh 
▪ Bronchi* 
▪ Respiratory Syncytial Virus  
▪ RSV 
▪ Bronchiolitis Mesh 
o Pneumonia  
▪ Pneumon* 
▪ Pnemon* 
▪ Streptococcus 
▪ Pneumonia Mesh 
o Influenza 
▪ Haemophilus influenza 
▪ Influenz* 
▪ Influenza Mesh 
o Whooping Cough 
▪ Pertussis 
▪ Whooping cough 
▪ Whooping cough Mesh  
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• Child  
o Child search terms 
▪ Infant* or infant (MeSH)  
▪ Infancy 
▪ Newborn* 
▪ Baby* 
▪ Babies 
▪ Neonat* 
▪ Preterm* 
▪ Prematur* 
▪ Postmatur* 
▪ Child* or Child (MeSH) 
▪ Schoolchild* 
▪ School age* 
▪ Preschool*  
▪ Kid* 
▪ Toddler* 
▪ Adolescent (MeSH) or adoles* 
▪ Teen* 
▪ Boy* 
▪ Girl* 
▪ Minors (MeSH) or Minors* 
▪ Puberty (MeSH) or Pubert* 
▪ Pubescen* 
▪ Prepubescen* 
▪ Pediatrics (MeSH) or Pediatric* 
▪ Paediatric* 
▪ Peadiatric* 
▪ Schools (MeSH) or school* 
▪ Nursery school* 
▪ Elementary school*  
▪ High school*  
o Air Pollution  
▪ Ambient air pollution  
• Outdoor air pollut* 
• Ambient air pollut* 
• Air pollut* 
• Air pollution Mesh 
▪ Particulate Matter 
• Particulate 
• PM10 
• PM2.5 
• Particle*  
• Particulate Matter Mesh 
▪ Nitrogen Dioxide 
• Nitrogen 
• NO2 
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• Nitrogen dioxide Mesh 
▪ Sulfur Dioxide 
• Sulfur 
• Sulphur 
• SO2 
• Sulfur dioxide Mesh 
▪ Carbon Monoxide 
• Carbon  
• CO  
• Carbon Monoxide Mesh  
▪ Ozone 
• O3 
• Ozone Mesh  
▪ Traffic pollution  
• Vehicle Emission 
• Traffic  
• Volatile Organic Compound* 
• VOC 
• Volatile Organic Compound Mesh 
o Systematic review  
▪ Systematic review 
▪ Meta-analysis  
▪ Intervention* 
▪ Exposure* 
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Appendix 6 – Table of excluded articles from overview of systemic reviews after full 
text analysis  
 
Author and year  Reason for exclusion  
J R Balmes 1993 [457] Narrative Review 
F Barone-Adesi 2015 [117] Looked at lung function 
C Black 2017 [458] Narrative Review 
M Brauer 2010 [459] Narrative Review 
C I R Froes Asmus 2016 [460] No specific disease outcome 
M Chan Yeung 2002 [461] Narrative Review 
M Dherani 2008 [83] Looked at indoor pollution 
R Etzel 2003 [462] Narrative Review 
A Falck 2015 [463] Narrative Review 
A Ferguson 2017 [464] Narrative Review 
F D Gilliland 2009 [465] Narrative Review 
L Gochicoa Rangel 2011 [466] Narrative Review 
N Gouveia 2017 [467] Not a systematic review 
A Heinzerling 2016 [468] Not pollutant of interest 
T W Hesterberg 2009 [469] Looked at total population 
W Hou 2016 [470] Not pollutant of interest 
S Jackson 2013 [471] Looked at indoor pollution 
H D Kan 2005 [472] Looked at total population 
Hak Kan Lai 2013 [473] Looked at total population 
P Landrigan 2002 [474] Narrative Review 
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U Latza 2008 [475] Looked at total population 
S Li 2012 [476] Looked at lung function 
J C Liu 2015 [477] Looked at total population 
Q Liu 2017 [478] Not examining primary outcome 
E C Matsui 2013 [479] Looked at indoor pollution 
D Mckee 1991 [480] Not examining primary outcome 
P Misra 2012 [481] Looked at indoor pollution 
M Nitschke 1999 [482] Looked at indoor pollution 
S Petruzzi 1994 [483] Narrative Review 
P Eggleston 2008 [484] Narrative Review 
M Raizenne 1998 [485] Narrative Review 
M Saric 1999 [486] Narrative Review 
E Schultz 2017 [487] Looked at lung function 
M Sonego 2015 [53] Not pollutant of interest 
D Strachen 1998 [488] Not pollutant of interest 
A O Tuazon 2012 [489] Narrative Review 
M Veras 2016 [490] No specific disease outcome 
S Vieira 2015 [491] Narrative Review 
D J Ward 2004 [250] Looked at lung function 
S Weichenthal 2007 [492] Looked at indoor pollution 
G Weinmayr 2009 [493] Not examining primary outcome 
D Zmirou 1997 [494] Not examining primary outcome 
J Voynow 2015 [495] Narrative Review 
M A Vigotti 1999 [496] Not a systematic review 
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J Heinrich 2002 [497] Narrative Review 
S Baldacci 1993 [498] Narrative Review 
Biela-Mazur 2017 [499] Not examining primary outcome 
Biggeri 2004 [500] Looked at total population 
Yarborough 2011 [501] Not examining primary outcome 
Chauhan 1998 [502] Narrative Review 
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Appendix 7 – Risk of bias assessment of individual included studies within systematic 
reviews for each disease 
 
 Appendix 7.1 Asthma Individual Studies Risk of Bias 
Individual 
Study Pollutant 
Selection 
Bias 
Exposure 
Assessment 
Adjustment for 
Confounders 
Risk Of 
Bias  
Abe 2007 SO2, CO High Medium Low High 
Babin 2007 O3 Low High Low High 
Carlin 1999 O3 High Medium Low High 
Dales 2000 
?in ozone 
review High Medium Low High 
Evans 2014 
PM2.5, CO, 
SO2, O3 High Low Low High 
Jazbec 1999 NO2 High Low High High 
Laurent 2008 
PM10, NO2, 
SO2, O3 High Low Low High 
Stieb 1996 O3 High Medium Low High 
Tao 2014 
PM10, SO2, 
NO2 Low Medium High High 
Tsai 2006 
PM10, NO2, 
SO2, CO, O3 High Medium Medium High 
Yamazaki 2009 
O3, PM2.5, 
NO2 High High Low High 
Yamazaki 2013 
NO2, O3, 
PM10, PM2.5 High Medium Low High 
Yang 2007 
SO2, NO2, 
CO, O3, 
PM10 Low Medium High High 
Meng 2010 
CO, NO2, O3, 
PM10, PM2.5 High  Medium Low High 
   
 192 
Thompson 2001 
PM10, SO2, 
NO2, O3, CO Medium High Low High  
Alhanti 2016 
O3, CO, NO2, 
SO2, PM2.5 Low Low Low Low 
Andersen 2007 PM10 Low Low Low Low 
Andersen 2008 
PM10 and 
PM2.5 Low Low Low Low 
Atkinson 2001 PM10 Low Low Low Low 
Byers 2016 
SO2, PM2.5, 
O3 Low Low Low Low 
Delfino 2014 
PM2.5, NO2, 
CO, O3 Low Low Low Low 
Erbas 2005 
NO2, O3, 
PM10 Low Low Low Low 
Glad 2012 O3, PM2.5 Low Low Low Low 
Gleason 2014 PM2.5, O3 Low Low Low Low 
Gleason 2015 O3, PM2.5 Low Low Low Low 
Halonen 2010 O3, PM2.5 Low Low Low Low 
Iskandar 2012 
PM10, 
PM2.5, NO2 Low Low Low Low 
Lee 2006 
SO2, NO2, 
PM10, 
PM2.5, O3 Low Low Low Low 
Norris 1999 
PM10, CO, 
NO2, SO2, 
O3 Low Low Low Low 
Silverman 2010 PM2.5, O3 Low Low Low Low 
Weichenthal 
2016  
PM2.5, O3, 
NO2 Low Low Low Low 
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Halonen 2008 
PM2.5, CO, 
NO2, PM10, Low Low Low Low  
Smargiassi 2009 SO2 Low Low Low Low  
Alman 2016 PM2.5  Medium Low Low Medium 
Amancio 2012 
PM10, SO2, 
O3 Low Medium Low Medium 
Anderson 1998 
O3, NO2, 
SO2 Low Medium Low Medium 
Anderson 2001 
PM10 and 
PM2.5 Low Medium Low Medium 
Atkinson 1999 
NO2, CO, O3, 
PM10 SO2 Low Medium Low Medium 
Babin 2008 
O3, PM2.5, 
PM10 Low Medium Low Medium 
Barnett 2005 NO2 Low Medium Low Medium 
Bates 1990 
SO2, NO2, 
O3 Low Medium Low Medium 
Chakraborty 
2014 O3, PM10 Low Medium Low Medium 
Chen 2013 PM2.5, O3 Low Medium Low Medium 
Chew 1999 
SO2, NO2, 
O3 Low Medium Low Medium 
Chimonas 2007 PM10, PM2.5 Medium Medium Low Medium 
Ding 2016 
PM10, 
PM2.5, SO2, 
NO2, O3, CO Low Medium Low Medium 
Fauroux 2000 
O3, SO2, 
NO2 Low Medium Low Medium 
Fletcher 2000 
PM10, SO2, 
NO2, O3, CO Low Medium Low Medium 
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Fusco 2001 
Particles, 
SO2, NO2, 
CO, O3 Low Medium Low Medium 
Grineski 2011 PM2.5, NO2 Low Medium Low Medium 
Hajat 1999 
SO2, NO2, 
CO, O3, 
PM10 Low Medium Low Medium 
Hua 2014 
PM2.5, NO2, 
SO2 Low Medium Low Medium 
Jalaludin 2008 
PM10, 
PM2.5, NO2, 
O3, CO, SO2 Low Medium Low Medium 
Ko 2007 
NO2, O3, 
PM10, 
PM2.5, SO2 Low Medium Low Medium 
Lavigne 2012 
NO2, SO2, 
CO, PM2.5, 
O3 Low Medium Low Medium 
Lee 2002 
SO2, NO2, 
CO, O3, 
PM10 Low Medium Low Medium 
Lee 2006 
CO, SO2, 
NO2, O3, 
PM10 Low Medium Low Medium 
Lee 2010 O3 Low Medium Low Medium 
Li 2011 
CO, NO2, 
SO2, PM2.5 Low Medium Low Medium 
Lin 2003 
PM10, 
PM2.5, SO2, 
NO2, O3, CO Low Medium Low Medium 
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Lin 2004 
CO, SO2, 
NO2, O3 Low Medium Low Medium 
Magas 2007 NO2 Low Medium Low Medium 
Mar. 2009 O3, PM2.5 Low Medium Low Medium 
Medina 1997 
NO2, SO2, 
O3 Medium Medium Low Medium 
Mohr 2008 
O3, PM2.5, 
SO2 Low Medium Low Medium 
Morgan 1998 
PM2.5, O3, 
NO2 Low Medium Low Medium 
Neidell 2010 O3 Low Medium Low Medium 
Park 2013 
PM10, CO, 
O3, NO2, 
SO2 Low Medium Low Medium 
Paulu 2008 O3, PM2.5 Low Medium Low Medium 
Pereira 2010 
PM10, O3, 
NO2, CO Low Medium Low Medium 
Petroeschevsky 
2001 
SO2, NO2, 
O3 Low Medium Low Medium 
Romieu 1995 
SO2, NO2, 
O3 Low Medium Low Medium 
Sacks 2014 O3 Low Medium Low Medium 
Samoli 2011 
PM10, SO2, 
NO2, O3 Low Medium Low Medium 
Santus 2012 
PM10, 
PM2.5, SO2, 
NO2, O3, CO Medium Medium Low Medium 
Son 2013 
PM10, NO2, 
SO2, CO, O3 Low Medium Low Medium 
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Strickland 2010 
CO, NO2, 
SO2, O3, 
PM10, PM2.5 Low Medium Low Medium 
Strickland 2015 PM2.5 Low Medium Low Medium 
Sunyer 1997 
SO2, NO2, 
O3 Low Medium Low Medium 
Szyszkowicz 
2008 
CO, NOW, 
SO2, O3, 
PM10, PM2.5 Low Medium Low Medium 
Tecer 2008  PM2.5, PM10 Low Medium Low Medium 
Tolbert 2000 O3, PM10 Medium Medium Low Medium 
Ueda 2010 NO2, SO2 Low Medium Low Medium 
Villneneuve 
2007 
SO2, NO2, 
CO, O3, 
PM2.5, PM10 Low Medium Low Medium 
Wendt 2014 
PM2.5, O3, 
NO2 Medium Medium Low Medium 
Wilson 2005 SO2, O3 Low Medium Low Medium 
Winquist 2012 O3, PM2.5 Low Medium Low Medium 
Yamazaki 2015 
PM2.5, 
PM10, O3, 
NO2 Medium Low Low Medium 
Lewin 2013 SO2, PM2.5 Medium Low Medium Medium  
Lin 2002 
PM10, 
PM2.5, SO2, 
NO2, O3, CO Low Medium Low Medium  
Morgan 2010 PM10 Low Medium Low Medium  
Strickland 2014 
CO, NO2, O3, 
PM10, PM2.5 Medium Medium Low Medium  
Sunyer 2003 SO2 Low Medium Low Medium  
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White 1994 
 
N/A N/A N/A N/A 
 
 Appendix 7.2 Pneumonia Individual Studies Risk of Bias 
Individual 
Study Pollutant 
Selection 
Bias 
Exposure 
Assessment 
Adjustment for 
Confounders 
Risk Of 
Bias  
Barnett 
2005 
PM2.5, PM10, 
NO2, SO2, CO, 
O3 Medium Medium Low Medium 
Darrow 
2014 
O3, NO2, CO, 
PM10, PM2.5 Low Low Low Low 
Farhat 2005 
PM10, SO2, 
NO2, O3, CO Low Medium Low Medium 
Gouveia 
2000 
PM10, SO2, 
NO2, CO, O3 Low Medium Low Medium 
Ilbabaca 
1999 
PM10, PM2.5, 
SO2, NO2, O3 Low Medium Low Medium 
Lv 2016 
PM2.5, PM10, 
CO, SO2, NO2 High Medium Low High 
Malig 2016 O3 Low Low Low Low 
Negrisoli 
2013 
PM10, NO2, 
O3 Low Medium Low Medium 
Ostro 2009 PM2.5 Low Medium Low Medium 
Pablo-
Romero 
2015 PM2.5 Low Medium Medium Medium 
Patto 2016 PM2.5 Low Medium Low Medium 
Santus 2012 
NO2, CO, O3, 
PM10, PM2.5, 
SO2 Low Medium Low Medium 
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Souza 2016 
NO2, O3, 
PM10 Low Medium Low Medium 
Strickland 
2016 PM2.5 Low Low Low Low 
Tuan 2016 PM10, SO2, O3 Low Medium Low Medium 
Winquist 
2012 O3, PM2.5 Low Medium Low Medium 
Xiao 2016 
CO, NO2, SO2, 
O3, PM10, 
PM2.5 Low Low Low Low 
 
 
Appendix 7.3 Bronchiolitis Individual Studies Risk of Bias 
Individual 
Study Pollutant 
Selectio
n Bias 
Exposure 
Assessme
nt 
Adjustmen
t for 
Confounde
rs 
Risk Of 
Bias  
Karr 2009 
PM2.5, PM10, NO2, SO2, 
CO, O3 Low Low  Low Low 
Karr 2009 PM2.5, NO2 Low Low  Low Low 
Karr 2006  PM2.5, NO2, CO Low Medium Low 
Mediu
m 
Karr 2004 PM2.5, NO2, CO 
Mediu
m Medium High High 
Girguis 
2017 PM2.5 Low Low  Low Low 
Rahman 
2017 PM10, CO, O3, NO2 High Medium Medium High 
Karr 2006  PM2.5, NO2, O3, CO Low Low  Low Low 
Segala 2007 PM10, NO2, SO2  
Mediu
m Medium Low 
Mediu
m  
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Appendix 8 – Search strategy for systematic review analysing pharmacogenomics and 
ADR’s in asthma medication  
 
Medline 
 
1. asthma.mp. 
2. asthma/ 
3. 1 or 2 
4. 
Pharmacogenetics.mp. 
5. 
PHARMACOGENETICS/ 
6. genetic 
polymorphism.mp. 
7. Polymorphism, 
Genetic/ 
8. 
pharmacogenomics.mp. 
9. pharmacogenomics/ 
10. single nucleotide 
polymorphism/ 
11. single nucleotide 
polymorphism.mp. 
12. SNP.mp. 
13. "Singl* nucleotid* 
polymorph*".mp. 
14. allele/ 
15. allele.mp. 
16. Muscarinic 
Antagonists/ 
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17. muscarinic 
antagonist.mp. 
18. ipratropium.mp. 
19. ipratropium 
bromide.mp. 
20. IPRATROPIUM/ 
21. atrovent.mp. 
22. respontin.mp. 
23. Adrenergic beta-2 
Receptor Agonists/ 
24. adrenergic beta-2 
receptor agonists.mp. 
25. formoterol/ 
26. formoterol.mp. 
27. formoterol 
fumarate.mp. 
28. oxis.mp. 
29. atimos.mp. 
30. easyhaler.mp. 
31. foradil.mp. 
32. salmeterol.mp. 
33. salmeterol/ 
34. neovent.mp. 
35. serevent.mp. 
36. vertine.mp. 
37. salbutamol.mp. 
38. salbutamol/ 
39. albuterol/ 
40. albuterol.mp. 
41. ventolin.mp. 
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42. airsalb.mp. 
43. airomir.mp. 
44. asmavent.mp. 
45. salamol.mp. 
46. salbulin.mp. 
47. terbutaline.mp. 
48. terbutaline/ 
49. terbutaline 
sulfate.mp. 
50. bricanyl.mp. 
51. 23 or 24 or 25 or 26 
or 27 or 28 or 29 or 30 
or 31 or 32 or 33 or 34 
or 35 or 36 or 37 or 38 
or 39 or 40 or 41 or 42 
or 43 or 44 or 45 or 46 
or 47 or 48 or 49 or 50 
52. corticosteroids/ 
53. corticosteroids.mp. 
54. hydrocortisone.mp. 
55. hydrocortisone/ 
56. sodium 
succinate.mp. 
57. solu-cortef.mp. 
58. prednisolone/ 
59. prednisolone.mp. 
60. pevanti.mp. 
61. deltacortril.mp. 
62. dilacort.mp. 
63. beclometasone/ 
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64. beclometasone.mp. 
65. beclometasone 
dipropionate.mp. 
66. clenil modulite.mp. 
67. clenil.mp. 
68. qvar.mp. 
69. asmabec.mp. 
70. budesonide.mp. 
71. budesonide/ 
72. budelin.mp. 
73. pulmicort.mp. 
74. symbicort.mp. 
75. ciclesonide.mp. 
76. ciclesonide/ 
77. alvesco.mp. 
78. fluticasone.mp. 
79. fluticasone/ 
80. flixotide.mp. 
81. flutiform.mp. 
82. seretide.mp. 
83. relvar.mp. 
84. mometasone 
furoate.mp. 
85. mometasone 
furoate/ 
86. asmanex.mp. 
87. 
beclomethasone.mp. 
88. beclomethasone/ 
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89. 52 or 53 or 54 or 55 
or 56 or 57 or 58 or 59 
or 60 or 61 or 62 or 63 
or 64 or 65 or 66 or 67 
or 68 or 69 or 70 or 71 
or 72 or 73 or 74 or 75 
or 76 or 77 or 78 or 79 
or 80 or 81 or 82 or 83 
or 84 or 85 or 86 or 87 
or 88 
90. omalizumab.mp. 
91. omalizumab/ 
92. monoclonal 
antibodies.mp. 
93. monoclonal 
antibody.mp. 
94. Antibodies, 
Monoclonal/ 
95. xolair.mp. 
96. 90 or 91 or 92 or 93 
or 94 or 95 
97. leukotriene receptor 
antagonists.mp. 
98. LEUKOTRIENES/ 
99. leukotrienes.mp. 
100. montelukast.mp. 
101. Singulair.mp. 
102. zafirlukast.mp. 
103. accolate.mp. 
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104. 97 or 98 or 99 or 
100 or 101 or 102 or 103 
105. mast cell 
stabilisers.mp. 
106. cromoglicate.mp. 
107. mast cells/ 
108. cromoglicate/ 
109. nedocromil.mp. 
110. tilade.mp. 
111. sodium 
cromoglicate.mp. 
112. sodium 
cromoglycate.mp. 
113. cromoglycate.mp. 
114. cromoglycate/ 
115. nalcrom.mp. 
116. intal.mp. 
117. 105 or 106 or 107 
or 108 or 109 or 110 or 
111 or 112 or 113 or 114 
or 115 or 116 
118. xanthine.mp. 
119. xanthine/ 
120. aminophylline.mp. 
121. aminophylline/ 
122. phyllocontin.mp. 
123. theophylline.mp. 
124. theophylline/ 
125. neulin.mp. 
126. uniphyllin.mp. 
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127. slo-phyllin.mp. 
128. slophyllin.mp. 
129. 118 or 119 or 120 
or 121 or 122 or 123 or 
124 or 125 or 126 or 127 
or 128 
130. 16 or 17 or 18 or 19 
or 20 or 21 or 22 
131. 51 or 89 or 96 or 
104 or 117 or 129 or 130 
132. 4 or 5 or 6 or 7 or 8 
or 9 or 10 or 11 or 12 or 
13 or 14 or 15 
133. 3 and 131 and 132 
 
 
EMBASE 
 
1. asthma.mp. 
2. asthma/ 
3. 1 or 2 
4. pharmacogenetics.mp. 
5. pharmacogenetics/ 
6. genetic polymorphism.mp. 
7. genetic polymorphism/ 
8. pharmacogenomics.mp. 
9. pharmacogenomics/ 
10. single nucleotide polymorphism.mp. 
11. single nucleotide polymorphism/ 
12. SNP.mp. 
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13. singl* nucleotid* polymorph*.mp. 
14. allele/ 
15. allele.mp. 
16. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. beta 2 adrenergic receptor stimulating agent/ 
18. adrenergic beta-2 receptor agonists.mp. 
19. formoterol.mp. 
20. formoterol/ 
21. formoterol fumarate.mp. 
22. oxis.mp. 
23. atimos.mp. 
24. easyhaler.mp. 
25. foradil.mp. 
26. salmeterol.mp. 
27. salmeterol/ 
28. neovent.mp. 
29. serevent.mp. 
30. vertine.mp. 
31. salbutamol.mp. 
32. salbutamol/ 
33. albuterol/ 
34. albuterol.mp. 
35. ventolin.mp. 
36. airsalb.mp. 
37. airomir.mp. 
38. asmavent.mp. 
39. salamol.mp. 
40. salbulin.mp. 
41. terbutaline.mp. 
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42. terbutaline/ 
43. terbutaline sulfate.mp. 
44. bricanyl.mp. 
45. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 
32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 
46. muscarinic antagonist.mp. 
47. muscarinic receptor blocking agent/ 
48. ipratropium.mp. 
49. ipratropium bromide.mp. 
50. ipratropium/ 
51. atrovent.mp. 
52. respontin.mp. 
53. 46 or 47 or 48 or 49 or 50 or 51 or 52 
54. corticosteroids/ 
55. corticosteroids.mp. 
56. hydrocortisone.mp. 
57. hydrocortisone/ 
58. sodium succinate.mp. 
59. solu-cortef.mp. 
60. prednisolone.mp. 
61. prednisolone/ 
62. pevanti.mp. 
63. deltacortril.mp. 
64. dilacort.mp. 
65. beclometasone/ 
66. beclometasone.mp. 
67. beclometasone dipropionate.mp. 
68. clenil modulite.mp. 
69. clenil.mp. 
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70. qvar.mp. 
71. asmabec.mp. 
72. budesonide.mp. 
73. budesonide/ 
74. budelin.mp. 
75. pulmicort.mp. 
76. symbicort.mp. 
77. ciclesonide/ 
78. ciclesonide.mp. 
79. alvesco.mp. 
80. fluticasone.mp. 
81. fluticasone/ 
82. flixotide.mp. 
83. flutiform.mp. 
84. seretide.mp. 
85. relvar.mp. 
86. mometasone furoate.mp. 
87. mometasone furoate/ 
88. asmanex.mp. 
89. beclomethasone.mp. 
90. beclomethasone/ 
91. 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 
69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 
85 or 86 or 87 or 88 or 89 or 90 
92. omalizumab.mp. 
93. omalizumab/ 
94. monoclonal antibodies.mp. 
95. monoclonal antibody/ 
96. monoclonal antibody.mp. 
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97. xolair.mp. 
98. 92 or 93 or 94 or 95 or 96 or 97 
99. leukotriene receptor antagonists.mp. 
100. leukotriene/ 
101. leukotrienes.mp. 
102. montelukast.mp. 
103. Singulair.mp. 
104. zafirlukast.mp. 
105. accolate.mp. 
106. 99 or 100 or 101 or 102 or 103 or 104 or 105 
107. mast cell stabilisers.mp. 
108. cromoglicate.mp. 
109. mast cells/ 
110. cromoglicate/ 
111. nedocromil.mp. 
112. tilade.mp. 
113. sodium cromoglicate.mp. 
114. sodium cromoglycate.mp. 
115. cromoglycate.mp. 
116. cromoglycate/ 
117. nalcrom.mp. 
118. intal.mp. 
119. 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 
120. xanthine/ 
121. xanthine.mp. 
122. aminophylline/ 
123. aminophylline.mp. 
124. phyllocontin.mp. 
125. theophylline.mp. 
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126. theophylline/ 
127. neulin.mp. 
128. uniphyllin.mp. 
129. slophyllin.mp. 
130. slo-phyllin.mp. 
131. 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 
132. 45 or 53 or 91 or 98 or 106 or 119 or 131 
133. 3 and 16 and 132 
 
CINAHL 
 
S101 S99 AND S100 
S100 S10 AND S18 
S99 
S9 OR S40 OR S69 OR S76 OR S87 OR S92 OR 
S98 
S98 S93 OR S94 OR S95 OR S96 OR S97 
S97 respontin 
S96 atrovent 
S95 ipratropium bromide 
S94 ipratropium 
S93 muscarinic antagonist 
S92 S88 OR S89 OR S90 OR S91 
S91 xolair 
S90 monoclonal antibody 
S89 monoclonal antibodies 
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S88 omalizumab 
S87 
S77 OR S78 OR S79 OR S80 OR S81 OR S82 
OR S83 OR S84 OR S85 OR S86 
S86 intal 
S85 nalcrom 
S84 cromoglycate 
S83 sodium cromoglycate 
S82 sodium cromoglicate 
S81 tilade 
S80 nedocromil 
S79 cromoglicate 
S78 mast cells 
S77 mast cell stabilisers 
S76 S70 OR S71 OR S72 OR S73 OR S74 OR S75 
S75 accolate 
S74 zafirlukast 
S73 singulair 
S72 montelukast 
S71 leukotriene 
S70 leukotriene receptor antagonists 
S69 
S41 OR S42 OR S43 OR S44 OR S45 OR S46 
OR S47 OR S48 OR S49 OR S50 OR S51 OR 
S52 OR S53 OR S54 OR S55 OR S56 OR S57 
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OR S58 OR S59 OR S60 OR S61 OR S62 OR 
S63 OR S64 OR S65 OR S66 OR S67 OR S68 
S68 beclomethasone 
S67 asmanex 
S66 mometasone furoate 
S65 relvar 
S64 seretide 
S63 flutiform 
S62 flixotide 
S61 fluticasone 
S60 alvesco 
S59 ciclesonide 
S58 symbicort 
S57 pulmicort 
S56 budelin 
S55 budesonide 
S54 asmabec 
S53 qvar 
S52 clenil 
S51 clenil modulite 
S50 beclometasone dipropionate 
S49 beclomethasone 
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S48 dilacort 
S47 deltacortril 
S46 pevanti 
S45 prednisolone 
S44 solu-cortef 
S43 sodium succinate 
S42 hydrocortisone 
S41 corticosteroids 
S40 
S19 OR S20 OR S21 OR S22 OR S23 OR S24 
OR S25 OR S26 OR S27 OR S28 OR S29 OR 
S30 OR S31 OR S32 OR S33 OR S34 OR S35 
OR S36 OR S37 OR S38 OR S39 
S39 bricanyl 
S38 terbutaline sulfate 
S37 terbutaline 
S36 salbulin 
S35 salamol 
S34 asmavent 
S33 airomir 
S32 airsalb 
S31 ventolin 
S30 albuterol 
S29 salbutamol 
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S28 vertine 
S27 serevent 
S26 neovent 
S25 salmeterol 
S24 foradil 
S23 easyhaler 
S22 atimos 
S21 formoterol fumarate 
S20 formoterol 
S19 adrenergic beta-2 receptor agonists 
S18 
S11 OR S12 OR S13 OR S14 OR S15 OR S16 
OR S17 
S17 allele 
S16 singl* nucleotid* polymorph* 
S15 SNP 
S14 single nucleotide polymorphism 
S13 pharmacogenomics 
S12 genetic polymorphism 
S11 pharmacogenetics 
S10 asthma 
S9 
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 
OR S8 
S8 slophyllin 
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S7 slo-phyllin 
S6 uniphyllin 
S5 neulin 
S4 theophylline 
S3 phyllocontin 
S2 aminophylline 
S1 xanthine 
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Appendix 9 – Risk of bias assessment for each study  
 
 
 
Cochrane risk of 
bias tool 
Newcastle Ottawa 
Score 
Risk of bias 
Hawcutt[267] - 9/9 Low 
Tan[389] Low - Low 
Israel[388] Low - Low 
Park[391] Low - Low 
Park[390] Low - Low 
 
 
 
